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LETTER FROM THE PROFESSOR

Neuroscience is interdisciplinary, not just ideally, but necessarily.
To fully understand why a particular behavior or cognitive state occurs,
one must dissect those chemical and electrical processes that underlie
them. Conversely, one has to consider how those cellular workings of
the brain actually affect the organism and how it might think, act, and
feel. It is a broad and multifaceted field, and thus it is fitting that you,
Class of 2020, can cover this breadth with your varied specializations and
areas of interest. This issue of Scientific Kenyon has culminated from your
collaborative efforts and training, and indeed, reflects the wide scope of
neuroscience seen in the greater field. This breadth can be found within
the articles; for instance, reporting how genetics can control behaviors across generations, how changes in
sleep result in molecular changes in the brain, and how drugs can shape not just behavior, but societies and
public policy. As a class, you can describe the methodology to study everything from basic biological systems
to cognitive states, both normal and otherwise. Your work clarifies the interactions of the nervous system to its
environment, from medications to social systems and even the seasons. And, critical for the medical field, you
can talk about how neurological disorders can be aided with rather surprising treatments - including a glass of
wine and good night of sleep.
However, when you first wrote these articles, you could not have imagined what the world would look
like when this magazine was ultimately produced. Just a few months after our Senior Seminar concluded, the
coronavirus global pandemic took hold, and your time at Kenyon was truncated - painfully so, before the end of
your senior year. At the time of publication for this issue of Scientific Kenyon, there still remains much to learn
about the scientific, medical, epidemiological, and societal impacts of the COVID-19 crisis. Like neuroscience,
understanding and managing COVID-19 will be an interdisciplinary conundrum, spanning basic chemistry and
organ systems, medical interventions and public health approaches. Perhaps now more than ever, it is critically
important both to have this broad scientific understanding and be able to communicate that information to
the public. In writing this magazine, you have already demonstrated your powerful abilities to read the data,
to synthesize it, and to discuss it in a way the public can understand. From studying scientific communication
theory in our class, you already know that the burden of translating this information falls to scientists, rather
than the public. We urge you to continue this work beyond Kenyon, so that others can understand the impact
of science as you, the scientists, do.
As you transition between these two great eras of your life, take heart and confidence knowing that you
are equipped to serve as scientific ambassadors in a world that needs them more than ever. We, your faculty
in the Neuroscience Department and at Kenyon College, wish you the very best as you take on this challenge.

Sarah C. Petersen
Ashby Denoon Assistant Professor of Neuroscience
Kenyon College
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LETTER FROM THE EDITOR-IN-CHIEF
A Perspective on Loss
Dear Class of 2020,
This has been a turbulent and stressful year for everyone. For you,
in particular, in addition to the normal life stressors that come with the
end of college (graduate school acceptance, jobs, internships, etc.), the
COVID-19 virus emerged and without warning, your time in residence at
Kenyon ended. You left for spring break never realizing that was the end
of your campus residency. But you rallied and continued your education
remotely, graduating on time. You kept your chin up and maintained
good spirits even as you earned the dubious distinction of being the first
Kenyon class to have an online graduation ceremony. As you began to
settle into your new identity as Kenyon Alumnae, the world again erupted,
this time with repulsive images of policemen on camera, torturing George Floyd, a black citizen, to death.
Perhaps it was the banality and callousness of this vicious crime, or maybe, coming on the heels of so many
others (Tamir Rice, Treyvon Martin, Breonna Taylor, Michael Brown, Ahmaud Arbery, Sandra Bland, to name a
few) it was too much for the world. Thousands of people took to the streets, demanding justice and changes
in American police practices and, to the surprise of many, those protests became global as citizens in England,
France, Kenya, Turkey and South Korea, among others, stood up and protested too, some holding up signs and
chanting Black Lives Matter. And as we adjusted to these unfolding events, we suffered yet another tragedy.
A local loss that was immediate, close, and wrenchingly painful: Professor Niemiec, a founding member of the
Neuroscience Department and an integral part of the program from its earliest days, and of your education,
suffered a stroke. And we lost him too. And this came on the heels of us losing your fellow student Sean Bush,
’17, the first artistic director of this magazine, in the summer of 2019. You could be forgiven, then, if you are
tempted to think of your senior year as a season of losses. But it was more than that. It was the time when you
found out just how resilient you and Kenyon are; it was the time when you learned of the enduring strength of
relationships forged in Kenyon’s academic halls, on middle path, and at the Kenyon Athletic Centre (KAC); it was
the time when the knowledge gained in your science classes allowed you to calmly navigate a changing world
wracked by a viral pandemic and your broad liberal education gave you historical perspective and clarity of
thought; it was the time you learned that the citizens of different countries around the world are tired of racism
in its various forms, the insidious practices that it spawns, and are willing to stand up and be counted as antiracists; it was the time you saw the world begin to transform itself and you were invited to participate in making
it a better place. Yes, you suffered some losses. But you received in return, a ticket to a world-transforming
party. I hope you accept that invitation. You are needed in so many ways. But whatever path you take, we are
confident that you will represent yourselves, the Neuroscience Department, and Kenyon College with grace
and distinction. We wish you well.

Hewlet G. McFarlane
Professor of Neuroscience
Kenyon College

IN MEMORIAM

Andrew Niemiec
(Andy)

1962 - 2020

Professor Niemiec would be the first person to tell you that few students pursue neuroscience
with a clear view of their future in mind. As an advisor, he was sensitive to the possibilities open to his
students, and often exhorted them to look beyond the well-worn paths of academia. He possessed
a rare and vigorous sense of compassion, which he conveyed through the candid, clear-eyed
counsel he offered his students. Professor Niemiec balanced his sincerity with great levity, candying
his lectures and conversation with puns and jokes. He was also a passionate and generous friend
of animalkind, to which he extended no less humanity than he did to his colleagues, friends, and
students. As an educator and a researcher, Professor Niemiec was keenly attuned to the intricacies
of neuroscience; he invoked biological complexity like a poet invokes the Muse. Science, in hvis
lectures, was rendered as a living organism, reflexively self-correcting and always unpredictable.
Unsurprisingly, he found it impossible to detach art from science, and was as authoritative on
the auditory system as he was on the music that so thrills its many receptors. The drama of
experimentation and discovery had the gravity of an epic when sung by Professor Niemiec. Kenyon’s
neuroscience program owes much to him. He will be remembered for his integrity and sense of
equity, his expansive and luminous instruction, and the grace with which he encouraged the class of
2020 and many, many classes of fledgling scientists before us.
- Kevin Crawford
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I took many classes with Professor
Niemiec throughout my time at
Kenyon. I will remember him for
the way he made his students feel
respected, his dedication to our
department, and his deep love for
non-human animals. I use the term
“non-human animals” because that
was the language that he used in
Animal Cognition. This specific choice
of words is one of the many ways that
he encouraged us to actively work to
evaluate the world in a way that does
not rely solely on our own subjective
realities. I am grateful for the time that
I spent in his classroom.
- Chloe Hall
Professor Niemiec was a fixture in my Kenyon
neuroscience career; he taught the first neuroscience class
I ever took at Kenyon. It is clear that Professor Niemiec
was one of those true academics, deeply invested in
the pursuit of knowledge for no other reason than that
something is worth knowing. However, the thing I, and
I’m sure plenty of my fellow students, will remember most
fondly was his penchant for storytelling. Rarely, if ever, did
we make it through a class without an anecdote about a
former pet or the Wild West that is the postdoc world,
where you used to be able to take a lab monkey out for a
spin on the handlebars of your bike. With Niemiec, what
you thought would be a quick five-minute conversation
could easily turn into half an hour without either of you
realizing it. He was a talented academic and an invested
teacher, and will be deeply missed.
- Lindsay Spitz

I only went to Professor Niemiec’s office hours a couple
of times. The first time I went, I ended up staying for
forty-five minutes, talking about music. We are both really
into music gear. He had found a cheap electric guitar on a
sketchy looking website that played just as well as the less
expensive Fenders. After I had bookmarked the page to
return to and potentially buy a guitar, he pulled a ukulele
out from under his desk and explained that he had four
or five ukuleles strewn about the places he frequents (his
office, bedroom, kitchen, etc.) so that he can play music
whenever he needs to. If I ever have an academic office, I
will be keeping a ukulele under my desk.
- Ethan Bradley

I went to Professor Niemiec for advice
on my post graduate plans and as always he
was very honest in his response. He told me
to definitely pursue a PhD if I could accept
the fact that my future students will likely
drive nicer cars than me. He continued to
go on about the somewhat discouraging
statistics of people with neuroscience
doctorate degrees finding jobs and returned
to the car argument that had clearly been
on his mind. He had actually just bought
a new car and realized after analyzing his
car-buying-behavior that, on average, that
happens about once every 20 years. His
conclusion was that this must be the last
car he’ll ever drive. While his stories weren’t
necessarily the most positive, he brought
them in a way that was comforting. The way
he was so kind to every living being around
him, even though life had not always been
the kindest to him, is inspiring and will be
missed.
- Mara Kaspers

From my first semester at Kenyon in Neuro 212
to my final semester senior year in Animal Cognition,
Professor Niemiec never failed to bring the subject of
every lecture to life. He always knew how to perfectly
fold his many stories of the animals he befriended
in his lifetime into his lectures to perfectly illustrate
just about every topic in neuroscience. His passions
also went beyond the natural sciences, and I knew
I could always get my fix for a good conversation
on the politics of the day from a quick trip to office
hours. He was never afraid to speak his mind and I
will treasure his advice always. I hope he knew how
much his students appreciated not only the lessons
we learned in class but also the unwavering support
and wisdom he provided outside of the classroom.
- Sarah Hudson
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By Lauren Graf

“New role identified for scars at the site of injured spinal cord”
By Dr. Michael V. Sofroniew from Flickr (CC BY-NC 2.0)
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October 18, 2010

T

his is the day that would
change a young man’s
life forever. On this
day, a man’s strength, faith, and
fortitude would be forever tested
and pushed to the limit. On this
day a promising college athlete,
dedicated student, and loving son
would lose the ability to walk8.
It began as a beautiful October
day. Chris Norton had proved
himself to be a valuable asset to
the Luther College football team
(Figure 1). As a 5’ 11”, 185-pound
freshman, he had worked hard
enough to earn playing time as
a starter on the team, a great
accomplishment for an undersized
freshman. The game against Central
College was in the third quarter,
and Luther College had just scored
a touchdown to bring themselves
back in the game. The play began
as routine as any other. Chris ran
down the field as fast as he could
toward the ball carrier. While the
other player was much bigger than
him, he knew he could make the
tackle. Chris dove towards his knees
and took the ball carrier down.
However, he mistimed the dive and
instead of hitting the other player’s
knees with his shoulder, Chris’s
head connected with his thigh and
the ball carrier’s knee hit his neck.
Chris did not feel any pain, nor did
he feel a pop.
Up until this point, everyone
still believed that it was a routine
play. But when the whistle blew
and his teammates told him to
get up, he couldn’t move. At first,
he believed it was just a stinger,
where part of his body goes numb
before regaining feeling in a
couple of minutes. However, when
the trainers and doctors came out
and tried to get him to move, Chris
still could not feel anything, could
not move, and remained lying face
down on the turf. The medical staff
proceeded to roll him over and cut
off his helmet. He could now see

Figure 1. Chris Norton, author of “The Seven Longest Yards: Our Love Story of Pushing the Limits
While Leaning on Each Other”, has overcome some of life’s toughest adversity.
“Chris Norton” by West Broward from Flickr (CC BY 2.0)

other players taking a knee out of
respect, waiting anxiously for their
teammate to stand. Once they put
the neck brace on and loaded him
onto the stretcher, he tried to give
the crowd a thumbs up to let them
know that he was going to be okay.
But he couldn’t do it. This was when
the realization began to sink in: he
was paralyzed.

Breaking Down SCIs
Experiencing a spinal cord
injury (SCI) has a profound impact on
a person’s life. It changes everything
they do, big and small. Some
people are not able to continue
with their education or career, or
they must modify it in some way.
Relationships may change, either
for better or for worse. In many
cases, people with a spinal cord
injury require extra support and
care, which can put extra stress
and pressure on themselves and
their loved ones, both mentally
and financially. Medical bills are
not always covered and the cost
of equipment and therapy can be
exceedingly expensive. Simple
daily actions such as getting dressed
or going to the bathroom are now
difficult or sometimes impossible

to accomplish by themselves. On
top of this, dealing with all of these
challenges can lead to depression
and anxiety13. Medications may
alter the way the brain processes
neurotransmitters,
messagebearing chemicals, making these
individuals more susceptible to
mental illness. People with spinal
cord injuries are forced to face
obstacles that others would not
ever think of, making it even harder
to deal with their circumstances.
Almost 5.4 million people in
the United States are paralyzed,
with difficulty or inability to move
lower or upper extremities10. To
this day, there is no reliable cure.
But why is that? What is stopping
us from being able to heal from
such an injury? When a spinal cord
injury occurs, the nerve fibers are
severed, thus causing a break in
communication from parts of the
body and the brain. These nerves
are made up of bundles of axons,
which are extensions of nerve cells,
that help to transmit information
to different parts of the body. Past
research shows that after an injury,
something blocks damaged axons
from regenerating and impedes
the healing process. This roadblock
2
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is called the astrocytic, or glial, scar.
Because of this blockage covering
the injured area and damaged
axons, it was determined that the
astrocytic scar is the reason that
people are not regaining function.
Astrocytes are the most
prominent type of cells found in
the astrocytic scar, and are found
to greatly aid in the regeneration
process after an injury. Since
astrocytes are a type of glial cell,
meaning non-neuronal nervous
system cells, they can be found
in both the brain and the spinal
cord. They help to form the bloodbrain barrier, provide nutrients
to neurons, and aid in the repair
process after an injury to the brain
or spinal cord17. When an injury
occurs to either of these areas,
reactive astrocytes answer the call
for help and rush to form a scar over
the injured site16. This scar helps to
initially prevent infection and helps
to minimize inflammation and
swelling. However, our knowledge
on the astrocytic scar’s role in
long-term recovery is still under
investigation.

Past Findings
Past research has shown
that while the formation of the
astrocytic scar may be beneficial
immediately after injury, it may be
detrimental in relation to long-term
recovery. These studies found that
the glial scar acted as a roadblock
that did not allow for the healing
process to occur. Imagine a road
that has been broken and needs
to be fixed. In order to do so, a
roadblock will be placed there and
the road will undergo construction.
However, cars now cannot go
through because of that roadblock.
In this case, the roadblock is the
astrocytic scar, the road itself can
be seen as the axons, and the
cars are information that cannot
get through (Figure 2). Studies
discovered that injuries in the
central nervous system (CNS) that
were treated by astrocytes did not
see axonal regeneration due to the
barrier of the astrocytic scar15. They
also found that reactive astrocytes
that make up the scar increase
the regulation of the expression
of inhibitory molecules. These
inhibitory molecules were thought
to prevent axonal regrowth from

occurring. So when the astrocytes
called
for
more
inhibitory
molecules to come to the area, it
was thought that they would also
be simultaneously working with the
astrocytic scar to prevent the axons
from regenerating. The researchers
determined that the tightly knit
astrocytic scar and the inhibitory
molecules do not allow for growth
factors to reach underneath the
scar, or for axons to grow through
it.
One 1997 study conducted by
Davies and colleagues2 investigated
the impact of the astrocytic scar on
regeneration. These researchers
specifically tested what would
happen to the axons when they
minimized glial scarring. They
found that when the glial scar
was minimized and axons made it
past this point, they were able to
regenerate along paths found in
the CNS. When the glial scar was
left to form normally, they saw that
the axons were not regenerating,
leading to the conclusion that
the glial scar is detrimental to the
regrowth of axons and inhibits
potential functional recovery.
In a 2004 review, the authors12
focused on the inhibitory molecules

Figure 2. Old versus new research. The old research (left) shows the astrocytes tightly bound together (yellow), forming the glial scar. The axon (pink)
can’t get through the roadblock. The new research (right) is depicting that the scar (yellow) can be loosened enough for an axon (pink) to cut through the
astrocytic scar and regrow. Original image by Lauren Graf, calligraphy by Mary Angela Ricotta.
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that were thought to be either
produced or brought to the injured
area by reactive astrocytes. They
mention that while there are some
benefits to the glial scar, they come
at the cost of long-term functional
recovery. One of the benefits
discussed is that the astrocytic
scar helps to prevent cellular
degeneration and inflammation,
thus saving the healthy tissue.
However, this benefit is wiped
out by the fact that astrocytes
were said to bring or produce
many inhibitory molecules. Due to
this, researchers concluded that
axonal regrowth was not possible
because of the barrier of astrocytes
and detrimental molecules that
followed.

Current Research
We have all experienced a
situation where the fear of being
criticized suppressed our desire to
speak out on a topic we viewed
as incorrect. That is exactly what
Anderson and colleagues recently
went through with their research on
the glial scar. Intuition would tell us
that if something is blocking a path,
then removing it should open up
the path and allow normal functions
to resume. Based on the results
from previous studies, Anderson
and colleagues believed that they
would have similar findings, which
would thus confirm this thought
process1. They decided to base
their experiment off of this premise
and they hypothesized that without
the glial scar blocking the axon’s
path, regrowth should occur. The
researchers prevented the scar
from forming altogether, assuming
that the axons would now have
the room and resources to grow.
However, they found that no axonal
regeneration occurred. They then
decided to let the astrocytic scar
grow and remove it after it had fully
formed. This also resulted in no
axonal regrowth and regeneration
occurring. Conversely, when they

allowed normal glial scar formation
to happen, they found that axonal
regeneration does occur. Based
on previous research showing that
growth molecules can help promote
axonal regrowth and regeneration4,
7
, the researchers decided to
locally inject these growth factors
at the site of injury. True to form,
Anderson and colleagues saw
even greater axonal regrowth and
regeneration with the introduction
of these growth factors at the
site (Figure 3). In addition to this,
rather than hindering the growth
process as previously believed, the
molecules that they believed to be
inhibitory were actually promoting
growth, therefore acting as growth
molecules. The researchers thus
concluded that the astrocytic scar
is not only beneficial, but necessary
for axonal regrowth and could be
a potential solution to achieve
functional
recovery.
However,
because of the established
literature recognizing the glial
scar as inhibitory, Anderson and
colleagues were hesitant to share
their results. All of the previous
research reported the opposite
of their findings, so they were
concerned that something was
wrong with their experiment or that
they had interpreted the results
wrong. After reviewing the data
and methods, they could find no
major fault in their process that
would cause these results. Due
to this, the researchers finally
decided to release their findings
to the community, which has since
reignited research in this area.
Recently, more research has
been done in order to unlock
the mystery of the glial scar.
Researchers have been particularly
interested in altering the formation
of the glial scar so that some of it
remains, but not enough to block
axonal regeneration. In one study
from 2015, Zhao et al.18 worked to
discover the impact of histamine
on the astrocytic scar. Histamine is

Figure 3. Axon (red) growing through an
astrocytic scar (green) and growth-promoting
molecules (blue). First observed regeneration
through a fully formed astrocytic scar1.
“New role identified for scars at the site of
injured spinal cord”
By Dr. Michael V. Sofroniew (CC BY-NC 2.0.)

a compound that is found in both
the brain and the body, involved
in immune and inflammatory
responses, and acts as a
neurotransmitter14. The researchers
thought that they could alter the
formation of the astrocytic scar by
locally administering histamine, as
histamine reduces the number of
astrocytes that are called to the
injured area. Histamine, much like
a key fits a specific lock, can only
bind to and activate its specific
receptor on an astrocyte. Once this
happens, the histamine receptor is
activated, which then triggers the
reduction of astrocytes called to
the area3. This thinner astrocytic
scar then allows for axons to
grow through it without as much
difficulty. As a result of this process,
some astrocytes were still being
recruited to the area, but not as
many. This is beneficial as it allows
the astrocytes to still bring certain
growth factors with them to aid the
axons regeneration process, while
also allowing the axons to have
more room to grow.
Another study conducted in
4
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By Yirui Sun.from Welcome Collections (CC BY 4.0)

20189 used anti-integrin antibodies
in order to alter the formation of
the glial scar. Integrin has been
found to help direct cells where to
go and acts as a glue to help them
stick together. However, antibodies
are proteins that attempt to
counteract specific substances. In
this case, anti-integrin antibodies
would theoretically counteract the
effects of integrin, thus not allowing
the cells to be glued together as
tightly. During the formation of
the astrocytic scar, collagen genes
were observed to be increasingly
expressed in spinal cord injuries.
These collagen genes have been
seen to aid in the formation of the
astrocytic scar, acting as the special
ingredient which helps to turn
reactive astrocytes into scar-forming
astrocytes. Because of this, Okada
and colleagues hypothesized that
by locally injecting anti-integrin
antibodies, the astrocytes would
not be as tightly bound together.
Proving their hypothesis correct, the
anti-integrin antibodies prevented
the reactive astrocytes from turning
into scar-forming astrocytes, even
in the presence of collagen genes.
The astrocytes formed a much
5

looser glial scar, spreading out
farther apart from one another and
allowing greater axonal regrowth
to occur. The researchers not only
found that this aided the growth
of axons, but this also resulted in
improved functional recovery.
How could we be wrong about
the function of the glial scar for so
many years? One reason for the
controversy in the field is that some
of these past studies, such as the
1997 Davies study, did not directly
alter the reactive astrocytes2, 5. Due
to the fact that the researchers
never directly changed the reactive
astrocytes, there could be a
number of other factors that had an
impact on the results of the study.
Since they never took into account
that these results may be caused
by other factors, they therefore
fell into the fallacious reasoning
that correlation translates to
causation. In order to account for
this, the researchers must be able
to account for all other factors and
directly alter the glial scar, thus
allowing conclusions to be causal,
instead of correlational. Another
potential cause for these opposing
conclusions is that there are different

types of reactive astrocytes. These
diverse types of reactive astrocytes
may vary, with some inhibiting
growth and some facilitating it.
While little is known about these
different types of astrocytes, we do
know that they can be triggered
by neuroinflammation, as seen in
spinal cord injuries6.

The Future of SCI
Based on the encouraging
results from the Okada and Zhao
studies9, 18, future research should
be conducted to further study the
role of histamine and anti-integrin
antibodies in the glial scar. Both of
these processes involve altering the
glial scar in some capacity to allow
for axons to grow through it, while
still bringing enough astrocytes
to aid in regeneration. With the
astrocytic scar as our roadblock,
we are currently trying to find
a way in which the road can be
worked on, while still allowing cars
to drive through it. An injection of
histamine has been seen to help
reduce the volume and thickness of
the astrocytic scar, providing axons
with an easier path to grow through.
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Anti-integrin antibodies introduced
through a local injection have also
been seen to loosen the glial scar
in such a way that it allows axons to
grow through it without inhibition.
These potential solutions should
be more thoroughly explored as
to how they can be improved to
lead to full functional recovery
in humans. One possible way to
do so would be to locally inject
either histamine or anti-integrin
antibodies with growth factors.
When Anderson and colleagues
introduced extra growth factors
to the glial scar, they saw robust
axonal regrowth. Based on these
results, adding extra growth factors
and breaking up the astrocytic scar
could result in even greater axonal
regrowth and regeneration, leading
to greater functional recovery.
Another way to potentially increase
axonal regeneration and functional
recovery would be to combine the
methods together. An injection of
histamine would help to decrease
the volume and thickness of the
glial scar, while the anti-integrin
antibodies would help to break
up and loosen the scar. Both of
these combined would allow the
axons even greater room to grow.
In addition to this, adding extra
growth factors would allow the
axons to have more resources to aid
them in regeneration. All of these
factors combined could potentially
lead to an increase in healing after
a spinal cord injury, which also may
result in the regaining of motor
functions.
However,
before
experimentation
proceeds
in
these areas, research should be
done on the exact interactions
that occur between histamine,
anti-integrin
antibodies,
extra
growth factors, and the astrocytic
scar. Based on these results, we
could use this information to
determine what would be the
best course of action involving
these methods. Researchers could

decide how to better implement
the use of histamine or anti-integrin
antibodies in a way that will
maximize their benefits in altering
the scar and allowing for greater
regrowth and regeneration. The
overall goal is that we need to get
to the point in which we can alter
the glial scar exactly as we need
in order to allow for axons to grow
through it by using histamine and
anti-integrin.
Another area that should
be further studied is axonal
regeneration
and
functional
recovery in fish, frogs, and
salamanders11. These organisms
can all experience a full recovery
after an injury to their spinal
cord, which we are just beginning
to understand. In the case of
zebrafish, instead of forming a glial
scar, the cells form a glial bridge.
This bridge allows the axons to
regrow and regenerate across the
injured site, thus restoring some of
the functional connections. While
some of the original connections
between the brain and body are
reformed, new connections have
also been seen to form. This helps
to provide evidence that the original
connections are not always needed
to regain functional recovery,
and that the brain and body can
be rewired in order to achieve
the same functional processes as
before. A substantial amount of
research needs to continue in this
area in order to determine what the
exact differences are between the
processes in these organisms and
humans. This could help lead us to
discover potential ways to improve
our own functional recovery.

Implications for the
Community
Finding a solution to help
individuals regain function after
spinal cord injuries would be a
tremendous accomplishment from
which millions of people would

benefit. A cure would be able to
help people not only physically, but
also mentally. Regaining function
could potentially lead to lower rates
of depression and anxiety, enabling
them to live happier lives. Finding
a cure for spinal cord injuries may
also lead to a possible cure for
other diseases which impair motor
function, thus aiding another subset
of the population. Helping people
to regain the ability to walk after
a SCI would have a huge impact
on the world, giving many people
hope at a time in which they may
have none.
That young man whose entire
life was rocked within the course of
one play has since accomplished
so much. The night of Chris’s injury,
he underwent surgery. He was then
given only a 3% chance to ever
regain movement below his neck.
However, the next day he shrugged
his left shoulder, already defying
the doctor’s prognosis. Since
then he has continued to defy his
circumstances. Through physical
therapy he worked immensely
hard to be able to regain some
function in his upper and lower
extremities. He has since been
able to walk across the stage at
graduation and down the aisle at
his wedding, both with the love
and support of his wife Emily. In
addition, Chris has also started
a foundation for those in similar
circumstances, began a family,
and has become a motivational
speaker. While Chris has been able
to do all of this through hard work
and perseverance, the scientific
community must do their part to
help. We are still currently in search
of a more reliable cure for those
with spinal cord injuries, and the
glial scar may be the answer to this.
However, research must continue in
order to find a way to allow these
axons to fully regenerate so that
we can help people to regain full
functionality in their lives.
6
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OCD-ADHD
Together
A Walking
Contradiction
By Chloe Hall

“For me, OCD feels like you’re not in control of
your brain. Intrusive thoughts — vivid, visual images
of the most horrendous things — plague me on a
daily basis. I pick up a knife to chop an onion and
see myself stabbing someone…. Ruminations over
past events play in my mind so loudly it’s almost as
though they’re audible. A constant soundtrack to my
days, it’s as though I’m listening to the same song on
repeat for years, only the song is a hellish event from
my past and it accompanies me from the second I
open my eyes to the second I finally manage to close
them at night”
9

OCD: Checking that
the Car Is Locked 17
Times

T

his is the testimony
of Alice Franklin, an
obsessive-compulsive
disorder (OCD) patient writing in
an attempt to explain what it feels
like to have the disorder. OCD is
a mental disorder characterized
by obsessions and compulsions.
Obsessions are recurring thoughts
or images that loop through the
mind to the point that the thoughts
become uncontrollable. A few of
the many examples of possible
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obsessions that someone could
have include fear of contamination,
unwanted
or
taboo
sexual
thoughts, thoughts of harm toward
others or toward one’s self, and/
or perfectionism to the point
that it reduces quality of life and
interferes with normal activities
and obligations. Compulsions are
attempts to control the anxiety
that these obsessions cause. The
word “compulsive,” when used to
describe a behavior, means doing
something because you feel like you
have to, not because you want to.
These compulsions usually take the
form of a behavior such as cleaning
the house repeatedly, excessive
hand washing, checking locks,
putting objects in particular orders,
avoiding triggers, or completing
tics. For example, if someone
has an obsession that involves
the fear of contaminated water,
they would perform compulsions
like only drinking bottled water,
avoiding washing hands, avoiding
public restrooms, and repeatedly
cleaning water filters with bleach
or another disinfectant. OCD
onset usually occurs during the
adolescent years, and a major risk
factor is having family members
with OCD. The predominant theory
of what causes OCD on a molecular
level is that there is too little of
the neurotransmitter serotonin
in the brain. Neurotransmitters
are chemicals that help the brain
function normally, and serotonin
specifically helps regulate mood
and sleep. If there is too little of it,
the brain generally becomes more
anxious and depressed, and in
some cases, develops obsessions
and compulsions2.
A real patient case study of
OCD symptoms comes from Allen,
a young janitor who sought out
help for crippling anxiety from a
local clinic. He could not control
the constant fear that he would
contract HIV. (This would be the
obsession element of OCD). In

an attempt to control the anxiety
that this obsession caused him,
Allen avoided touching things
outside of his own home, washed
his hands multiple times a day with
bleach, avoided physical contact,
and avoided romantic and social
relationships. These behaviors are
the compulsive element of the
disorder. Allen additionally feared
hurting people. His mind was
bombarded with images of hitting
strangers or offending his neighbors
during casual conversation. His
compulsions that stemmed from
these anxieties included replaying
conversations he had with these
people repeatedly, as well as
attempting to avoid interactions
with people altogether. These
compulsions, if the disorder is
severe enough like in Allen’s case,
can completely consume a patient’s
life. Thankfully, many patients find
successful treatment with SSRIs
(serotonin
reuptake
inhibitors
like Prozac) and CBT (cognitive
behavioral therapy), a type of
psychotherapy that has been
shown to be effective at treating
a range of anxiety and mood
disorders2. As mentioned before,
OCD is believed to be caused at
least in part by a lack of serotonin.
SSRIs are medications that stop
the brain from recycling serotonin
so that there is more serotonin
floating around in the brain to help
normalize thought patterns and
behavior.
Another
interesting
component of the OCD brain is
that the disorder is comorbid with
many other disorders, including
(but not limited to) anxiety,
depression, and eating disorders2.
When a disorder is “comorbid”
with another disorder, this means
that they commonly occur together.
For example, among people with
anxiety, there is a higher proportion
of people who additionally have
OCD when compared to the
proportion of people with OCD in

the rest of the population. Another
disorder that is considered to be
comorbid with OCD is ADHD.
Comorbid disorders are disorders
that are often diagnosed together,
as the rates of one illness is higher
in populations who have the other
illness, suggesting that their root
causes or underlying neurobiology
may overlap. OCD and ADHD
comorbidity has been found to be
significant: a recent study found that
the rate of ADHD in OCD patients is
11.8%, much higher than the 5% of
people estimated to have ADHD in
the general population4,. Even more
significantly, 25.5% of pediatric
OCD patients are diagnosed with
ADHD. While anxiety, depression,
and eating disorders (as well as
most other mental disorders that
are comorbid with OCD) share a
similar symptom set and underlying
neurobiology, ADHD is set apart
because it is actually very different
from OCD in almost every way.

ADHD: Leaving the
Car Running and
Losing the Keys
“People will be talking to
me, and I’ll stop hearing what
they’re saying. And it’s the same
sort of thing [as with reading]. I’ll
go through the motions, nod my
head, mirror their body language
and stuff. But the information
isn’t coming through…. I could
see my classmates finishing the
assignments in 10 to 30 minutes,
but they’d take me hours and
hours and hours and sometimes
I couldn’t complete them…The
processes that needed to go on
simultaneously to complete the
tasks just wouldn’t line up”
This is a statement from Eliana,
a young woman with ADHD,
describing the difficulties she has
faced as a result of her condition.
ADHD is a common mental
disorder that can also be referred
10
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to colloquially as “ADD.” ADHD,
or attention-deficit/ hyperactivity
disorder, is a mental disorder
characterized by an inability
to sustain focus (inattention),
hyperactivity, lack of inhibition,
disorganization, and impulsivity.
Having a lack of inhibition /or being
impulsive means having trouble
controlling one’s impulses. People
with ADHD have trouble with
paying attention and self-control
more than people in the general
population. It was thought up until
fairly recently that only children
could have ADHD, however,
symptoms can continue throughout
adulthood. ADHD patients tend to
struggle in school, have trouble
completing tasks that require
sustained focus, interrupt others
frequently, struggle to regulate
emotions, lose objects, and forget
various day-to-day tasks8.
ADHD has three different
subtypes, including predominantly
inattentive (ADHD-I), predominantly
hyperactive-impulsive (ADHD-H),
and
combined
symptoms
(ADHD-C). People with the
predominantly inattentive type do
not tend to struggle as much with
being impulsive or hyperactive like
people with the predominantly
hyperactive-impulsive type, but
they do display symptoms of
inattention
significantly
more
than their peers. This subtype can
also be referred to colloquially as
“ADD,” because it was previously
considered a different disorder
than the other two ADHD subtypes
until psychologists agreed to
classify ADD as a subtype of
ADHD. This population may also
be referred to as having ADD
(attention deficit disorder, ADHD-I).
The fact that these patients may
not display abnormal amounts of
hyperactivity or impulsivity makes
this subtype more difficult to
diagnose. Most of the time these
are the kids who are not necessarily
getting in trouble, and the adults
11

who can more successfully mask
their symptoms. They tend to be
labeled as spacey, disorganized, or
off in their own world. On the other
hand, patients with predominantly
hyperactive-impulsive
ADHD
disproportionately display the
impulsive
and
hyperactive
symptoms such as fidgeting and
lacking in self-control, although
they tend to struggle less with
sustaining attention than their peers
with the predominantly inattentive
type. In fact, patients with this
subtype can display an uncommon
ability to sustain attention for long
periods of time on things they are
very interested in10. Patients of the
combined type would experience
both inattentive and hyperactiveimpulsive symptoms in somewhat
equal measure9. This essentially
means that people diagnosed
with the umbrella term “ADHD” as
outlined in the DSM V can actually
have one of three subtypes that can
present very different symptoms
that fall under the same umbrella
of one disorder. The first line of
treatment for ADHD of all three
subtypes tends to be stimulants
like Adderall and, in some cases,
CBT to help patients understand
how to deal with the symptoms of
their disorder. Doctors commonly
prescribe
stimulants
because
the predominant theory of what
the underlying cause of ADHD is
believed to be a lack of dopamine
in the brain. Dopamine is a
neurotransmitter that is involved
in helping the brain focus and
perform tasks that require attention
and mental energy9. Just like
OCD brains don’t have enough
serotonin, ADHD brains don’t
have enough dopamine. Just like
serotonin is the neurotransmitter
whose dysregulation is believed to
be a root cause of OCD, dopamine
is viewed in a similar manner when
it comes to ADHD.

Dual Diagnosis of
ADHD and OCD:
Impossible?
The stories of Alice, Allen, and
Eliana are the narratives of three of
the millions of people worldwide
who suffer from OCD or ADHD.
These mental disorders, when
directly comparing symptoms, may
seem unrelated or even mutually
exclusive. Many patients who have
OCD describe the feeling of being
unable to control the near-constant
and excessive focus on obsessions
(Allen’s struggle to focus on anything
besides his fear of contracting
HIV),
while
ADHD
patients
describe not being able to focus
on anything at all (Eliana’s inability
to complete schoolwork or listen
during conversations). There is also
the compulsive versus impulsive
paradox: how can the same person
display abnormal amounts of
both compulsive and impulsive
behaviors simultaneously? Despite
these
inherent
contradictions
between the two disorders, they
are actually considered comorbid
conditions. Despite the many dual
diagnoses of these disorders and
some overlap in symptomatology,
including inattention and below
average executive function, many
psychologists and neuroscientists
suggest that they cannot occur
in the same patient, despite the
immense number of patients who
are diagnosed with both disorders6.
A prominent example of
someone who argues that they are
mutually exclusive disorders is Eric
Hollander, a famous psychiatrist
and neuroscientist who developed
the theory of the impulsivitycompulsivity spectrum. This theory
essentially argues that certain
mental disorders fall somewhere on
an impulsive-compulsive spectrum.
This would suggest that impulsivity
and compulsivity would be sets
of symptoms falling on opposite
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ends of the spectrum. According
to this theory, the compulsive
end of this continuum would
represent OCD (risk-avoiding,
excessive self-regulation, excessive
thinking before acting) and the
impulsive end of the spectrum
would represent ADHD (risktaking, lack of self-regulation,
lack of forethought)5. On such a
continuum, these two disorders
could not coexist. To understand
this theory, evaluate its accuracy,
and reconcile the degree to which
these disorders are diagnosed
together with the opposing nature
of the two disorders, we must
examine the underlying cognition,
behavior, and neurobiology of
OCD and ADHD respectively.
Comparison of the two
disorders’
symptomatology
presents inherent contradictions.
ADHD patients who tend to
experience the more impulsive/
hyperactive symptoms of the
disorder tend to have risk-taking
and novelty-seeking behaviors. My
father could serve as an example
of this behavior. When he was 7
years old, he decided to jump from

the roof of his house into a kitty
pool with about a foot of water
in it. This is just one example of
the risky and impulsive behaviors
that he engaged in throughout
his childhood and well into his
adolescent years. After a trip to the
emergency room and yet another
broken bone, when asked why he
did it, his reply was “I didn’t really
think about it, but I guess I just
wanted to see what would happen.”
This response, as well as the act of
jumping off of a rooftop with no
intent to self-harm, illustrates a lack
of inhibition (impulsivity), and is
certainly an example of risk-taking
and novelty-seeking behavior.
On the other hand, patients with
OCD generally avoid situations
associated with risk or harm, to
the point that they feel at risk in
situations that do not pose risk or
harm to them at all. This can lead
to extremely restrained behavior to
avoid perceived risk4. An extreme
example of this is Howard Hughes,
an entrepreneur, filmmaker, and
aerospace engineer who suffered
from severe undiagnosed OCD.
His OCD was so severe that it

caused him to not leave a darkened
screening room for four months due
to his phobia of the unpredictable
outside world. In the last years of his
life, he became almost completely
recluse to the point that the public
questioned whether or not he
was still alive5. Although these are
two fairly extreme examples of
behaviors associated with the two
disorders, it illustrates that there
are behavioral components of OCD
and ADHD that seem irreconcilable.
How can one person display two
traits that seem to occupy polar
ends of a spectrum?
fMRI data collected on
ADHD and OCD patients present
evidence that suggests that the two
may not be able to coexist. fMRI,
or functional magnetic resonance
imaging, is a way for neuroscientists
to measure the activity of patients’
brains and compare them to the
average brain. fMRI is commonly
used in clinical studies and can be
used to diagnose various mental
disorders. A region of the brain that
fMRI has identified differences in
between ADHD and OCD patients
is the frontostriatal region. The

Common Symptoms of ADHD and OCD6,17,18 Original image by Chloe Hall
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Figure 1. Frontostriatal Region & Prefrontal Cortex6,17,18
”Brain” by Servier Medical Art by Servier (CC BY 3.0)

frontostriatal system of the brain
includes several brain structures
that are implicated in concentration,
planning, and self-control. This
complex system controls our
responses to environmental stimuli
and regulates responses to stimuli
through information processing. If
the brain is a team, the frontostriatal
region could be thought of as the
coach or team captain. Patients
with ADHD have been found
to have less active frontostriatal
regions while patients with OCD
display too much activity in this
same region6. Additionally, a recent
study found that the more severe
the OCD patient’s symptoms were,
the more active their frontostriatal
region was. This same study found
that the more severe an ADHD
patient’s symptoms were, the less
active their frontostriatal regions6.
Also, OCD is also associated with
too much activity in the prefrontal
cortex, while ADHD is associated
with too little activity in the
prefrontal cortex6. The prefrontal
cortex is greatly implicated in
planning, organization, setting
13

goals, working memory, and filtering
stimuli. It can be compared to the
calendar or compass of the brain: it
makes plans, helps save memories,
and tells you what to do and when.
Both the prefrontal cortex and the
frontostriatal regions of the brain
are highlighted in Figure 1.

The Complexity of
the Brain: It May
Not Be So Black and
White!
Essentially, the above data
suggests that ADHD and OCD
cannot logically occur in the same
patient. How could a patient have
a brain that is both under and
overactive in the same regions?
How could the same patient
display both abnormally impulsive
and
compulsive
behaviors?
Recent data seems to support the
impulsive-compulsive continuum
theory that these two disorders are
on opposite sides of the spectrum,
while the neurotypical brain falls
somewhere in the middle of this

same spectrum11. In the purely
theoretical sense, this all checks
out. But looking at the fact that
OCD and ADHD are so commonly
diagnosed together (especially in
children) that they are considered
to be comorbid disorders, the
theory does not hold up. Why are
so many people being diagnosed
with both if they are seemingly
opposite disorders in their clinical
presentation, patient behavior, and
biology? There are only two possible
answers to this immensely complex
question of whether or not the two
can possibly occur together: yes,
they can; or, no, millions of people
are being misdiagnosed and given
the wrong medication each year.
Either way, the answer has huge
implications for the millions of
people diagnosed.
The first possibility to explain
this phenomenon is that OCD and
ADHD cannot occur in the same
patient, and somehow all of the
dual diagnoses are OCD (or ADHD)
symptoms presenting as the other
disorder. This would support the
theory of the impulsive-compulsive
continuum. Neuroscientists who
support this side of the argument
believe that the set of OCD
symptoms can include ADHDlike symptoms rather than fullblown ADHD symptoms. These
ADHD-like symptoms can include
inattention and poor performance
in school relative to intelligence.
This argument is referred to as the
Executive Overload Model of OCD.
It suggests that the comorbidity
between ADHD and OCD actually
is due to the fact that OCD includes
ADHD-like symptoms. This theory’s
name is derived from the argument
that people who have OCD are so
overstimulated by the obsessions
and compulsions that they have a
lot of trouble paying attention to
everyday tasks. Essentially, their
brains are so busy with the OCD
that their brains do not have the
capacity to perform normal tasks.
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An example of this could be a
student with OCD in a math class.
This student is constantly distracted
and cannot pay attention or work
with the same efficiency as his
peers due to his obsession that
every number has to be even.
He is also anxious because of his
obsessions, causing him to be
more fidgety than his peers. This
restlessness and inattention can
easily be misinterpreted as ADHD
rather than OCD causing ADHDlike symptoms13.
Another potential confounding
factor that could affect how we
think about and explain the
comorbidity between OCD and
ADHD is that a growing number of
neuroscientists and psychologists
are arguing against the DSM V that
the three subtypes of ADHD should
be classified as one disorder. This
would have important implications,
especially considering that maybe
OCD can only be comorbid with
one or two of these subtypes.
This could certainly aid in
explaining the confusion. More
and more people are arguing
that predominantly inattentive
ADHD (ADD), ADHD of the

combined type, and predominantly
hyperactive/impulsive type should
be considered separate diagnoses.
The reason for this is that some
recent studies are arguing that the
primary disturbance in ADHD of
the inattentive subtype is actually
in an entirely different brain circuit
than the other two subtypes. If
this is the case, this could mean
that ADHD-I ADD and OCD
could potentially reasonably occur
together. An additional idea that
could explain the confusion is that
some specialists in the field are
starting to argue that familial OCDADHD may be a blending of both
disorders when they are inherited
together. A recent study has
argued that ADHD and OCD, when
diagnosed together, is actually a
distinct condition when one parent
passes down OCD and the other
passes down ADHD15. Although
this theory is only a theoretical
framework, it poses an interesting
question
that
the
scientific
community should explore.
This is clearly a complex
problem
the
potential
that
psychiatric patients may be
routinely
misdiagnosed
or

prescribed the wrong medications
is a complex and dangerous
problem that affects the lives of
millions of people. If someone is
misdiagnosed with either of these
disorders, it could mean that they
are prescribed a medication that
they do not need. Of even greater
concern, it could mean that they
are prescribed a medication that
makes the disorder they actually
have worse. An example of this is
that if OCD patients (especially
those who do not have ADHD) are
prescribed stimulants, there is a
large chance that this will worsen
their OCD symptoms. The change
could happen immediately or
over time, but dramatic changes
in behavior and brain chemistry
can put the patient in danger.
This is why it is so important to
continue to research ways we
can get better at diagnosing and
identifying differences between
OCD and ADHD symptoms. So
many people depend on being
prescribed and treated with the
correct interventions, and research
is the first step to this process of
improving the lives of people like
Alice and Eliana.
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How Do We Get a Good Night’s Sleep?
By Srila Chadalavada
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ave you ever woken up
in the middle of the night
and had trouble falling
back asleep? While you may have
been concerned that you were not
getting proper sleep, studies show
that such wakeful periods may not
be an unnatural occurrence. In fact,
research has shown that this may
actually be quite normal among
the human population. In 1992,
Thomas Wehr conducted a study
resulting in a theory that when
people are given more leisure time
to relax and sleep, they tend to
fall into a unique sleeping pattern.
Participants of this study would
sleep for 4 hours, wake up for about
2 hours, and then go back to sleep
for another 4 hours1.
This work was later backed
up by historian Roger Ekirch, the
author of the seminal book At Day’s
Close: Night in Times Past. Ekirch’s
publication was a culmination of his
16 years of collecting anecdotes
and citations in literature supporting
the case that humans used to sleep
in two distinct phases. He was able
to provide historical evidence that
in pre-industrial society, when light
was limited and people had more
leisure time, humans would partake
in two sleeps. Between these
periods there would be an hour
or two of time spent awake, just
like in Wehr’s study. Ekrich pulled
examples from a variety of sources
ranging from Homer’s description
of Poseidon’s servant waking up
after his first sleep in the Odyssey
to 15th century prayer manuals
that contained prayers specifically
meant for between sleeps. In the
break between the first and second
sleep, people would get out of
bed and partake in activities such
as smoking tobacco, completing
chores, and holding conversations
with others. Since the early 1900’s
the concept of two sleeps has
faded from western culture, likely
due to the vast changes in the way
people consider working hours and

leisure time. While the majority of
Ekrich’s references are from British
sources, there is also evidence that
this sleep pattern is not specific
to a certain geographic area.
Anthropologists cite the Tiv, G/wi,
and Chagga communities, each in
various parts of Africa, as examples
of societies that also have a first
and second sleep as recent as the
late 1960s2.
So what does this idea of
two sleeps mean in relation to
how we view sleep in our modern
society? We may be able to answer
this question about modern sleep
by diving into the molecular players
involved through a neuroscience
perspective. In order to better
understand behavioral patterns
of sleep, let’s take a closer look at
the science behind our beloved
slumber.

What Do We Know
About Sleep?
While humans have always
been curious about sleep, scientists
only started studying sleep in the
mid 1950s. Dreams and rapid eye
movement (REM) sleep were of
particular interest. In the 1980’s,
polysomnography (PSG) gave
scientists an avenue to study sleep
objectively. This tool measures
brain waves, in addition to other
physiological characteristics3. Since
then, great strides have been made

in the field to better understand
sleep. However, there is still so
much that we do not know. We
have established that sleep is a
necessary physiological process,
but what is its purpose? Are naps
good or bad for you? Is there such
a thing as “bad sleep”? While
we may not be able to answer
all of these questions, this article
will discuss some key concepts
regarding the mysteries of sleep.
Sleep can be divided into
different stages that you cycle
through when you sleep for an
extended period of time. Generally,
sleep can be categorized into Rapid
Eye Movement (REM) sleep and
Non-REM (NREM) sleep. During
REM sleep, brain waves appear to
mimic the same brain waves when
you are wide awake. This stage is
characterized by increased brain
activity and increased heart rate and
respirations. Most dreaming is done
in REM sleep. Recent studies have
shown that aging decreases REM
sleep. On the other hand, NREM
consists of multiple substages
that repeat often throughout the
duration of sleep. This type of
sleep is essential as it is responsible
for the regenerative properties
associated with sleep, like tissue
regrowth and blood vessel repair.
It is also crucial for proper brain
maturation and connectivity. A
stage of NREM sleep that is of
particular importance is slow-wave
16
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Figure 1. Sleep Spindles (shown in red) during NREM.
© 2013 by IEEE

sleep. One of its roles is to heal
damaged muscles and tissues4.
Sleep studies often look at
what happens when sleep goes
wrong. A popular approach in this
field is to look at the effects of sleep
deprivation, meaning any case of
insufficient sleep. All mammals
require some sort of sleep to
maintain functions. The need for
rats to sleep is comparable to their
need to eat. A rat can go up to 15
days being deprived of any sleep
before fatal consequences. This is
just as long as they can go without
any food5. This is not unexpected
as we have always known that
some sleep is absolutely necessary
for survival. Depriving people
of sleep leads to decreased
cognitive function. Ability to recall
information and do tasks that
require concentration decrease
significantly. It can also increase
the risk of specific diseases such
as diabetes. In the United States,
sleep deprivation is correlated with
obesity prevalence4.
Proper sleep has many
benefits for memory and learning.
Let’s take a look at one study
that was conducted on healthy
participants to better understand
the relationship between sleep and
these processes. One group was
allowed a 90-minute nap whereas
the other was not permitted any
nap time and spent this interval
17

of time doing mental activities.
Napping amounted in a 20%
learning advantage and improved
memory when subjects were tested
later in the evening. So how does
napping or sleep in general aid
in cognitive tasks? This can be
partially answered by taking a closer
look at a mechanism through which
learning is affected during sleep.
Lighter sleep stages during NREM
allow for the formation of sleep
spindles. These spikes in brain
activity, shown in red in Figure 1,
occur frequently over a short period
of time. They are contrasted against
the regular brain activity during
these stages of sleep indicated
in blue. The spindles are thought
to lower mental processing and
allow for more restoration to occur.
Therefore, people wake up feeling
more refreshed and ready to take
on mental tasks. Taking naps, a
form of light sleep, can improve
the ability to learn afterwards and
this is likely due to the abundance
of these spindles. Although details
regarding the functions of sleep
spindles are still being figured out,
they are correlated with greater
memory and decrease as people
age6.
Dreams have been a well
documented aspect of sleep
throughout
human
history.
Reasons for dreaming have been
hypothesized for centuries. A

prominent figure in ancient Greece,
Aristides, was known to have
believed in the healing power of
dreams and the medical benefits
of interpreting dreams. Ekrich
also found historical and literary
references to dreams in his work7.
Oftentimes, between first and
second sleep, people would recall
their dreams and share them with
those nearby. Evidence shows that
people recalled such visions as
being rather vivid. They stated that
dreams would not be considered
as intruding if they had slept until
dawn without interruptions2.
Dreaming is difficult to study
as they are fairly subjective, ranging
from person to person. Have you
ever been asked the question, “Do
you dream in color?”. Not only
might people answer the question
differently, but they may also not be
able to answer it at all due to the
fleeting nature of dreams. We used
to think that all dreaming occured in
REM sleep. When someone wakes
up in the middle of REM sleep,
they often remember their dreams
more vividly. However, more recent
studies show that they can occur
in NREM sleep as well. Overall,
little current scientific research
is available on the functions of
dreaming but there are numerous
theories.
As you probably know from
experience, the amount of light
present greatly affects sleep. A
circadian rhythm is the 24-hour
internal clock that is closely related
to the availability of natural light.
Also called a sleep/wake cycle, this
pattern affects how awake or how
sleepy you are at different times
of the day. Most living organisms
that are exposed to sunlight
exhibit some sort of circadian
rhythms. This is usually expressed
biologically and has an effect on
behavior. According to research on
the effects of these rhythms, adults
are the least energetic and alert
between 2-4 am and again in the
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afternoon between 1-3 p.m.8. This
makes sense as this is when most
people sleep or choose to take a
nap. It also further supports Ekrich’s
idea of two sleeps.
Adults are often advised to
aim for between 7 to 9 hours of
uninterrupted sleep each night to
function at their best. However,
we have seen thus far that this has
not been the case in pre-industrial
society and our current practices
might not follow our circadian
clock. Let’s take a look at other
examples that break away from this
traditional model of sleep that we
are often told to follow.

What Are Alternative
Sleep Cycles?
The traditional sleep cycle of
about 8 hours a night might not be
considered the gold star standard
by everyone. In fact, there are a
multitude of sleep schedules that
people swear to live by on a daily

basis. Figure 2 shows some of the
major sleep schedules, a couple
of which are common and others
that are far rarer. The alternative
cycles shown in this figure all show
examples of getting less sleep than
the standard. The biphasic cycle is
pretty common and is seen when
you don’t get a full night of sleep but
take a nap midday. The Everyman,
Dymaxion, and Uberman are less
popular and result in considerably
less sleep. Nevertheless, they are
still found around the world and
throughout history.
Could burning the candle on
both ends correlate with greater
success? You might be convinced
after taking a closer look at the
sleep habits of some renowned
people throughout history. Winston
Churchill would often work through
the night and take 2 hour naps in
the evenings, following a biphasic
cycle. Leonardo da Vinci and Nikola
Tesla are known to have only slept
2 hours a day on an Uberman cycle.
Issac Newton often got 3 to 4 hours

of sleep a night and Madonna
sleeps about 4 hours without taking
naps, both of which do not fit into
any of the official cycles.
The examples of sleep cycles
shown in figure 1 cover schedules
with decreased amounts of sleep
in comparison to the standard
cycle. Many people also fall into
the opposite case in which they
get more than the recommended
8 hours of sleep. Albert Einstein
supposedly got more than 10 hours
of sleep a night and took additional
naps throughout the day. Calvin
Coolidge got his 8 hours at night
but also got an additional 2-3 hour
long nap in the afternoon. Mariah
Carey beats all of the previously
mentioned with an estimated 15
hours of sleep a night9.
Correlations to success is not
a valid measure of how much sleep
one should receive a night. In fact,
it is probably best to not compare
your sleep habits and needs with
anyone else. How much sleep
your body requires depends on

Figure 2. “Sleep Cycles” original image by Srila Chadalavada
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numerous factors. Most importantly,
age, general health, previous sleep,
and sleep quality affect your needs
for getting more hours of sleep.
Beyond that, needs vary between
individuals because of personal
habits. Let’s take a closer look at
what happens when sleep does
not occur in the way it is intended
to and the numerous physical and
cognitive consequences.

What Is Disrupted
Sleep and How Does
It Affect Your Body?
Poor
quality
sleep,
or
disrupted sleep occurs when
someone’s sleep pattern does
not follow their circadian rhythms.
Therefore quality sleep occurs
when you get sleep at the times
that your internal clockwork
intends for you to rest and for you
to be active when your biological
rhythms are programmed to keep
you awake. Some might consider
Eckrich’s examples of biphasic
sleep consisting of a first and
second sleep to be an occurance
of disrupted sleep. The alternative
sleep schedules in Figure 2 are
also examples of disrupted sleep,
especially the Dymaxion and
Uberman that have relatively little
sleep during nighttime. So why
might these disruptions occur and
who is at risk?
There is a common
misconception
that
modern
societies and constrained working
hours are the root of getting poor
quality sleep. While it is easy to
assume that in a previous era,
people had an abundance of
leisure time to sleep at their will,
this was not necessarily the case.
Eckrich mentions an abundance
of disrupted sleep, often through
literature and artwork. While no
societal class was spared of sleep
disruptions in the middle of the
night, the poor and urban class
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Figure 3. Sleep Disruption through a portrait of an Idle ‘prentice. Engraving by William Hogart,
174710.

were especially at risk. He quotes
G.C.L. Canali saying that, “They
feel their sleep interrupted by the
cold, the filth, the screams and
infants’ cries, and by a thousand
other anxieties.” (Ekrich 359).
The wealthy were able to escape
the noise by paying for quieter
quarters. Niclar Boileau described
the situation as, “Sleep like other
Things are sold. And you must
purchase your Repose with Gold.”
(Ekrich 359). Wiliam Hogart, a wellknown artist of the 18th century
often portrayed the lack of sleep
among all classes. In an engraving
of an “idle ’prentice” Hogart shows
a man that is disturbed from his
slumber by a cat, ultimately a
result of the squalid surroundings
(Figure 3). Oftentimes people were
left with no choice but to sleep
for extended periods of time in
daylight, something that certainly
does not follow circadian rhythms2.
Quality sleep is essential
to attaining effective rest and
recuperation. Even in today’s world,
we struggle to get good sleep. We
need to take a closer look at what
is happening on a molecular level

to fully understand the effects of
disrupted sleep. Disturbances
to normal sleep can occur when
there are changes in environmental
cues such as excessive light
or switching light and dark
periods. These interruptions are
called environmental circadian
disruptions (ECD) and can cause
reharmonization of the internal
clockwork to match the changed
external conditions8.
The disrupted sleep that
causes misalignment of the
circadian system can affect the
amount of time spent in each of
the stages of sleep. Poor quality
sleep can decrease the amount
of time spent in NREM sleep
and slow-wave sleep which are
pertinent for their properties in
restoring damaged tissues and
strengthening immunity10. Studies
have shown that prolonged ECD
can affect short-term spatial working
memory, meaning your ability to
store and process information
temporarily. Additionally, object
recognition can also significantly
decrease12. Overall, there is
abundant research supporting that

SCIENTIFIC KENYON

circadian disruptions in sleep can
cause a plethora of cognitive and
behavioral hindrances.
ECD has been shown to
cause inflammation of both the
brain and the peripheral system.
This inflammation is a response
to interleukins, a type of protein
released by immune system cells
throughout the body. This occurs
through the molecular pathway
as shown in Figure 2. When the
interleukin-6 receptor (IL-6R) is
activated by poor sleep, it becomes
released. This protein then binds
to its receptor, gp130, found on
the membrane of many cells.
Further signaling occurs in these
cells through a domino effect,
telling these cells that something
is wrong. Eventually, this process
results in inflammation, a common
physiological
response
that
occurs when our body identifies
something as bad for us (Figure
4). Thus, the IL-6 protein is one
of several that is often used to
study inflammation. This pathway
can also affect how we sleep. This
means that not only does poor
sleep quality cause inflammation,
but that the proteins like IL-6 also
play a role in further worsening
sleep. Specifically, less time will
be spent in restorative stages of
sleep previously described, such as
slow-wave sleep. A cyclical pattern
of ECD and pro-inflammatory
proteins can exacerbate any
previous conditions or cause new
inflammatory diseases to arise11.
Symptoms of these diseases may
include chronic pain, redness,
stiffness, or damage to previously
healthy tissue.
The most common example in
which people experiencing shortterm ECD is as a result of jet lag.
Women also endure ECD when
going through menopause. More
long-term circadian disruptions can
be a result of certain medications
that cause people to stay up or
as a consequence of shift work.

ECD can lead to serious sleep
disorders such as chronic insomnia.
Moreover, especially in the case
of long-term disruptions, people
may become at risk for mood
disorders like depression or chronic
inflammation8.
In order to make informed
decisions about getting effective
slumber, you should take into
account the consequences of
disrupting normal sleep patterns.
Some people don’t have the option
of choosing when to sleep. This
is the case for shift workers and
ranges from occupations such as
nurse to pilot. Knowing that there
are potentially detrimental effects
of such poor sleep, there has to be
something that we can do to help.

What Can Be Done to
Treat Environmental
Circadian
Disruptions?
Most
people
do
not
consciously make the decision to
disrupt their sleep even without
knowing that it can lead to a proinflammatory immune response
and other serious health effects.
It is fairly easy to notice when you
get poor quality sleep because
your body feels the toll. So, what
is the scientific community doing
to help? In order to find solutions,
we can first separate the problem
into two categories: the brain and
spinal cord versus the nerves in the
rest of the body.
Disrupted sleep is harmful
as it elicits neuroinflammation.
Targeting the brain requires a
different approach than the rest
of the body. This is because the
brain is so well protected in our
body that we cannot reach it in the
same ways that we would for the
rest of our organs. One current
target for neuroinflammation is
microglia. These brain cells act as
the first responders of the brain

and are responsible for activating
the immune system when anything
goes wrong. Microglia have IL-6
receptors. If we can stop the
binding process of the IL-6R protein
to its receptor, gp 130, as shown
in Figure 1, then we can block the
rest of the pathway. This can stop
the downstream domino effect
that causes inflammation from
ever occurring. Current research
is being conducted on how to
best inhibit this signal without
affecting the normal and healthy
immune functions that microglia
provide for our brains11. While
no specific treatments have been
developed, this is a promising area
of therapeutic research.
Circadian disruptions can also
cause inflammation in areas outside
of the brain, such as the digestive
tract. Issues with gaining nutrition
from properly breaking down food
can arise through oxidative stress,
a process that creates harmful
unstable atoms in the gut and
hinders the surrounding nerves
from doing their job. ECD also
plays a role in the availability of
healthy bacteria in the gut. Recent
studies show that certain diets
like intermittent fasting can help
by eliminating such factors. This
is because the amounts of these
healthy bacteria are also regulated

Figure 4. Overview of IL-6 pathway resulting in
inflammation11
© 2016 by Elsevier. Adapted with permission.
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by what and when you eat. This
method has shown promising results
in reducing gut inflammation. It
allows for food to be processed
more smoothly without causing
harmful side effects13.
As we have seen, disrupted
sleep can cause issues throughout
the body and people are working
together
to
find
solutions.
Interventions are not limited
to biological therapies and
scientists are not the only people
getting involved. There are also
numerous policy changes in the
works. Various fields are creating
stronger mandatory regulations
on work hours for employers. The
National Institute for Occupational
Safety and Health (NIOSH) has
provided suggestions for industries
to implement policies, drawing
from scientific research on sleep
and circadian rhythms. Although
some industries such as airlines
have already made notable
changes for pilots, other fields
such as manufacturing, retail, and
agriculture have yet to do so. It
would be safe to say that enforcing
such regulations can benefit the
employees’ health in addition to
their performance on the job14.

Why Is Sleep Still So
Mysterious?
Humans sleep for about a third
of every day. That is a considerable
amount of our lifetime. We have
seen that some aspects of sleep
are becoming well understood.
However, there is so much more
that is yet to be uncovered. In
some ways, our question of what
is considered to be effective sleep
will never be answered. Sleep is
incredibly specific to individuals
and it is important to do what feels
right to you. However, keep in mind
the dangers of getting unhealthy,
disrupted sleep.
Ekrich’s examples of waking
up between two sleeps could be
considered a disruption in sleep,
and so could the various alternative
sleep schedules that people follow.
Perhaps Leonardo Da Vinci and
Issac Newton have something in
common and it is not just that they
are icons in their respective fields.
This makes us stop and wonder if
people all those years ago were
experiencing the inflammation
and other side effects that we
are able to study scientifically
today. We now have the skills and

tools to understand the effects of
disrupted sleep on a molecular
and behavioral level and sharing
this information with the world
is important. Without doing so,
people cannot implement changes
in their own lives or create policies
to help us lead healthier lives.
Scientists
are
constantly
working to learn more about areas
of sleep that we currently know very
little about, not just disrupted sleep.
As a rapidly expanding area of
research, new tools and innovative
ideas are being implemented in this
moment. Sometimes, advancing
into the future requires taking
a look at our past. Ekrich tied
together many interesting historical
aspects of sleep and the role it
once played in society; knowledge
that would have otherwise been
forgotten. So next time you wake
up in the middle of the night, fear
not. Your ancestors likely got up in
the middle of the night and future
generations will continue to do so
as well. It is just the nature of our
biological clockwork.
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harmacological science
has
produced
many
miracles in the last 70
years or so. From the invention of
antidepressant drugs to Narcan, it is
clear that major progress has been
made towards the treatment of
historically untreated or mistreated
conditions such as depression,
anxiety, and addiction. All is not
perfect in the realm of psychiatry,
however, as approximately 17.3
million American adults suffer
from depression in a given year,
approximately 40 million suffer
from anxiety, and, in 2017 alone,
approximately 19.7 million over the
age of 21 suffered from a substance
abuse disorder. What’s worse,
according to a study conducted by
the Depression and Bipolar Support
Alliance, about 50% of unsuccessful
treatment for depression is due to
medical noncompliance, meaning
that patients are not taking their
medicine as prescribed. The fight
to treat mood disorders is not
won yet, and it may be time to try
approaches that were previously
declared
off-limits.
Enter:
psychedelics.
In 2006, researchers at Johns
Hopkins University published a
breakthrough study on the sustained
qualitative effects of a single
session of psilocybin (popularly
known as magic mushrooms) use
in a clinical setting1. The people
that participated in this study
were primarily college-educated,
employed adults who reported
not having used psychedelics
in their lives prior to the study.
Furthermore, the participants were
not financially compensated for
their participation in the study,
which is quite uncommon. These
participants made time in their
busy schedules to participate in
this study for the primary reason
that they were interested in the
psychedelic experience.
The researchers in this study
were well aware that doing clinical
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research using psychedelics is not
an easy sell, so they took many
precautions they felt would protect
both the participants and the
researchers from the deleterious
effects of conducting research with
such substances. Participants met
with the researcher that would
monitor their session four times
prior to taking the psilocybin
and four times afterwards in
order to establish a rapport with
the researcher that would make
them feel safe during the height
of their psychedelic experience.
The dosage of psilocybin was
determined using data from several
previous studies and intended to
be a high-safe dose that would
occasion a psychedelic induced
hallucinogenic state, also known
as a trip, but not so high that there
would be any reason for concern
about the patient. Participants and
their monitors would spend the
entire trip (an eight hour session, in
total) in a special living room-style
space arranged specifically for this
study, complete with calming music
and mood lighting. All of these
steps were intended to minimize the
chances that someone experiences
the negative aspects of a trip, a
carefully made decision that we will
return to later.
Breaking
the
norms
of
psychedelic research, this study was
the first of the new generation of
research to explore the behavioral
effects of psychedelics rather than
just investigating their biochemical
mechanics. What they found would
lay the groundwork for those that
would follow in their footsteps and
pave a new path in the search for
treatments for mood disorders.
The team found in both the twomonth and the 14-month followups that individuals reported their
experience had fundamental and
overwhelmingly positive effects on
their lives. The average participant
reported that they had felt more
altruistic and vastly more likely

to be positive, in general as well
as specifically about themselves.
Moreover, the average participant,
all of whom were reportedly new to
psychedelics, rated this experience
among the most significant
spiritual experiences of their lives.
And the real kicker: they rated this
experience among the ten most
meaningful experiences of their
lives2. While this is only one study,
it does cause one to wonder why
more research isn’t done in this
area. To understand that, one has to
look at the history of psychedelics
in America.
The
story
of
American
psychedelic use begins, oddly
enough, in the year 1943 in
Switzerland, with a chemist by
the name of Albert Hofmann. An
employee of Sandoz Laboratories,
Albert spent his days synthesizing
derivatives from plants and fungi,
and led an unremarkable life. But on
April 16, 1943, Albert inexplicably
decided to revisit a compound he
had synthesized four-and-a-half
years prior when he was working
on derivatives of lysergic acid, a
compound produced in wild ergot
fungi. Specifically, he chose to
revisit LSD-25, so named because
it was the 25th compound he had
derived from lysergic acid (LS) and
because its characteristic shape
included diethylamide (D). It was
on this day that he accidentally
absorbed some of it through the
Psilocybin Mushrooms
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tips of his fingers and began the
first documented human acid trip.
This incident triggered a
cascade of effects that went on
to transform the face of American
culture. In 1949, LSD made its way
to America, where it was hailed as
a psychotomimetic, or a simulator
of psychosis. Regardless of the fact
that the understanding of how the
drug worked on a physiological level
to produce its effects was limited,
LSD was distributed by Sandoz to
therapists in the states to facilitate
more effective psychotherapy in
patients with depression and/
or anxiety, particularly related to
death and alcoholism. A recent
survey of the studies conducted
during this period from 1949-1973
found that there were generally
positive outcomes with respect to
unipolar mood disorders (major
depression or anxiety, for example),
with 79.2% of patients judged to
improve when treated with either
LSD or mescaline, a psychedelic
compound derived from the buds
of certain cacti3. Another more
recent review of the literature
from this era found that patients
seeking treatment for alcoholism
had a significantly better chance to
improve over a period of months
when treated with LSD than those
who were not4.
At this point, you might be
wondering how it is possible
that these drugs that are heavily
associated with socially deviant
behavior like living in communes,
dropping out of the workforce,
and paranoid outbursts could
possibly have a beneficial effect
on an individual’s life. Well, we’ll
talk about how these drugs that
seemed to have such potentially
positive effects came to be seen
this way, but first a little discussion
of the neuroscience of the situation.
Since it emerged in the late
19th century, neuroscience has
been permeated by a belief that
colors everything that it has been
25

Swiss chemist Albert Hofmann
By Stepan from Wikimedia (CC BY-SA 2.0 de)

able to say about the mind: the
mind is what the brain does.
That means that all of the mood
disorders that people suffer from
are the results of things going
askew in the brain. The brain is
basically a big network of neurons
and other cells working together
to process stimuli from the outside
world and turn that data into a
response the body can then enact.
The easiest way to distinguish the
myriad different networks that exist
in the brain when it comes to talking
broadly about families of disorders
is by talking about what messenger
molecule these networks use, also
known as neurotransmitters.
Now for Neuro 101 in a few
sentences. Neurons communicate
with one another by releasing
neurotransmitters from one end
of their body, called the axon, into
what is known as the synapse. The
synapse is a miniscule gap, just wide
enough to allow for the flow of the
fluid-matrix-of-choice for whatever
type of neuron you are observing
between the two neurons. The
area of the next neuron that is
specifically designed to receive the
neurotransmitter signal is called the
dendrite. The neurotransmitters are
released from the end of one axon
and they bind with the dendrites
of the next neuron in their path.

Due to the directionality of this
interaction we call the neuron that
releases the neurotransmitters
the presynaptic neuron and the
neuron that receives them the
postsynaptic neuron. After a little
while, the neurotransmitters that
haven’t bound to the postsynaptic
neuron are dealt with in a couple of
ways: they are degraded by special
molecules in the synapse or they
are reabsorbed by the presynaptic
neurons. It’s important to keep in
mind that the things moving around
are all inanimate particles which
cannot, once sent into the synapse,
decide to go anywhere of their own
volition. Rather, these movements
are entirely probabilistic, which is
a challenge for those who would
like to manipulate the behavior of
these dang things. Right then, back
to our discussion.
Generally,
we
in
the
neurosciences have been able to
narrow down the disorders that
affect your mood to the functioning
of networks in your brain that all
have one thing in common: they
all employ the neurotransmitter
serotonin. Serotonin is generally
thought to be closely linked with
mood regulation in the central
nervous system5. It works by
decreasing the likelihood that the
neuron it communicates with sends
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a signal of its own, also known as
suppression. This comes in handy in
areas where an increase in activity
would cause you trouble. For
example, when your amygdala isn’t
appropriately suppressed, you are
likely to experience an unhealthy
amount of anxiety that doesn’t
match the environment that you
are in6. Healthy levels of serotonin
help keep networks like this one
quiet until it’s time to get riled up
for a good reason.
Drugs that are typically
prescribed to people diagnosed
with mood disorders can work
on these networks in a variety of
ways. The most well-known and
common drugs prescribed to treat
depression belong to the family
of selective serotonin reuptake
inhibitors (SSRIs). These drugs
work by closing the channels
on the presynaptic neuron that
are designed to reabsorb the
serotonin it released. This allows
for the serotonin to stay in the
synapse for longer and have a
better chance of suppressing the
postsynaptic neuron. Another class
of these drugs, monoamine oxidase
inhibitors (MAOIs), operate by
inhibiting the molecule monoamine
oxidase. Dear reader, it is only the
intrepid biochemists among us that
don’t get a sense of dread from
reading a name like that, but fear
not: it is actually rather simple.
All monoamine oxidase does
is deactivate neurotransmitters
known as monoamines, to which
serotonin belongs. Most of the
popular antidepressants operate
by some variation of these two
mechanisms,
either
inhibiting
reuptake or inhibiting degradation
of serotonin. They do not, on their
own, increase the firing of the
neurons that use serotonin. They
simply improve the functioning of
these neurons when they do fire.
So how do psychedelics fit
into all of this? Well, as you might
guess, they primarily act on systems

that use serotonin. They do so,
however, in a very different manner
than any of the antidepressants
discussed above. Rather than by
simply facilitating and enhancing
the normal behavior of these
serotonin systems, they actually
mimic the behavior of serotonin in
the synapse and attempt to bind
to and activate the same receptors
that serotonin does. Notably, they
do this even in microscopic doses
(a normal dose of LSD ranges from
50-300 micrograms—millionths of
a gram). While this difference may
seem trivial at first, the implications
for the brain—and mood—of
anyone who takes these drugs are
profound.
As
opposed
to
typical
antidepressants, these drugs don’t
have to wait for the serotonin
systems to work on their own.
Simply introduce a little LSD, or
whatever your psychedelic of choice
might be, to the brain and watch
those circuits hum as though they
were working all on their own. This
helps to explain why the effects of
psychedelics are felt immediately,
whereas it takes several weeks in
most cases for antidepressants
to begin to have their behavioral
effects. This is basically where the
understanding of psychedelics got
to before the public perception
of them shifted and the political
pressure mounted significantly
enough to banish them from the
minds of mainstream scientists.
Researchers in the first wave were
not able to successfully explain the
long-term beneficial effects that
were observed in a minimal number
of exposures to psychedelics
before the political tide turned
against further exploration. Why
did this come to pass? There are
many factors at play, and it would
be unfair to cast this at the feet of
any one person, but it is useful to
take up the story of one person
and follow it through the end of the
first wave of psychedelic research

in order to illuminate some of the
pitfalls of psychedelic research
around which the current wave
of researchers should take care.
This character is one of the most
infamous in the history of popular
science: Timothy Leary.
If you’ve heard the expression
“turn on, tune in, drop out,” then
you have been exposed to a
significant aspect of what made
Leary so polarizing. In 1962, Leary
was a professor at the Harvard
School of Psychology, and ran the
Harvard Psilocybin Project. The
problem with Leary was that he
was a public preacher of the virtues
of psychedelic experience before
there was a solid grasp of the
potential dangers of psychedelic
use, the proper procedures of their
administration, and the things that
they might actually be able to treat.
Amidst, albeit unverified, reports
that LSD was causing people to
leap from buildings believing
themselves able to fly or committing
horrible acts of violence, Leary was
publicly espousing bad science. He
entreated the populace to indulge
in poorly understood chemicals
without the supervision of trained
researchers, paying no mind to the
potential dangers. This drug was
classified as a psychotomimetic
when it first arrived in the US, after
all. For his public pronouncements
and failure to follow through on his
obligations as a researcher, he was
removed from his post at Harvard,
and the Harvard Psilocybin Project
was shuttered.
This
didn’t
stop
Leary
from being a prominent public
figure, much to the detriment of
psychedelic research across the
country. While there was certainly
reason to think that psychedelics
were a potent treatment for a wide
variety of disorders, Leary’s lack of
discretion and scientific scruples
were responsible for a large part
of the change in public perception
of these new drugs. Nixon once
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Figure 1. Comparison between mood disorder treatment with prescription drugs (top) versus psychedelics (bottom)
Original image by Adam Roesner

called him “the most dangerous
man in America.” By 1970,
psychedelics, including LSD and
psilocybin, were declared to be of
no medical use and to pose a high
risk of abuse under the Controlled
Substances Act. This marks the end
of the first wave of psychedelic
research. It would be a long time
before we could come to a better
understanding of how these drugs
work to produce the therapeutic
effects that had been unequivocally
observed.
A minute amount of psychedelic
research went on between 1970
and 2006, and almost none of it was
focused on clinical applications of
the drugs. This was due to a variety
of reasons, but not the least among
them that, due to the scheduling
of these drugs, obtaining a
license to conduct research on
human participants was extremely
difficult, and the stigma around
doing this research was such that
serious researchers who might be
meritorious enough to receive one
tended to shy away from it for fear
of it staining their reputations. In
2006, Roland Griffiths became the
first of the new wave of psychedelic
researchers to put his well27

connected neck out and reopen
the American investigation of the
behavioral effects of psychedelic
compounds with the study that
opened this article. But where has
this new wave gone since then?
Since Griffiths cracked open
the door to this area of research
in 2006, a handful of studies have
been published investigating the
clinical effects of psychedelics
have been done on a wide variety
of conditions from anxiety related
to terminal illness7–9 to obsessivecompulsive disorder10, with a strong
trend towards positive outcomes.
As the scope of the types of
conditions that these drugs can
treat expands, so too does our
understanding of how these effects
are achieved.
Some
researchers
have
proposed
that
the
reason
psychedelics are so effective and
efficient at engendering longterm improvements in behavior
is related to the effect that they
have on your brain’s default mode
network (DMN)11,12. This network
is largely responsible for what
you are thinking about when you
aren’t thinking about anything in
particular13,14; that is, it turns off

when you start to intentionally
do something and turns back on
when you stop and return to quiet
repose. An advantage of doing
clinical research in this modern
era is that we have much fancier
machines and we can take really
high-def snapshots of brain activity
during a psychedelic trip than we
used to. One study endeavored
to do just that and found that the
DMN was significantly thrown
out of its normal rhythms11, which
has previously been shown to
be related to personality15 and
disorders of thinking16. While this
is not a comprehensive explanation
of how psychedelics function to
achieve the effects that have been
observed time and time again,
it is certainly a step in the right
direction.
“Okay,” you might be thinking
to yourself, “but what about those
reports you mentioned earlier of
people going crazy and doing
heinous things while under the
influence of these drugs?” Well,
there’s not a lot of evidence to back
up these stories. One should always
use caution when considering
any new medical intervention
and psychedelics are no different.
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One study17 asked nearly 2000
people about their worst bad trip
experience after taking psilocybin
and found that about 7.6% of
people sought treatment for
enduring psychological symptoms
from their bad trip. Furthermore,
three
individuals
reported
sustained, impairing psychotic
symptoms brought on by the bad
trip, leading to diagnoses ranging
from schizophrenia to bipolar
disorder.
Despite
this,
84%
of
respondents
endorsed
the
experience as overall beneficial,
and 60% said that it was among
the top ten most psychologically
and
personally
meaningful
experiences of their life. The
study also reported that the rates
of these extremely challenging
experiences
are
significantly
lowered in laboratory research
where drugs are administered
in a controlled environment by
experts (three of 250 participants
reported negative impact on their

life due to the experience, one of
which was resolved within a week,
one of which was undiagnosed
hyperthyroidism, and one of which
was resolved by the 5 month
check-in). All of that is to say that
there is some risk, however unlikely,
associated with psychedelic use,
and this article should not be taken
as an endorsement of wanton
psychedelic use. With more data
we will more readily be able to
say what the risk factors are. Until
we can, any use of psychedelics
without the supervision of experts
carries an implicit risk.
The aggregate of the studies
that have been conducted since
2006 yields some interesting data
demonstrating the potential for
psychedelic therapy to become a
viable alternative to more standard
medical interventions. In fact, there
are some ways in which the benefits
offered by psychedelics are
preferable to typical drug courses,
and a comparison between the two
can be seen in figure 1.

We
have
reached
the
contemporary moment in the
story of American psychedelic use.
We’re up to date. That means that
we don’t know where the story goes
from here, and that we largely get
to decide. When Albert Hofmann
decided to take a dose of LSD, he
had no idea where it was going
to go either, but he braved the
unknown and it changed the world.
In that spirit, and in the absence of
sufficient reason to act otherwise,
we should move forward into the
next chapter of the story not with
fear, but with excitement and
courage. Timothy Leary was right
to be excited by the prospects of
psychedelic therapy; let us learn
from him and move forward with
cautious optimism. The greatest
advances in the history of human
understanding were made possible
by the intrepidation of those who
chose to take them on, and great
rewards were reaped for their
fellow man in the process.
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Illustration of a girl masking autism
“puzzle” by Psyon from Wikimedia (CC BY-SA 3.0). Adapted by Sarah Hudson

P

icture a child with autism.
How do you know they
have autism? Do they
act a certain way? Do they look a
certain way? What is the gender of
the child you imagined?
Chances are, when you
imagine a child with autism,
you imagine a boy, maybe even
someone you know. If so, you are
in the majority. Autism, or Autism
Spectrum Disorder (ASD) as it’s
been referred to in more recent
years, is a developmental disorder
with a diagnosis ratio of around four
to five males for every one female
diagnosed1,2. While it is common to
see a higher prevalence of males
with developmental disorders, the
disparity between diagnosis ratio
of males and females begs an
important question: Is it true that
ASD affects males more frequently
than females, or have the ways in
which we researched and defined
autism made it so that we only
know how to recognize autism
in male populations? Recent

discoveries
in
developmental
neuroscience suggest the latter,
and have acknowledged the
problematic nature of the fact that
almost all of the data that we use
to understand autism has been
performed on almost exclusively
male participants3,4. This wouldn’t
be an issue if the diagnosis rate
of autism was identical for both
men and women. However, the
discrepancy between the ratio of
men and women diagnosed with
autism is significant enough to
question whether the criteria for
autism diagnosis is accurate and
applicable to all populations. To
understand this inconsistency, we
need to understand the history of
autism diagnoses.

History of Autism
The discovery of autism is
usually associated with Austrian
psychiatrist Leo Kanner, who began
seriously studying the disorder in
the 1940s3,5. However, descriptions
of autism in psychiatry date back to

the beginning of the 20th century.
In 1911, Swiss psychiatrist Eugene
Bleuler, described people with
autism as having a very severe form
of schizophrenia, a disorder he
also discovered3. Bleuler described
autistic individuals as people who
suffered from ‘infantile wishes’
and attempted to avoid reality by
creating their own hallucinated
fantasies3. From then until more
dedicated research in the 1940s,
autism was described as a
symptom of a specific and severe
form of schizophrenia3. It wasn’t
until Kanner began acknowledging
autism as its own unique
developmental disorder that more
accurate descriptions of autistic
symptoms began. Kanner described
symptoms of unnecessary word
repetition, extreme loneliness, and
an ‘anxiously obsessive desire for
the maintenance of sameness’3.
He also noted cases of individuals
with
autism
symptomatology
and
impressive
intelligence,
acknowledging the disorder as
one of development rather than
cognition.
Kanner’s
research
sparked the movement to further
understand behaviors of autism
over the next few decades. Yet
it wasn’t until the early 1980s
that autism was included in the
Diagnostic and Statistical Manual of
Mental Disorders, more commonly
known as the DSM, version III4.
This meant that autism was not
considered a condition in its own
right, but a symptom of more severe
psychiatric disorders. This lack of
dedicated research means that the
understanding of autism in these
four decades was extremely limited,
which allowed for uneducated and
often cruel assumptions to be
perpetuated about people affected
by the condition. For many years,
professionals cited cold parenting
techniques as the cause of autism,
further propagating the negative
stigma behind the disorder. In
addition, as was common practice
30
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in the 20th century, women were
scarcely included as research
participants
for
psychiatric
disorders such as autism, and were
usually purposefully excluded from
research because of the belief
that hormonal changes in women
would confound the experimental
results. Because of this lack of
inclusion in research, the female
experience of autism was rarely
acknowledged in academia. Even
Hans Asperger, a famous early
autism researcher and namesake of
‘Asperger’s Syndrome,’ believed at
one point that autism did not affect
females at all, a viewpoint that he
did eventually change6.
Once autism was eventually
included in the DSM and was
validated
as
an
observable
disorder, diagnosis rates increased
exponentially. With the new
inclusion, more individuals formerly
diagnosed with schizophrenia and
a host of personality disorders
were properly diagnosed with

autism3. This increase in diagnosis
leads to a marked improvement in
social awareness of autism and the
formation of an autism community.
Today, there are many successful
people who live with autism, and
the stigma around the diagnosis
has lessened significantly in the
last few decades. Nevertheless,
our understanding of ASD is still
growing each year, and each new
discovery is important for the
understanding of treatment of the
community as a whole.

What Is Autism?
The idea that autism may be
expressed differently between
men and women begs important
questions: Are males and females
suffering from the same disorder?
How can we be sure that what we
are observing is autism?
Although
the
possible
nuances in the expression of
autism are innumerable, we

Side view of the right hemisphere of the brain. Brain regions affected by autism are shaded: frontal
cortex (yellow), parietal cortex (blue), limbic system (green), and the cerebellum (red)
By Mike Birkhead from Wikimedia (CC BY 4.0)
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know that, at its core, autism is a
developmental psychiatric disorder
that affects communication and
behavior1. This means that the
symptoms of autism stem from
some hindrance in an individuals’
ability to communicate and behave
compared to a neurotypical, or
‘normally’ functioning, individual.
As we will soon explore, the
symptoms commonly expressed in
both male and females with autism
fall into this category. Additionally,
there are distinct neuroanatomical
differences that are observed in
autism that are expressed in both
males and females with ASD.
Recent research, however, seems to
have uncovered slight sex-related
differences in the neuroanatomy
of ASD that could be connected
to the differences in symptoms
exhibited by males and females.

The Expression
of Autism as We
Understand It
Autism,
as
previously
discussed, is a spectrum disorder.
This means that it is characterized
by a broad range of symptoms that
not every individual diagnosed
with autism may suffer from.
Therefore, symptoms displayed by
individuals with the same diagnosis
of ‘autism’ can be as mild as
difficulty making eye contact and
reading social situations to severe
epilepsy and complete lack of
vocalization1. Even with this broad
range of possible symptoms, a few
specific, core symptoms that have
been consistently attributed to
ASD throughout the years, most
of which you probably recognize.
This includes difficulty making eye
contact, repetitive or obsessive
behaviors, unusual fixations on
specific subjects or items, difficulty
with imaginative play, lack of facial
expressions,
extreme
sensory
sensitivity, and difficulty or inability
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to behave appropriately in social
situations1. These are also among
the most universally recognized
symptoms of ASD, and are some
of the main behaviors noted when
diagnosing an individual with ASD7.
However, while these findings are
well-established, we must always
keep in mind that almost all of the
studies used to describe autism
come from observing the male
autistic experience

Neuroanatomy of
Autism
One of the most popular
explanations related to the
neuroanatomy
of
individuals
with ASD is that it is caused by
improper connectivity between
neurons in certain brain areas8.
This idea comes based on the
understanding that, during early
childhood development, children
with autism experience an aboveaverage growth of neurons and
neural connections in the brain1,
8
. Typically exponential growth
of neurons in children is normal
during development, as children
are learning new concepts and skills
constantly. During late childhood,
neurotypical brains go through a
process called ‘pruning,’ in which
neural connections in the brain
that are deemed unnecessary or
redundant are removed to conserve
energy, commonly known as the
“use it or lose it” phenomenon.
However, the brains of children
with autism do not adequately
prune, or remove, the connections
made during development, leaving
autistic individuals with more neural
connections than are necessary for
a particular area8. While having an
abundance of neurons may not
sound like a bad thing, having too
many neurons can make it difficult
to send signals efficiently from one
neuron to the next. Imagine it like
this: you and your many siblings
are trying to tell your mom a story.

When only one person is telling
the story, it is much easier to follow
along the timeline. However, when
everyone starts speaking at once
to try to convey their version of the
story, it becomes a lot more difficult
to follow. This over-excitation of
neurons can cause severe problems,
such as seizure disorders, in some
autistic individuals.
Although there are many
specific brain areas of the brain
that are responsible for the
countless possible symptoms of
ASD, the general areas associated
with autism expression are the
frontal lobes, the limbic system,
the cerebellum, and the parietal
cortex9. Although it is difficult
to ascribe specific symptoms
to specific areas, we do know
generally how improper function
of certain areas of the brain are
related to general abnormalities
related to autism. The frontal
lobes are responsible for executive
function and decision making, and
impairments in this area usually
revolve around difficulty with
comprehending social norms and
the desire for consistency and
sameness in autistic individuals,
such as only being able to eat
meals at specific times of the day9.
The limbic system is responsible
for emotional regulation, and
dysfunction of this system in autism
is associated with social deficits
and increased anxiety7,9. The
cerebellum is a large structure
that sits below the brain and is
responsible for many functions,
including movement regulation,
coordination, balance, speech, and
the sense of where your body is in
space, and dysfunction in this areas
likely results in issues with fine motor
control and ability to understand
body language9. The parietal
cortex is responsible for a host of
functions including integration of
sensory information and movement
coordination. In autism, improper
function of the parietal cortex leads

to the extreme sensitivity to certain
sensory stimuli9. Very broadly, these
areas can be associated with the
behavioral abnormalities commonly
observed in autism. There has,
however, been promising research
pointing to a sexual dimorphism in
the neuroanatomy of ASD.

Sex and Its
Relation to Autism:
Neuroanatomy of Sex
Differences
As the understanding of ASD
grew in the 21st century, so too did
the acknowledgement that sex may
be a defining variable of autism
symptomology. Within the past
decade, more focus and funding
has gone into understanding the
sex-specific neuroanatomical and
behavioral differences observed
in autism, with promising results.
Consistent findings show sexrelated
differences
in
the
neuroanatomy of females with
ASD that correlate with differences
in certain behaviors. Specifically,
neuroimaging research has found
consistent sex-related differences
in the size of the limbic system
and cerebellum in females with
ASD compared to their male
counterparts7,10,11. Based on these
sex-based variations, we can
attribute some of the behavioral
differences observed in women with
ASD. Although women with autism
do show signs of increased anxiety
compared to males, the difference
in limbic system size could also be
attributed to the more impacted
social deficits seen in males with
ASD7. Additionally, differences
in cerebellar are consistent with
differences in fine-motor control
between men and women, with
men showing more disturbances in
fine-motor function than women10.
These, however, are not the only
behaviors that distinguish autism
expression in men and women.
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Sex-Based
Differences in
Expression
Although
we
are
able
to attribute some sex-based
differences in autism symptomology
to differences in neuroanatomy, the
research is still too novel to attribute
all observed behavioral nuances to
neuroanatomical differences. It is
commonly accepted that behaviors
such as trouble making eye contact
and
repetitive,
stereotypical
gestures are hallmarks of ASD1.
Nonetheless, increased focus in
research on the female expression
of ASD has questioned the
universality of these symptoms.
Modern research has found that,
when compared to boys with ASD
of similar intelligence, girls with
ASD showed far less expression
repetitive stereotypic behaviors,
in addition to being less engaged
with “unusual” interests, showing
far more interest in subjects similar
to their neurotypical peers12-15.
Additionally, girls with autism
showed far more imaginative
play, use and recognition of facial
expressions, and exhibited more
instances of spontaneous echolalia,
or unnecessary word repetition,
than males with ASD13-15. Girls with
autism also seemed to express
more of the emotional symptoms
related to ASD, such as anxiety and
depression, when compared to
boys12-15. Even though researchers
aren’t totally clear with why these
differences in symptoms occur,
they have a very real impact on the
women they affect.
Contemporary findings of
sex-related differences in ASD
patients have also uncovered a
completely new symptom of autism
that had not been considered in in
males: a behavior termed by the
autistic community as “masking”
or “camouflaging”2,8,16,17. This is
best described as the way in which
33

individuals, usually women, with
autism constantly hide their autistic
traits when interacting with others,
like keeping up a continuous
public façade17. Many people can
empathize with the idea of feeling
like a different person in public than
in private. However, for women
with autism, this feeling is ever
present when they’re interacting
with their peers, and this struggle
of constantly feeling the need to
monitor and control their behavior
is described as exhausting. One
mother describes her daughter’s
own struggle with this:

“[W]hen she’s doing
her job she’s a very
professional lady, but
ordinary things, ordinary
life exhausts her. She is
exhausted just by the
business of running an
ordinary life”12.
This constant feeling of fatigue
just by merely existing in public
is all too familiar in women with
autism, and for those who lack the
proper diagnosis, this exhaustive
loneliness can feel debilitating.

Problems
Concerning a Lack
of Understanding of
Female Autism
Although
there
have
been promising discoveries in
understanding the sexual dimorphic
nature of ASD, our understanding
of the female expression of autism
is still in its infancy. As we previously
mentioned, the commonly cited
ratio for autism expression in males
vs females is around four or five to
one18. However, when we consider
the level of functioning an individual
has, the ratios become even more

concerning. In high-functioning
ASD, the diagnosis ratio is around
nine men diagnosed for every one
woman diagnosed; conversely,
in low-functioning ASD, the ratio
is a lot closer, with the diagnosis
rate being two men diagnosed
to every one woman1. This
inconsistency between high and
low-functioning ASD individuals is
even more telling of the difficulty
of diagnosing females with lesssevere ASD. The belief behind
these extreme discrepancies is
as simple as this: low-functioning
ASD is easier to recognize. Since
symptoms of low-functioning ASD
usually involve lack of an ability to
vocalize, seizures, and self-harming
behavior, the signs for both males
and females are much more
conspicuous to their caretakers.
As we continue to emphasize,
our
understanding
of
the
nuanced behavioral differences
exhibited by females with ASD
has barely scratched the surface.
It is not uncommon for psychiatric
professionals to not recognize and
therefore not diagnose a woman
with ASD. As one woman describes:
“When I mentioned the
possibility to my psychiatric nurse
she actually laughed at me…I
asked my mum, who was a [general
practitioner] at the time…if she
thought I was autistic. She said, ‘Of
course not’. At the time, a good
10 years ago now, there just wasn’t
much information about how girls
presented, and from what she
knew, I was nothing of the sort”2.
Because of this, it is not
uncommon for women to go
undiagnosed until middle or
late adulthood, and often, the
descriptions of their experiences
pre-diagnosis are heartbreakingly
similar. Stories are often riddled
with
instances
of
improper
diagnoses or complete dismissal
from psychiatric professionals2,16.
These women express common
feelings of weariness in their
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diagnosis, feeling as if they are
constantly being forced to advocate
for themselves in their pursuit of
effective treatment. This unease is
only heightened when it comes to
functioning in public, when each
human interaction feels like an
uphill battle to appear ‘normal’:
“It’s very draining trying to
figure out everything all the time,
everything is more like on a manual,
you’ve got to use one of those
computers where you have to type
every command in”2.
There is also a common
feeling of a loss or total absence
of identity when women describe
their experiences with masking prediagnosis:
“I honed something of a
persona which was kind of bubbly
and vivacious, and maybe a bit dim,
because I had nothing to say other
than adult novels. So I cultivated an
image, I suppose, that I brought out
to social situations as my partner’s
girlfriend, that was not ‘me’”2.
Masking is often accompanied
by feelings of loneliness, as
individual’s feel as if interacting
as their authentic self will lead
to social isolation. Nonetheless,

whether masking is an additional
symptom of ASD or a coping
mechanism to fulfill an individual’s
need for connection, the emotional
consequences of masking are
extremely real and important in
understanding how to treat all
individuals with ASD17.

Where Do We Go
from Here?
The diagnosis of ASD may seem
daunting to a neurotypical person,
but for a woman or girl struggling
in silence, it can be extremely
empowering and a positive lifechange. Increased social awareness
of autism spectrum disorder has
allowed for more individuals on the
spectrum to be vocal about their
experiences with autism and how
their diagnosis has impacted their
life in a positive manner:
“Something that I really
appreciate about having the
diagnosis is actually being in this
club now where people talk about
their experiences and having so
many echoes of my own”2
Famous individuals on the
spectrum such as animal scientist

Temple
Grandin
and
Greta
Thunberg actually cite their autism
as a kind of superpower, and say
that their condition helps them
to see the world differently than
other people. However, although
there are many inspirational stories
of higher-functioning individuals
accepting and taking pride in their
diagnosis, many individuals who
function at the lower end of the
spectrum and those who remain
undiagnosed still struggle with
the symptoms of ASD. Continued
research into the potential causes
of ASD are vital to both the
improvement of autism treatment
and a more comprehensive
understanding of what autism looks
like in all its forms.
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Optogenetic Treatment of Blindness
By Mara Kaspers
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e are moving to a
world where a single
injection into the
eye can restore vision of the blind.
In September of 2018, a patient
suffering from retinitis pigmentosa,
a common disease resulting in
complete blindness, was the first
to receive optogenetic treatment
designed to restore their vision.
This patient at the UPMC Eye
Center in Pittsburgh is part of a
pioneer clinical trial carried out
by biopharma company GenSight
Biologics. What are some of the
recent developments in molecular
biology that have made this therapy
possible? What is so novel about
this technique and what are some
things to consider before starting
large scale implementation?

What Is
Optogenetics?
Optogenetics is a very young
lab technique first developed in
2005 by a group of researchers
at
Stanford
University
and
spearheaded by Dr. Karl Deisseroth.
The technique allows researchers
to control neurons, the building
blocks of the brain, with the use of
light by changing the genetic code,
or blueprint, of a living organism.
Dr. Deisseroth and his team were
inspired by a certain type of algae
that has the ability to detect light
with an endogenous light-sensitive
protein called Channelrhodopsin-2
(ChR2). These algae use this
information to swim towards the
light, which is beneficial for certain
biological processes and like all
proteins, Channelrhodopsin-2 is
coded for in the algae’s DNA. Dr.
Deisseroth and his colleagues
were successful in extracting that
exact piece of DNA and placing
it into neurons of living organisms
like mice and eventually people.
When expressed in neurons, these
algae-derived
opsins
operate
much like a switch, allowing the

SCIENTIFIC KENYON

researcher to activate or silence
the neurons simply by shining
light on them. This switch is very
fast and can change brain activity
within milliseconds. This technique
was so innovative and promising
for the neuroscientific field that it
was awarded with “Method of the
Year” by Nature Methods in 2010
and received “Breakthrough of the
Decade” by Science BotD in 2013.
However, for medical application in
people, turning all neurons in the
brain on and off at the same time
would not be helpful. Rather, we
want to be able to control certain
groups of neurons in certain parts
of the brain selectively. Luckily,
we have a lot of knowledge about
the genetic blueprints of mice,
humans, and many other organisms
so we can choose which type of
neuron and where in the brain
this biological switch should be
produced.
It didn’t take long for
researchers to use this extremely
exciting technique in people as
optogenetics has now been used
to expand our understanding
of brain mechanisms involved
in
neurological
conditions
like
depression,
Parkinson’s,
Schizophrenia, autism, aggression,
and addiction. This research then
quickly developed into the use of
optogenetics in clinical treatment
of these disorders. However, since
the opsins need direct light to
activate a cell, treatment of these
disorders would require people
to walk around with a power cord
through their skull, emitting light
directly on their brain. While this
is certainly not impossible and
has been successful in other living
organisms like mice, it is not the
ideal starting place. An easier first
step into optogenetic treatment of
human diseases is targeting neurons
that are more easily accessible with
light, like the ones found in your
eye. When produced in neurons
in the eye, the switch is easily

accessible for light and treatment
would be minimally invasive. This
is why patients suffering from
genetically determined blindness,
like patient Pittsburgh, are the
first to receive this cutting-edge
optogenetic treatment, which will
have an incredible impact on the
neuroscientific community if proven
successful.

Restoring Vision of
the Blind
Optogenetic
treatment
provides hope for over 1.5 million
people across the world that suffer
from degenerative retinal diseases
like retinitis pigmentosa. Retinitis
pigmentosa is a heritable disease
causing the first line of cells in
the eyes, the photoreceptors, to
die. Photoreceptors are the only
light-sensitive cells in the eye and
degeneration therefore results in
complete blindness. Rosalinda
Barrero, a retinitis pigmentosa
patient advocate, recalls not
wanting to go out for trick or
treating when she was younger
because it was already hard for
her to see in the dark. At a board
meeting of the California Institute
for Regenerative Medicine, her
husband shares that they met
because she accidently got into his
car instead of her date’s. This funny
anecdote of the beginning of their
relationship eludes to the fact that
by the time she was in her twenties,
Rosalinda had lost nearly all vision.
She is now a mother of three and
has never been able to see her
husband or kids. The family shares
their excitement about optogenetic
research and the beginning of the
clinical trials.
As illustrated by Rosalinda’s
story, onset of the retinitis
pigmentosa often begins during
childhood and develops into early
adulthood. It often starts with loss
of peripheral vision as the sides
of the visual field become blurry.
36
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Within the span of a couple years,
this loss of vision will gradually
expand to the middle of the visual
field until all photoreceptors are
lost and no amount of light can
elicit visual perception. While this
first layer of crucial photoreceptors
will be completely lost over time,
the other cell layers of the retina
remain intact and provide a perfect
target for optogenetic treatment.
By making the remaining healthy
cells produce the extracted algae
opsins, researchers can restore the
eye’s sensitivity to light. This way,
most of the visual system’s healthy
wiring remains intact and the patient
should be able to produce a picture
of the world by simply “skipping”
the dead photoreceptors.
The
Pittsburgh
patient
received one injection into one of
their eyes. This injection contained
the algae DNA and targeted the
retinal ganglion cells, the cell layer
following the photoreceptors,
to
express
channelrhodopsin
proteins. The newly engineered
light-sensitive
ganglion
cells
should now cause the visual
pathway to be activated when
exposed to light and hopefully
restore some vision of the patient
(Figure 1). However, this therapy
will not restore vision perfectly
because channelrhodopsins are
not as complex as photoreceptors.
There are many photoreceptor
functions that these opsins simply
37

read the visual input of the world
and translate it into a code that the
brain can understand. The most
successful microchip treatment
allowed blind patients to read
about 10 words per minute, which
is slow compared to the healthy
speed of 200 words a minute.
Nevertheless, this was a great
success, but Dr. Sahel also explains
how there is a limit to the restorative
abilities of these implants. With
current technological limitations,
the chips will never be able to
produce a resolution resembling
healthy vision. In other words, the
restored vision will always be blurry.
Therefore, GenSight decided to
switch to a biological technique
and use optogenetics to:

cannot mimic like adapting to
different light intensities or optimal
detection of contrast. Therefore,
we cannot expect vision to be
perfectly restored, but hopefully
the treatment will allow
patients to observe large
“Transform any type of
objects and move through
the world independently remaining neuron in the retina
again. Sean Ainsworth, into a photoreceptor”
CEO
of
biopharma
company RetroSense says
he hopes the patients will be able to
This was the beginning of the
“see tables and chairs” and maybe current clinical trials that patient
even read large letters with the help Pittsburgh is a part of.
of light-enhancing goggles. The
While RetroSense has yet
neuroscience community is waiting to have published any results
in suspense as these first transgenic regarding their first trials, GenSight
patients are being assessed for has confirmed the safety of the first
safety. If proven successful and treated patients in three centers
safe, the implications for the future across the United States, United
of brain medicine are incredibly Kingdom, and France in May of
promising.
2019. Bernard Gilly, another cofounder of GenSight, is pleased
to be able to move forward to the
second phase of their trials and
Two
major
companies, says that they “look forward to
GenSight and RetroSense, are confirming the safety of GS030 at
dedicated to advancing the field higher doses and to demonstrate
of optogenetic treatment of efficacy in restoring useful visual
blindness and are currently running functions in RP patients”. They
clinical trials studying a total of have since injected the next three
39 patients suffering from retinitis patients with a higher dose of the
pigmentosa,. Dr. Jose Sahel, co- treatment (GS030) and hope to
founder of GenSight, explains how release their preliminary results in
they are already able to partially late 2020. Since human testing is
restore impared vision with the still in the safety testing phase and
use of microchips placed in the no treatment efficacy assessments
back of the eye. These microchips have been made, we are basing
work much like a scanner as they

Clinical Trials
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our excitement for possible vision
restoration on preliminary animal
research. What are the findings that
are driving these human trials?

Preclinical Research
Mice lend themselves well for
initial testing of genetic treatment
as we know a lot about their
genetic blueprint and have some
widely applied ways to test their
behavior. About 8 years ago, a
team of researchers located across
the United States collaborated to
achieve one of the first successful
optogenetic vision restorations in
blind mice. After treatment, they
compared how long it took for
healthy, blind, and treated blind
mice to find a platform in a maze
of water. As you might expect, the
healthy mice were rather quick
to find the platform, whereas
the blind mice were swimming
around seemingly aimlessly before
accidentally stumbling upon it.
What was amazing about this study
is that the blind mice that were
treated with optogenetics were just
as fast as the healthy mice to find

the platform, suggesting that their
vision was restored to the quality
of healthy mice, and the treatment
worked. In a TED Talk around that
same time, a leader in the field, Dr.
Ed Boyden, shares his excitement
about this particular study and
says that the results bode hope for
potential therapeutic application
in people. The data presented in
this study were monumental for the
current clinical trials on optogenetic
treatment of blindness.
These findings were confirmed
by many other behavioral studies
of mice in the years after, among
which were research groups in
France associated with GenSight.
One GenSight study tested the
efficacy of optogenetic treatment
by comparing how long it took for
healthy, blind, and treated mice
to respond to light at the end of
a tube and return to the safety of
darkness. Again, the researchers
were pleasantly surprised to see
the treated mice to behave in the
exact same way as their healthy
counterparts and run away from
the light as quickly as possible,

suggesting the treatment was
effective.
While these results were
important and exciting, preliminary
research had to be done on human
retinas to further strengthen the
translatability of the therapy. This
led the GenSight groups in Paris
to test optogenetics in human and
monkey retinas. They were able to
successfully make the remaining
healthy cells in the retina produce
channelrhodopsin proteins and
found that the cells were activated
in response to light. This data
showed efficacy and safety of
optogenetic treatment in deceased
human retinas. This was the last bit
of data necessary for the human
clinical trials to be launched and
the first patients to be enrolled
in the GenSight study. If this
treatment shows to be safe and
effective in people suffering from
retinitis pigmentosa, it will have
great implications for optogenetic
treatment of other brain disorders
including epilepsy, post-traumatic
stress disorder, anxiety, depression,
and many more.

Figure 1. Infographic illustrating optogenetic treatment of an eye suffering from retinitis pigmentosa.
”Cataract”, DNA”, “Retina” by Servier Medical Art by Servier (CC BY 3.0.).“Spectrum” by Megabeckett27 from Wikimedia (CC BY-SA 3.0). Graph was
adapted from figure 6D from Sengupta, et al. (2016)..Adapted by Mara Kaspers.
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Optogenetics Beyond
Blindness
People like Dr. Deisseroth
and Dr. Boyden let their minds
wander far past optogenetic
treatment of blindness. There are
endless research and treatment
opportunities
that
this
lab
technique introduces in the world
of neuroscience that has and will
change the way we approach
modern questions of the brain.
Imagine all the things you can
explore by having the ability to
activate and silence whole parts
of the brain, or even types of brain
cells, within milliseconds. This ultraprecise control of neurons provides
hope for treating previously
untreatable disorders including
post-traumatic stress disorder
(PTSD) or epilepsy.
PTSD is characterized by high
levels of anxiety and fear related
to a memory. Dr. Boyden and his
team were able to reverse this
type of fearful memory in a mouse
model using optogenetics. They
had induced a model for PTSD into
the mouse by introducing a shock
every time a tone was played. As
a result, the mouse would freeze,
a behavior expression of fear,
every time the tone was played. To
treat the mouse of this memory39

related fear, they activated the
prefrontal cortex, often referred
to as the cognitive center of the
brain, by shining light on the newly
expressed channelrhodopsin. By
activating the prefrontal cortex
simultaneously with playing the
tone, the fear of the tone was
reversed, and the mouse was cured
of its induced PTSD within only 10
minutes.
Another
application
that
Dr. Boyden mentions with great
excitement is the treatment of
epilepsy. A symptom of epilepsy is
greater risk of seizures, which are
characterized by overactive neurons
and sporadic brain activity. Seizures
can have major effects on the brain
and leave permanent damage if
not controlled quickly enough.
As an optogenetic treatment, we
could make neurons in the brain
express a different type of lightsensitive opsin which silences cells
instead of activating them. During
a seizure, you would expose the
brain to light, causing the switches
to turn the cells off and thus reduce
brain activity and restore healthy
firing patterns.
As
mentioned
before,
treatment of PTSD and epilepsy
are just the tip of the iceberg of all
possible optogenetic applications
in medicine. However, while the

current clinical trials and novel data
are promising, they do not come
without risk and there are various
ethical considerations to be made
before wide application is possible.
Optogenetic treatment involves
editing the human genome and
contributes to the transhumanism
movement as we introduce
exogenous DNA into people. This
brings up the ethics of clinical
testing, a more philosophical
debate of free will, and questions
about how comfortable we are
disrupting human evolution on a
large scale.

OptogenEthics
For obvious reasons, people
like Dr. Deisseroth and Dr. Boyden
refrain from discussing the ethical
implications of gene editing and
prefer to focus on the medical
benefits. However, editing the
DNA of a person to treat a disease
remains controversial and should
be discussed as the first clinical
trials are being conducted.
The primary goal of phase
1 testing in the GenSight and
RetroSense clinical trials is safety
rather than efficacy. This brings up
an interesting ethical debate about
phase 1 human trials and riskbenefit ratio for the patient. If the
researchers are only assessing safety
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and not the medical benefit, what is In the case of treating blindness,
in it for the patient? And who really however, the aim of the treatment
benefits from the research? The risk- is much different. The treatment is
benefit ratio seems disadvantaged designed to improve the quality of
for patients as they are receiving life, but adverse outcomes of the
an irreversible treatment that will treatment could quickly outweigh
only be assessed for safety. On top the potential benefits.
Optogenetic
treatment
of that, participants are excluded
from any future innovative, perhaps also brings a more philosophical
more effective, therapeutic trials, question to the table. Optogenetic
increasing the individual risk of headlines often include phrases
enrolling in these trials even more. like “how to take over a brain” or
Including efficacy in phase 1 clinical “external control of the brain”.
trials has long been a debate in While these statements speak to the
the medical field and there are incredible power of optogenetics, it
many cancer treatment trials that also introduces an ethical dilemma
have already accepted the efficacy of free will. You might argue that
endpoint as a norm1. The highly externally controlling the brain can
invasive aspect of optogenetic threaten human autonomy and
identity by questioning:
treatment
and
skewed
risk-benefit
ratio are important
“What becomes of the
points
of
debate
individual, whose brain can now be
when discussing the
manipulated via remote control?”11
future of the current
optogenetic clinical
Are these patients potentially
trials.
losing
a part of their autonomy and
Another interesting aspect of
the optogenetic trials on blindness identity? Will introduction of algae
is the nature of the disease. Since proteins into a human brain have
blindness is not a terminal illness, unforeseen effects on the psyche?
this treatment is considered to be a Are treated patients under too
non-life-preservative intervention. much control of the environment?
Some argue that patients suffering With so little knowledge about
from a terminal illness might only how the mind is formed from our
have one shot at a potential new biological brain structures and
treatment, therefore increasing interaction with the world, these
the ethical acceptability of phase 1 are questions worth asking.
Finally,
altering
human
safety testing in these individuals.

genomes with DNA derived from
a different organism, could lead
to unpredictable effects on human
evolution. Richard Dawkins, author
of The Selfish Gene, argues that
our genetic building blocks, our
DNA, are the oldest driver of
human evolution. Genes have been
passed on for many generations
and we are, as Dawkins argues,
mere transporters of the genes
through time. This is how human
evolution has always worked,
but with current developments
in cheap DNA sequencing, gene
editing techniques like CRISPR,
and genetic therapeutics like
optogenetics, we are at risk of
disrupting the natural process of
evolution. This could have major
effects on humankind that we
simply cannot predict. As we enter
an age where transhumanism is a
rapidly growing field, these are
topics necessary to discuss before
moving forward with novel genetic
therapies like optogenetics.
Nevertheless, these clinical
trials are a source of hope for
families like patient Pittsburgh’s
and Rosalinda’s. About a decade
ago, their doctors would have
nothing to offer them, no hope
for improvement, just acceptance
of living in the dark for the rest
of their lives. Now, with the rapid
improvement
of
optogenetic
treatment, there is light at the end
of the tunnel again.
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How Intergenerational Trauma Shapes
Mental Health
By Ariel Neumann

H

elen
Epstein
was
haunted by a sense of
lurking danger, always
feeling as if something terrible was
just around the corner. She was
pursued by mental images of the
Holocaust, vivid visions of “piles
of skeletons and hills of suitcases.”
With these mental images came
a sense of isolation, anger, and
numbness. On paper, Epstein
looked like a Holocaust survivor
who was feeling the lasting effects
of past trauma. But Epstein had
not survived the Holocaust. The
memories that seemed to haunt
her were not hers.
Instead, they belonged to her
parents. Epstein was the daughter
of Holocaust survivors. Both her
mother and her father had survived
41

concentration camps, and both of
their families had been killed by
the Nazis. Her parents had rarely
discussed their past with her, and
she had always been hesitant
to ask them for details that she
knew would be painful for them
to describe. For her, this silence
produced a sense of the Holocaust
as a “black box,” something she
conceptualized as inaccessible and
far away. But despite this mental
distance from the events of the
Holocaust, Epstein was still reacting
emotionally as though she had
been intimately involved in these
events—as if she’d gone through
them herself.
Though she felt isolated, her
experience was not unique. In
the 1960s, psychiatrists started

noticing a pattern of mental illness
among many children of Holocaust
survivors. Dr. Vivian Rakoff, the
psychiatrist who first documented
the phenomenon, wondered if it
was possible that the psychological
distress of the first three people
he observed—two of whom had
attempted suicide—could stem
from what happened to their
parents. He wrote, “it would almost
be easier to believe that they, rather
than their parents, had suffered the
corrupting, searing hell.” 1
Today, we call this experience
“intergenerational trauma.”2 The
term refers to the effects of a
traumatic event—such as a period
of war, starvation, or genocide—
that leaves its mark on a population
even
generations
later.2 The
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concept that began with informal
descriptions of small numbers
of Holocaust survivors’ children
soon gave rise to controlled
studies of this group, and has
since been applied to many other
populations.3 In the Americas,
for example, research has been
conducted into how the history of
displacement and genocide affects
Indigenous people, and how the
legacy of slavery affects African
Americans.3 Elsewhere around the
world, researchers are studying the
impact of other traumatic historical
events, like the genocide of the
Tutsis in Rwanda, the Dutch Famine
during WWII, and the Holodomor
in Ukraine.3, 4

The Legacy of
Trauma
While not all studies find mental
differences in the descendents of
people who have survived trauma,
most studies do support the idea
that past traumas leave their
marks on the mental health of the
communities subjected to them.3
Take the legacy of residential
schools in Canada. Through much of
the 20th century, these institutions
separated Indigenous children from
their parents, harshly punished
them for speaking their native
languages, and often subjected
them to malnutrition and abuse.
Fast forward to the present, and
children and grandchildren of those
forced to attend residential schools
are more likely than controls to
experience psychological distress,
contract drug-related diseases, and
attempt suicide.3 Likewise, adult
children of Holocaust survivors have
been found to have higher risk of
anxiety, depression, and PTSD than
controls. 4 Indeed, studies have
found psychological symptoms of
intergenerational trauma among
many
populations,
including
Cambodians,
Palestinians,
Russians, Native Americans, and

African Americans. 5
Beyond
psychological
symptoms, there’s a case to be
made
that
intergenerational
trauma can be observed in the
physical properties of the body
and brain. Research has shown that
compared to controls, traumatized
people’s descendents have altered
brain anatomy and hormone levels.
For example, Holocaust survivors
who experienced PTSD were
found to have children with lowerthan-usual levels of the hormone
cortisol. Cortisol is involved in the
body’s fight or flight response, and
when this response is not properly
contained (as in the case of PTSD),
cortisol levels are unusually low.4
Thus, one interpretation of the
low levels of cortisol in children of
survivors is that they, like someone
with PTSD, are stuck reacting to the
world as if permanently threatened.
Their hormones behave as though
not just their mothers, but they
themselves are traumatized.
In fact, this hormonal profile
may actually make children of
survivors more likely to develop
PTSD if they go through a
traumatic event themselves. Low
cortisol levels before experiencing
a trauma puts people at greater
risk of developing PTSD. 4 This
fact may account for the finding
that children of Holocaust survivors
who became soldiers were more
likely than others to develop PTSD,
even if they had no psychological
symptoms before going to war.6
Essentially, their mothers’ trauma
had given them a hormonal profile
that made them more vulnerable to
the disorder.
In addition to these hormonal
differences, the children of stressed
mothers may have anatomical
differences in areas of the brain
related to emotion. One study
found that children of mothers
with prenatal anxiety had less gray
matter in the prefrontal cortex,
while another found reduced

hippocampal
growth.4
These
areas play a role in how we react
to fear and stress,4 so it makes
sense that people who may be
more prone to these feelings due
to intergenerational trauma would
have differences here. All in all,
the hormonal and anatomical
differences seen in the children of
traumatized parents suggests that
intergenerational trauma is not just
a metaphor. Instead, it’s a physical
reality.
Despite
this
physical
evidence, though, the concept
of intergenerational trauma can
still sound suspiciously mystical,
a step away from saying that
certain populations are haunted by
negative energy. For the concept
to really be convincing, it would
need to provide an explanation for
how psychological and biological
signs of trauma get transferred
from the generation that actually
experienced that trauma to their
descendents.

Psychological
Transmission of
Intergenerational
Trauma
At first, the psychiatrists who
initially described the phenomenon
looked to family dynamics to
answer this question. An early
paper proposed that parents who
had survived the Holocaust were so
preoccupied with their grief over
murdered relatives, and in many
cases so taxed by the mental and
physical illnesses that the Holocaust
had left them with, that they had
less energy and patience for
parenting their children. This, the
authors speculated, led the children
to become more anxious and
aggressive. They also suggested
that children might learn to fear the
outside world from their exposure
to their parents’ Holocaustinspired anxieties.7 Descriptions of
42
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“secondary traumatization” in the
children of Vietnam war veterans
followed similar logic, seeing
children’s symptoms as the result
of growing up with parents who
showed visible signs of trauma
and told stories of disturbing
events.2 These explanations did
not necessarily view trauma as a
single entity transmitted from one
generation to the next. Instead,
they thought these children were
reacting to their own trauma,
trauma that came from the way
they were raised.2
As intergenerational trauma
has become a focus of controlled
studies, researchers have tested
these explanations. In many cases,
research supports the idea that
it can be traumatizing to grow
up around a traumatized person.
For example, some studies have
found that parents who survive a
traumatic event are more likely to
abuse their children.8 Even without
clear abuse or neglect, though,
parents’ behavior may pass their
trauma on to their children.
Researchers studying Holocaust
survivors’ families found that certain
ways of emotionally adapting to
trauma in parents lead children to
be overprotective of their parents
and fixated on the Holocaust. The
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“victim” adaptive style (in which
the parent was hyperfocused on
the past trauma and overprotective
of the child) and the “numb” style
(in which the parent didn’t discuss
the Holocaust and discouraged
weakness in others) both led to
higher rates of these behaviors in
children. Children who showed
these behaviors, in turn, had more
mental health problems.3 Thus,
the study supported the idea that
intergenerational trauma can be
transmitted through interpersonal
dynamics in the families of survivors.
Individual accounts greatly
support the idea that psychological
factors contribute to transmission
of intergenerational trauma. Helen
Epstein, discussed previously,
went on to write a book in which
she interviewed other children of
survivors. She found that just as she
remembered being hesitant to ask
her parents questions about their
past, other children of survivors
reported feeling a need to protect
their parents. One said, “we had to
be gentle with them, because they
could shatter very easily.” Others,
many of whom were named after
murdered relatives, told her about
feeling a pressure to succeed in life
and have families of their own, as if
to replace those who had died.1 It’s

easy to imagine that the stress of
this responsibility could account for
the higher rates of mental illness in
these populations.
When
discussing
the
psychological
fallout
from
intergenerational trauma, it’s also
important to note that wars and
genocides can be economically
and culturally devastating to the
groups who endure them. This
destruction may play an additional
role in the transmission of trauma
from one generation to the next.
The Rwandan genocide resulted
in poverty for many children of
survivors, requiring some to leave
school and work to keep their
families afloat.3 The stress of these
conditions could be a contributing
factor in this generations’ trauma.
Cultural effects like the loss of
language and tradition may also
play a role. And in addition to
this loss, subsequent generations
may
experience
“vicarious
traumatization,”
absorbing
ancestral pain as a result of growing
up in a community that keeps
traumatic events alive through oral
tradition.5
But as much evidence as there
is that psychological, social, and
cultural factors can pass trauma
to the descendents of survivors,

SCIENTIFIC KENYON

these explanations don’t tell the
full story. More and more, we are
looking at ways that trauma may be
passed down independently of the
environment that a child grows up
in. It seems that even without abuse
or other types of psychological
damage, trauma may be passed
down through the body itself.

Biological
Transmission of
Intergenerational
Trauma
Studies in animal models
seem to support the idea that
intergenerational trauma can be
transmitted biologically. One study
in mice subjected them to painful
foot shocks whenever they smelled
certain scents. Unsurprisingly, the
mice learned to fear those scents.
The researchers predicted that the
mice’s scent-related stress would be
transmitted to their offspring when
they reproduced. Sure enough,
the next generation of mice also
avoided that scent.9
This kind of finding suggests
that in cases of intergenerational
trauma, there is something more
going on than children growing
up in a traumatizing environment.
After all, the mice who feared
these smells probably didn’t do so
because of anything their parents
had told them. Instead, researchers
observed that these second
generation mice were physically
different than the offspring of
mice who had not been trained

to fear these smells. Descendents
of the “traumatized” parents had
more sensory neurons dedicated
to detecting the feared smells
than controls did. These changes
stemmed from alterations to the
genes that coded for those sensory
neurons. This experiment, and
others like it, tell us that children
can physically inherit the stress of
their parents through their DNA.9
To understand how this
could work, it’s important to first
understand the relatively new
field of epigenetics. For a long
time, scientists believed that life
experience could not affect the
traits a person passed on to their
children. After all, the logic went,
a dog with its tail cut off doesn’t
give birth to tailless dogs. But more
recent findings have shown that
some experiences in life actually
can affect what traits we pass on
to our children. This is because
environmental factors can lead
certain molecules—methyl, for
example—to attach to DNA. These
molecules function as “tags” on the
genes they attach to, alerting the
body to activate or repress these
genes.10 Importantly, this “tagging”
process can affect the DNA of a
persons’ sperm or egg cells, or
the DNA of their fetus if they are
pregnant. As a result, epigenetic
changes like methylation can be
passed on to the next generation.4
Trauma is one experience that
appears to be able to cause DNA
methylation. A gene called NR3C1,
which codes for molecules that
are involved in the body’s fight or

flight response, is one example
that has received attention in
recent years. Fathers with PTSD
from the Holocaust were found to
have offspring with greater NR3C1
methylation. So were mothers who
were pregnant during the Rwandan
genocide. Indeed, many studies
of people who have experienced
stress or PTSD from a variety of
sources showed the same pattern
of methylation changes in offspring.
Given that NR3C1 is involved in the
fight or flight response, the fact it is
methylated in children of survivors
may help explain their sensitivity to
anxiety and PTSD.4 And methylation
of other genes may also be
involved in epigenetic transmission
of trauma. For example, FKBP5,
another stress-related gene, was
found to have different patterns
of methylation in Holocaust
survivors and their children than
in controls. This gene has been
linked to PTSD and depression,
so it is another example of how
the emotional distress of trauma
can be transmitted from parents to
children on the molecular level.3

Future Directions
Ultimately, there is strong
evidence that trauma can pass
from parents to children in multiple
ways, from the cultural level to the
psychological level to the molecular
level. But while these findings
are fascinating, they can also be
disheartening.
When
Epstein
published her interviews with other
children of survivors, exploring

Methylation of certain sections of DNA “tags” genes, which can activate or repress them
© Copyright 2020 Biosciences for Farming in Africa.
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the effects of the Holocaust on
her generation, she provoked an
intense backlash from some. She
said, “it really upset Holocaust
survivors who were invested in
normal children, and in not giving
Hitler a posthumous victory.” In
addition to challenging this desire,
the concept of intergenerational
trauma can also be emotionally
difficult to accept. Ian Brown, after
reading Epstein’s book, wrote,
“you can’t help but think of all the
agony that has been stored up and
passed on—by survivors not just
of the Holocaust, but of Hiroshima
and of Cambodia and of Rwanda,
of residential schools and wars and
countless other public and private
calamities.”3 If the reality of these
atrocities is difficult for us reckon
with, how much more so to consider
whole new generations of victims?
But while intergenerational
trauma is in many ways a sobering
concept, it is also one that offers a
foundation for positive change. For
one, simply shifting our medical
understanding to include the
insight that people’s mental health
is shaped by their community’s
history provides a foundation
that can help shape better
health policies.5 Programs like
“Strengthening Families,” which
works to prevent early substance
abuse
in
Native
American
and First Nation communities,

counters the cultural loss that
often drive substance abuse by
bringing together families and
communities.3 In addition, research
into intergenerational trauma can
also help define specific parenting
styles that reduce transmission
of trauma. To use an example
already discussed in this article,
the knowledge that the “victim”
and “numb” adaptive styles are
related to mental health problems
in descendents could help mental
health professionals counsel new
parents who have survived a
trauma away from such styles. And
beyond giving an idea of what to
avoid, research can also cast light
on parenting styles that promote
resilience, as in a study that found
that better family communication
reduced transmission of trauma to
the second generation of Holocaust
survivors.11
Finally, one of the most
hopeful insights that the study
of intergenerational trauma has
yielded comes from the same
team of researchers who showed
that mice can inherit their parents’
fear of smells. After that finding,
the researchers repeated the
experiment, but made an important
change. After teaching a parent
generation of mice to associate a
smell with a shock, and therefore
to fear it, they taught them to
stop fearing it. They exposed the

mice to the smell over and over
again without shocking them,
so that eventually, they stopped
associating it with pain (a process
called extinction). And when the
mice who had undergone extinction
reproduced, they had offspring who
did not fear those smells. Moreover,
the offspring exhibited none of the
changes to their sensory neurons
that the other descendents had
shown. Essentially, these mice had
not inherited their parents’ stress.9
Although there are certainly
differences
between
mice
experiencing fear conditioning and
humans surviving a trauma, this
could be a very promising finding.
The researchers who conducted
this experiment compared the
process of extinction in mice to
the process of therapy in humans.
That the extinction process
prevented the next generation
of mice from inheriting their
parents’ stress suggested to the
researchers that therapy for parents
before conception could help
protect children from inheriting
trauma. Such interventions, they
concluded, could break the cycle
of intergenerational trauma.9 This
idea requires more research, but if
this study is anything to go on, it’s
not just the parents’ trauma that can
be passed down through the body.
Their healing could be as well.
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Sleep It Off
How Sleep Quality
Influences Outcomes of
Traumatic Brain Injury
By Greg Boyer

O

n March 16, 2009,
actress
Natasha
Richardson suffered a
traumatic brain injury (TBI) when
she fell while skiing. She claimed
to be fine; however, she started
to experience severe headaches a
couple hours after the fall. Two days
later she died from a hematoma, or
bleeding in the brain, induced by
a TBI. In 2014, the latest year the
CDC has published statistics, there
were 56,800 deaths related to TBI
in the US. Additionally, there were
2,870,000 emergency room, urgent
47

care, and hospital visits for TBIs in
the US.1 While the term TBI may
not be a part of everyone’s lexicon,
concussion, which describes a
mild traumatic brain injury (mTBI),
most likely is. Due in large part
to a rapidly increasing scientific
understanding of concussions, it
has become quite the hot button
issue. While contact sports have
captured much of the notoriety,
there is a risk of TBI among all
populations. It is true that there
is a heightened risk of sustaining
a TBI in contact sport athletes,

however, 72% of hospitalizations
for TBI in 2014 were from falls and
motor vehicle accidents, displaying
the significance of TBI among all
populations. Professional football,
which has come under fire for the
many former athletes who are
suffering the consequences of
brain trauma years later, has spent
a great deal of effort reforming
rules, safety equipment, and
awareness to protect players. This
dedication to improve the lives of
those who suffer TBIs has not been
seen, however, outside the realm of
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sports. This is in part from TBI being
thought to only affect athletes,
which, as explained, is not the case.
One of the most enigmatic
clinical discussions revolves around
concussion protocol. While there
is still no consensus regarding
all aspects of how to treat,
manage, and mitigate symptoms
experienced following TBI, there
has been extensive research in
recent years into best practices. The
reason for the difficulty in studying
TBI is that there is immense
individual difference in severity,
symptomatology, location of injury,
and outcomes of TBI patients.
This has created opportunities
for misinformation concerning
treatments to be perpetuated.
We’ve all heard it: Don’t fall
asleep after a concussion. Like all
myths, there is a reason that this
has been considered good form.
Brain imaging has only been in
our scientific repertoire for a few
decades. Meanwhile, humans have
been experiencing TBI since the
beginning of our existence. Thus,
assumptions have been made
on observation. It is not wholly
uncommon in TBI patients to suffer
head trauma, feel fine for a few
hours, then suffer seizures, strokes,
or death when they go to bed
that night. This is precisely what
happened to Natasha Richardson.
In the hours following her accident,
she was experiencing bleeding on
the brain, but unfortunately did
not experience severe headaches
until the critical window of time
for treatment had passed, and
ultimately Richardson succumbed
to her injuries.2
A severe impact to the brain
can cause brain movement within
the skull, which sometimes leads
to bleeding. This, along with
neuroinflammation, which is a result
of the immune response to the
injury, leads to increased intracranial
pressure. The buildup of pressure
occurs over a period of time, which

is why patients may not experience
a deterioration of symptoms until
several hours later. If that time
when symptoms deteriorate occurs
when one is asleep, then the
patient would not be able to reach
out for medical attention when it is
needed. This timeline could easily
be misinterpreted as sleep itself
being the culprit for a deterioration
in symptoms; however, the true
criminal is hematoma.
While there is no inherent risk of
sleeping following a concussion, it
is understandable why the opposite
was believed to be true. If a TBI may
have caused a hematoma, then it is
crucial to seek treatment as soon as
possible. Therefore, it is important
to know the signs. Some symptoms,
including confusion, headaches,
blurred vision, and nausea, often
overlap with that of a concussion.
Most concussions are not medical
emergencies; however, if there
is an improvement of symptoms,
followed by a sudden deterioration,
then medical attention should be
sought immediately. Seizures are
also a tell-tale sign of hematomas.
During the night after the TBI, it is
good practice to have a relative
or friend check on you throughout
the night to ensure that all is well.
In short, be alert of worsening
symptoms, but sleeping is not the
cause of mortality following TBI.
After 24 hours, this precaution is
not really necessary because if
bleeding were a concern, then the
complications would have already
risen. Thus, the goal should then be
to recover quickly and completely.
The thought that sleep could
hurt recovery is not only wrong, but
the opposite effect is actually true.
Falling asleep after a concussion
will not kill you, but preventing
yourself from having a good night’s
sleep will only make it worse. Not
only will poor sleep quality worsen
your immediate symptoms, but also
lead to worse long-term outcomes.
There are many reasons to believe

quality sleep is beneficial to TBI
outcomes. This is because sleep
mediates brain plasticity, the ability
to learn new information, which is
very important in the brain’s memory
as well as the ability to heal itself.
The problem is that TBI symptoms
make sleeping well difficult. One
of the most common complaints
in patients is poor sleep. This is
obviously problematic. Poor sleep
exacerbates feedback from TBI
symptoms disrupting sleep, and
disrupted sleep, in turn, worsens
symptoms of TBI, which makes it
all the more difficult to achieve a
healthy sleep routine, also known
as a circadian rhythm.

What Is Your
Circadian Clock, and
How Does It Affect
Your Sleep?
Almost all living organisms
follow a circadian rhythm, which is
an internal clock that aids sleepwake cycles. This is why most
people feel tired at night and
alert during the day. In healthy
people, there is a complex system
of biological processes that aim
to normalize your sleep routines.
There is a combination of internal
cues, such as stress levels, and
external cues, such as sunlight, that
the body uses to determine when
it is time to get some z’s. However,
this system is based on routines,
which is why disruptions to our
daily routines can easily affect our
circadian clock. Common examples
of disruptors include jetlag, staying
up late studying for a test, or binge
watching your favorite new TV
show until 4 a.m.
There are many benefits to a
good night’s sleep, such as boosting
the immune system, improving
memory and attention, and
regulating metabolism, which is the
ability to convert food into energy.3
The best outcomes in adults occur
48
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from going to bed at the same
time each night and having roughly
8 hours of uninterrupted sleep.
Obviously, this is difficult to achieve
in practice, but it is something to
consider when debating whether
to press play on that next Netflix
episode.
Poor sleep quality or duration,
however, has the inverse effect.
Furthermore, when there is a
disruption to your sleep routine, it
can be quite difficult to get back
on schedule. It can take days or
even weeks to recover from your
overseas vacation or the all-nighter
you pulled.
While these examples are due
to external disturbances, there are
a variety of mechanisms the body
uses internally to regulate sleep. In
fact, there are even genes that are
responsible for regulating sleep.
These genes can have varying
levels throughout the day, too,
telling neurons when to be active,
and when it is time for sleep. One
of these genes, Per1, is responsible
for making the internal clock 24
hours long. Per1 follows a daily,
predictable pattern of expressing
at high levels at dusk, and low
levels at dawn. When there is too
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much Per1 released in the brain, the
internal clock becomes too long.4
This would make someone sleep
for too long and then be awake for
too long, as opposed to the ideal
situation of waking up and going
to sleep at the same time each day.
Per1, in addition to external cues
such as brightness, help us to sleep
during the night and be awake
during the day.

The Immune System
Is also Hard at Work
The purpose of the immune
system is often thought to be to
fight viruses. While this is one of its
functions, there are many methods
the immune system utilizes to
repair and protect the body. When
you get a bruise or catch a cold, the
immune system works overtime to
nurse everything back to health. In
addition to repairing vulnerabilities,
the immune system is always
playing an active role in maintaining
homeostasis in the brain. There
are immune cells that respond to
unwanted changes in the brain by
secreting small molecules that latch
onto receptors throughout the

brain to communicate information
between cells. One family of
these molecules are known as
proinflammatory cytokines, which
are regulators of inflammation.
There is always some amount of
these floating around the brain.
However, levels of proinflammatory
cytokines skyrocket when there
is stress on the immune system.
Proinflammatory cytokines have
the ability to interact with neurons
in a localized area or throughout
the brain as a whole, such as when
they induce a fever.
Interleukin-1 (IL-1) and Tumor
Necrosis Factor (TNF) are two types
of proinflammatory cytokines that
play a key role in sleep regulation.
While they both have very similar
sleep regulatory effects, there are
a couple differences between IL-1
and TNF. One of the main functions
of IL-1 is to regulate temperature.
Overnight, we actually sleep at a
lower body temperature than we
function at during the day. This is
in part why it is especially difficult
to fall asleep on those scorching
hot summer nights. Increased
concentration of IL-1 in the brain
decreases temperature, thus IL-1
levels dip during the night.5 TNF,
on the other hand, plays more of a
role in regulating inflammation in
the brain. More TNF in the brain
results in more neuroinflammation.
While these are the primary roles
of IL-1 and TNF, they each overlap
in function to a great degree, so
they really can be paired together
when talking about their effects on
sleep regulation. The quantity of
both IL-1 and TNF peaks during the
night, and reaches a trough during
the day. To determine the effects of
IL-1 and TNF, studies have injected
these substances in the brain, which
resulted in sleepiness, fatigue, poor
cognition, and other symptoms
as a consequence of sleep loss.17
This shows that regulation of these
cytokines is necessary for healthy
maintenance of circadian rhythms.
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Hormone Regulation
Despite their reputation for
orchestrating puberty, hormones
are used as a method of
communication in the brain and
body for a wide variety of tasks.
In fact, hormones often work in a
very similar manner to cytokines,
which has led to quarrels among
scientists over when to classify
certain molecules as cytokines or
hormones.6 Still, there are a couple
characteristic differences. Unlike
cytokines, hormones exclusively
communicate over long distances.
While cytokines can be released by
a variety of immune cells, hormones
are released only by glands in the
endocrine system. The endocrine
system regulates a variety of human
functions including physical and
sexual development, metabolism,
mood, and—you guessed it—
sleep.
The three hormones that are
most involved with sleep regulation
are melatonin, progesterone, and
histamine. The quantity of each
of these actually varies cyclically
throughout the day, helping to
contribute to circadian rhythms.
Each of these hormones plays
a significant, specific role in
regulating sleep. Melatonin is a
hormone that promotes sleep by
delivering messages to neurons
all over the brain to power down.
Therefore, in people with healthy
circadian rhythms, melatonin levels
are highest overnight, and lowest
during the day. Due in part to
societal pressures for maintaining
health,
dietary
supplements,
including melatonin, have become
increasingly popular in recent
years. While there is reason to
believe melatonin supplements
could help improve sleep quality
and duration, it is important to take
these supplements at the roughly
the same time each day to achieve
the intended benefits.7
Progesterone also aids in
sleep, though in a slightly different

manner. Progesterone diminishes
the effects of sleep disturbances.
Heightened progesterone levels
are correlated with a better quality
of sleep, due to this reduction in
sleep disturbances. For example,
you are less likely to be awakened
by a loud noise if your progesterone
levels are higher. Like melatonin,
progesterone levels should peak
overnight. Considering the natural
effect of progesterone in aiding
sleep quality, it is not wholly
unsurprising that progesterone
supplements will also reduce
sleep disturbances.8 While also
contributing to sleep wake cycles,
histamine has the inverse effect of
melatonin and progesterone, as
histamine promotes wakefulness
and arousal.9 Thus, histamine
levels should peak during the
day and decrease at night. Given
the importance of these three
hormones in regulating sleep, any
unwanted changes to the quantity
each hormone in the brain will have
troubling consequences.

What Goes Wrong in
TBI?
If there is anything to take
away from Richardson’s tragic
death, it’s that the potential risks
of concussions should not be taken
lightly. Without a doubt, immediate
medical attention should be sought
if you think you are concussed.
Establishing there is no risk of
immediate health complications
should be the primary concern.
Nevertheless,
taking
the
appropriate steps to ensure a
timely and full recovery is essential.
Before discussing what those steps
look like, the mechanisms by which
TBI harms the brain should be
understood.
There
is
an
interaction
between TBI and all three
mentioned
components
of
sleep: circadian clock, immune
response, and hormone regulation.
Recent studies have found Per1,
the circadian rhythm gene, to
upregulate following mTBI.4 The
50
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overproduction of Per1 results in
longer circadian rhythms, increased
light sensitivity, and an overall
reduction in movement for mice
models. Mice are good model
organisms for TBI as mice brains
are affected by head trauma in a
way very similar to humans. The
increase in light sensitivity can be
explained by disturbances to the
internal clock. We are naturally
more sensitive to light at night
when Per1 levels are high. We’ve
all experienced this when needing
to turn down the brightness of
your phone at night. Given that
heightened Per1 levels at night
increase light sensitivity, the same
increase in sensitivity is to be
expected so long as Per1 levels are
elevated.
Hormones
are
just
as
susceptible to dysfunction from
TBI. Following injury, patients
experienced a decrease in all three
previously mentioned hormones:
melatonin, progesterone, and
histamine.10 These hormones all
play a role in sleep-wake cycles, so
their deterioration is evidence of the
effects of TBI on sleep. While the
circadian clock is disrupted directly
from Per1, the disruption of sleep
due to dysregulation of hormones
also negatively affects circadian
rhythms. However, there is a great
deal of individual difference. Not
everyone is going to respond to
TBI in the same manner. With that
said, recent studies have explored
methods to predict an individual’s
response to a TBI. Some of the
variability can be attributed to
gender. Given that hormone
regulation plays an integral role in
the effects of TBI, it is not surprising
that there will be sex differences.
Evidence suggests that males with
TBI may have a greater memory
deficit than females with TBI.
Also, TBI affected mitochondrial
respiration, which is related to the
development of oxidative stress,
in males only. Females face their
51

own set of challenges and are
more likely than men to report
depression and anxiety following
TBI. Furthermore, TBI is very
prevalent among adolescents,
especially those in athletics. Age
may play a factor in treatment as
well due to the changes in hormone
production during development,
but more research needs to be
done to understand the ins and
outs of these differences.11
Understanding the role of TNF
in TBI is even trickier. In the days

right after suffering a TBI, TNF is
thought to be a necessary part of
the immune response, helping to
prevent some of the more serious
and fatal symptoms that can occur.
However, prolonged increases of
TNF that are present in TBI can lead
to the detrimental sleep effects
described from injection of TNF into
the brain. Since TNF and IL-1 go
hand in hand, IL-1 also upregulates
following TBI. Recent studies
have used antibodies that aim to
decrease IL-1 levels. This treatment

Figure 1. The effects sleep regulation can have on mTBI consequences and symptomatology. Green
lines indicate primary effects and dotted red lines represent delayed effects.
“CES illustration” by Lorie Shaull from Flickr (CC BY-SA 2.0). Adapted by Greg Boyer
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has shown promise as mice with
this treatment show memory
and
cognitive
improvements.
Heightened levels of both TNF and
IL-1 are responsible for increases
in neuroinflammation that is
characteristic of TBI.17
While
there
are
short
term consequences of each of
these sleep disruptors, long
term consequences are just as
problematic.
The
experience
of TBI, especially multiple TBIs,
is correlated with increased
likelihood of developing several
neurodegenerative
diseases,
including
Chronic
Traumatic
Encephalopathy (CTE), Alzheimer’s
Disease,
and
Parkinson’s
Disease.12 Thus, it is crucial to
treat TBI as early and effectively
as possible. The goal is to prevent
neurodegeneration, a fancy term
for neuron death. The primary
causes of this neurodegeneration
are from the neuroinflammation
and the downstream effects of
oxidative stress.
Oxidative stress occurs when
excess reactive oxygen species
(ROS) exceed healthy levels. These
are simply waste products that
occur naturally. In healthy people,
they do not cause much harm, as
antioxidants clear them away. You
may have heard of antioxidants
advertised as a must-have super
nutrient, present in blueberries, kale,
dark chocolate, and more. Whether
intaking more antioxidants though
diet truly prevents these diseases
is open for debate, however, the
role that antioxidants play is most
definitely vital. When there is more
ROS than can be processed by
antioxidants, it can be toxic for the
brain. This excess ROS binds to and
attacks lipids, protein, and DNA in
the brain. ROS, in the absence of
antioxidants, essentially go on a
killing spree, attacking molecules
and neurons in the brain.9 As
it turns out, hormones play an
important role in regulating ROS,

so the changes to hormone levels
in TBI also have adverse effects on
oxidative stress.
Neuroinflammation,
as
previously described, is the result
of the immune response. The
consequences of inflammation
are much more straightforward.
Increases in neuroinflammation
essentially suffocate neurons, as the
inflammatory tissue occupies the
space in the brain that is typically
reserved for neurons. Imagine the
brain inside the skull as a full glass
of water, and the inflammatory
response as a golf ball that is
dropped in. There just isn’t enough
room for both.
While the intercorrelations
between all aspects of sleep in TBI
make it easy for the entire system
to be disrupted, the bright side is
that treatments that target one area
can often have widespread benefits
throughout the system shown in
Figure 1.

Sleep Disorders
In case it has not been made
clear, sleep is necessary to recover
after TBI. Unfortunately, it is difficult
to maintain healthy circadian
rhythms without intervention, as
patients recovering from TBI often
have poor sleep quality. Research
in developing treatments is still
very young, meaning there is often
a lack of knowledge in how sleep
should be regulated following
mTBI. Additionally, symptoms of
TBI, including anxiety, fatigue and
headaches, further disrupt sleep.
In fact, many TBI patients develop
specific sleep disorders. Following
TBI, 50% of patients experience
sleep disturbances in general, 29%
develop insomnia, 28% develop
hypersomnia, and 25% acquire
sleep apnea.10 Given that TBI
patients frequently develop sleep
conditions that they previously
did not have, it is logical that TBI
will exacerbate pre-existing sleep
conditions.

Studies
exploring
sleep
disruptions
alone
have
shown that there are shared
consequences to those of TBI,
including
neuroinflammation,
cerebrovascular
dysfunction,
and dysregulation of hormones
associated with circadian rhythms.
Chronic insomnia, for example,
can alter the timing of when TNF is
secreted in the brain.13 One of the
most dangerous sleep disorders,
especially if left untreated, is
sleep apnea. Sleep apnea is
characterized by repeated stops
in breathing while you sleep. This,
too, results in oxidative stress.
A common treatment of sleep
apnea is continuous positive airway
pressure (CPAP). Studies have
shown CPAP’s effectiveness in
reducing oxidative stress in those
with sleep apnea.14 Considering
the overlapping mechanisms of
disfunction, it can only be assumed
that the combination of TBI and
sleep apnea would exacerbate all
symptoms. Given that one in four
TBI patients develop sleep apnea,
more research should be dedicated
to preventing the onset of sleep
apnea in TBI patients and exploring
treatments that would remedy both
conditions simultaneously.

What Can Be Done?
A few treatments have been
mentioned, but if you are hoping
for a comprehensive overview of
TBI treatments, you are in luck.
First, let’s take a step back. The
ultimate goals of TBI treatments
is to aid recovery and prevent
neurodegeneration. Sleep aids
recovery through its effect on brain
plasticity. With that said, there is
such a thing as too much sleep.
Too much sleep can further disrupt
circadian rhythms, as most adults’
circadian clock is designed to have
7-9 hours of sleep. Sleeping all day
and not partaking in daily activities
will actually limit brain plasticity.
In short, finding balance, and
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returning to normalcy will provide
the best results.15
This is easier said than done,
especially due to the prevalence
of sleep disruptors in our lives.
Alcohol, high stress environments,
and bright light from your phone, all
can have effects on your circadian
rhythms.19 Alcohol use, which
inhibits quality sleep and increases
inflammation, has also been found
to increase oxidative stress.16 So,
consuming alcohol while you are
recovering from a TBI will have
negative effects. Furthermore,
bright light exposure at specific
times during the day has shown
to be beneficial for some sleep
conditions that are characterized
by irregular circadian rhythms.20
However, bright light exposure
right before bed, which can come
from your phone or laptop, will
have the opposite effect.
As
mentioned,
hormone
supplements have shown promise
for their ability to regulate circadian
rhythms. Studies involving rats
have shown that treatment of
progesterone diminishes cognitive
and sensorimotor deficits that are
present in untreated rats induced
with TBI. Furthermore, progesterone
reduces the effects of oxidative
stress and neuroinflammation.
The efficacy of progesterone in
treating TBI symptoms displays
that circadian hormones, oxidative
stress, and neuroinflammation are
all relevant to the progression of
neurodegeneration due to rmTBI.21
Studies using animal models have
also shown the benefits of histamine
and
melatonin
supplements,
however, researchers have had
difficulty replicating findings in
human subjects.18 One potential
problem of hormone focused
treatment is that hormones can
act differently in men and women.
Progesterone, in particular, is
expressed differently between
sexes. Progesterone supplements
have shown an ability to treat
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“Mental Maintenance; Tools to keep the mind fit”
By Staff Sgt. Micaiah Anthony from Royal Air Force Mildenhal

certain symptoms in females alone,
including reduced tissue loss.
Nevertheless, progesterone was
able to treat the mitochondrial
respiration
dysfunction
that
11
exclusively affects males. There is
still more research that needs to be
done to better understand all the
moving parts of this condition.
One
surprising
direction
research has traveled is into
cannabis.
Tetrahydrocannabinol,
commonly known as THC, excites
certain receptors in the brain, one
being CRB-1. Studies are often
conducted with compounds that
bind to the same receptors as
THC, but do not share the same
psychoactive effects. Agonists of the
cannabinoid receptor have shown a
variety of promising effects. These
range from increasing histamine
production,22 to suppressing IL-1,
to decreasing neuroinflammation.23
This does not necessarily mean
that consuming marijuana will
solve all of your problems, but it
is interesting to note the potential
benefits of certain compounds in

this commonly used substance.
While Natasha Richardson will
not be able to reap the benefits
of the many recent advances in
knowledge regarding TBI, she
will be remembered for sparking
a conversation. Advances in
treatments of TBI have already
saved countless lives, and will only
continue to be more and more
effective. Although it is usually
treatable, traumatic brain injuries
should not be taken lightly.
Whether it be societal pressure
or desire to show grit, the ‘tough it
out’ culture that often persists is not
beneficial to anyone. This pressure
to keep playing is highly prevalent
in athletics; however, continuing
physical exertion immediately after
sustaining a brain injury only serves
to increase the recovery time you
face. The same way that a physical
injury would be treated, like a
broken arm with a cast, traumatic
brain injuries need time to heal. As
much as you may want to get back
on with your life, trust your gut and
get some rest.
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Insight and the Wandering Mind
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t is so common to experience
a sudden flash of creative
thinking in the shower that
there is a Reddit page dedicated
to it. And yet the phenomenon of
spontaneous insight is, scientifically
speaking, a mystery. The usual
routes of study fail researchers
investigating insight. Rats, mice,
monkeys, fish—the menagerie
of organisms essential to brain
research is of little use because it
is impossible to determine what
constitutes a eureka moment
to a subject that cannot speak.
Investigating human subjects is
the best option, but how best to
contrive a eureka moment within
the confines of a lab? An MRI
machine?

Anecdote Provides
a Window into the
Invisible Process of
Sudden Insight.
The
eponymous
eureka
moment predates Christ. It
occurred, as many ideas do, in a
bathtub. Archimedes, the ancient
Greek scientist and mathematician,
had just lowered himself into his
evening bath when, noticing the
water lapping over the edge, he
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leapt out and ran—naked as a
babe—screaming, Eureka! Eureka!
In English: I found it! I found it!
Archimedes had discovered a
fundamental law of our universe:
the force of buoyancy is equal to
the weight of the fluid displaced.
This apocryphal tale is one
of many similar stories that have
circulated
throughout
history.
The chemist August Kekulé, after
struggling to divine the structure of
the molecule benzene, dreamt one
night of a snake devouring its own
tail—the mythical ouroboros. Upon
waking, he realized that benzene
takes the form of a ring, and later
won a Nobel prize.
You do not have to travel
beyond Kenyon’s campus to find
someone with a eureka moment
to share. In the late 80s, professor
of physics Ben Schumacher was at
work figuring out how information
could be conceptualized in a
quantum system.
For background: information
in quantum systems is different
from information in binary systems,
where a unit of information (a bit) is
either 0 or 1. In a quantum system,
a unit of information exists in a
superstate. That means any one
unit of information is both 0 and 1
until it is measured, and whether
it is 0 or 1 depends on dizzyingly

Archimedes exclaiming “Eureka!”
Original image by Alec Clothier

“Benzene molecule in an ouroboros”
By Haltopub from Wikimedia (CC BY-SA 3.0)

complex quantum probabilities.
The problem puzzling Schumacher
was how this quantum unit of
information could be modeled.
For three years, he and fellow
physicist Bill Wootters grappled
with this question without headway.
Then they gave up. Years later,
however, Wootters visited Kenyon
and they got to talking again.
The two physicists had three days
together and decided they would
give the problem one final push.
Again: no luck. While Schumacher
drove him to the airport, Wootters
joked about a unit for quantum
information. He called it a “qubit,”
a play on cubit, the Biblical unit
used to measure the Ark. On his
way back to Kenyon, Schumacher
realized the qubit was more than
just a great pun—it was a great
idea. As Schumacher tells it, “six to
eight things suddenly fit together
and I saw everything—no problems
to solve, just work to be done.”
Schumacher saw a revolutionary
new framework for quantum
information, all that remained
was to fit the pieces together.
Fast forward a few decades and
the qubit is a cornerstone of
quantum information theory and
Schumacher’s landmark article has
been cited over 1,400 times. (Qubit
has also made its way into the
Scrabble lexicon—16 points.)
Spontaneous insights need
not be grand. Hence the Reddit
56

SCIENTIFIC KENYON

page r/Showerthoughts, which
defines the phenomenon as “the
miniature epiphanies you have
that highlight the oddities within
the familiar.” Showerthoughts
range from oddly tragic (“People
say life is short even though it is
literally the longest thing we will
ever experience.”) to absurd (“Your
stomach thinks all potatoes are
mashed.”). One does not need to
be in the shower, but it is conducive
to the phenomenon. Schumacher
credits long drives with many of
his breakthroughs, and prefers to
speak not of showerthoughts but
of carthoughts.

The Biology of
Memory
Insight ranges from the
marvelous and era-defining to
the mundane and entertaining.
But where does it originate from?
Why does the brain seem to do its
best thinking when it is at rest? It
starts with the basics: how the brain
stores and retrieves information.
Everything you know is
encoded in the structure of your
brain. This includes both semantic
memories (i.e., facts and ideas) and
episodic memories (i.e., scenes
from your life). This is not to say
that individual cells or portions of
the brain contain explicit pieces of
knowledge; rather, decentralized
ensembles of cells work in unison
to encode information. When
you remember something, all the
pertinent sensory and conceptual
details are gathered as these
neurons fire—it is as though your
brain is reliving the experience. This
has been confirmed by way of fMRI
imaging: brains viewing an image
of, say, a bird light up in exactly
the same way as brains tasked with
recalling the same bird2.
The Office quotations, the
twenty digits of pi you memorized
to impress your high school
math teacher, the address of
57

your childhood home—all of
these things represent structural
realities within the brain. Clusters
of neurons, spread out across the
roughly 100 billion cells within the
adult brain, activate to form what
we term a memory, a thought, a
concept. At the cellular level, this
occurs because experiencing or
learning
something—especially
repeatedly—causes neurons to
literally wire themselves together.
Emotions, sights, smells, textures,
and ideas are all encoded in your
brain as networks of interconnected
cells. In the course of memorizing a
fact, for example, the same groups
of neurons are firing repeatedly.
Each time they fire together,
more connections between these
neurons form. These connections—
called dendrons, from the ancient
Greek for tree—make it easier for
these same clusters of neurons to
fire together in the future3. In this
way, it becomes easier and easier
to recall something because the
cellular pathway promoting the
electrochemical transmission of this
information becomes more and
more established.
The recall of memories is better
understood at the anatomical scale.
Generally, information is processed
first in the neocortex associated
with thinking and executive
function, and then consolidated
in the hippocampus, which acts
as a directory for memory in the
brain. This means that memory is
not stored in the hippocampus,
but rather that the hippocampus
knows where in the brain to retrieve
a memory. Tangled networks of
neurons link the hippocampus
with a diffuse array of brain
regions associated with sensation
and
semantic
information4.
When recalling the experience
of eating an apple, for example,
the hippocampus retrieves visual
information (red, shiny), taste and
smell information (sweet, a little
tart), tactile information (crunchy),

and high-level abstract knowledge
(nutritious, wards off doctors).
And what does the brain do
with information besides recall it?
Most notably, it solves problems—
it thinks. Problem-solving generally
requires effort and occurs in steps,
like a math problem. Regardless
of the type of problem being
solved, your brain recruits not just
one special problem-solving cell
ensemble, but a whole array of cells
from all across the brain, involved
in everything from visuospatial
reasoning to critical judgement to
emotional associations. And this
process—again, like algebra—
takes time. It is not spontaneous.
This, then, is the mystery: how
is it that sometimes the brain seems
to arrive at an answer instantly,
and usually when you are least
expecting it? How does disparate
information, stored all over the
brain, coalesce all at once into
insight?

How Scientists Study
Insight
First: a definition. There is
something intuitive and obvious
about the experience of insight.
Cognitively, it can be thought of as a
transformation or rearrangement of
things you know. From this cognitive
shake-up of the known comes
new knowledge—knowledge that
allows you to think or act in a new
way. Neuroscientists have become
quite good at experimentally
prompting these sorts of cognitive
breakthroughs.
In a landmark 2004 study, a
team of scientists designed a task
where participants were given two
simple rules and told to decode a
string of numbers. There was also a
hidden third rule that said the first
and last two digits of the decoded
sequence were the same, which
greatly expedited solving time. The
fact that this rule was undisclosed
meant the researchers, by timing
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the participants, could pinpoint
when they gleaned the hidden rule
via insight. Participants completed
the tasks at two time points, with
some of them sleeping in between
and some remaining awake.
The results of the study would
come as no surprise to Kekulé.
Those who were allowed to sleep
before trying the task again were
significantly more likely to discover
the hidden rule. In order to rule
out the obvious argument that
exhausted participants were less
likely to have insight, the researchers
included a group without exposure
to the task who attempted it after a
night of sleep. This group did as well
as the exhausted participants. The
take-home message? Something
seems to happen in our brains
when we sleep—a restructuring of
knowledge that allows us to have
waking insight.
But what of showerthoughts,
carthoughts, and daydreams?
In 2018, the same number task
was presented to participants,
except
instead
of
allowing
some participants to sleep, the
researchers simply allowed some
participants to have a brief period
of quiet rest (think meditation).
The results echoed those of the
2004 study: participants who were
allowed a quiet rest were much
more likely to have an insight that
revealed the hidden rule.

words (for example, HOUSE-BARKAPPLE) and are asked to provide
a related word that would create
three compound nouns (the answer
in this case is TREE, which gives tree
house, tree bark, and apple tree).
An analytical approach to this task
is tedious: to consider every word,
one by one, would take forever.
An insight solution always presents
itself sooner, because as soon as
you hear house, bark, and apple,
the word tree has already drifted to
the surface of your consciousness.
fMRI data tells a similar but
more complex story8. For starters,
there is the clunkily named cast of
anatomical characters. The nucleus
accumbens is the star, integrating
input from the hippocampus,
dorsolateral prefrontal cortex,
and the ventral tegmental area.
The hippocampus, as previously
described, calls up memories
from all across the brain and
sends information to the nucleus
accumbens.
The
dorsolateral
prefrontal cortex, besides being a

mouthful to say, is responsible for
goal selection. In other words, it sets
the agenda and prevents the chatty
hippocampus from overwhelming
the nucleus accumbens with
unnecessary input. The ventral
tegmental area is responsible for
both motivating and rewarding
problem solving.
Together with sensory input
and help from language processing
centers in the temporal lobes, these
parts of the brain seem to drive
insight formation. The words house,
bark, and apple cause ensembles
of neurons to fire that are linked
through conceptual associations
with tree. This information is
assembled by the hippocampus,
which, guided by the dorsolateral
prefrontal cortex, then informs the
nucleus accumbens. The nucleus
accumbens integrates hippocampal
memory input with higher level
processing to bring conscious
awareness to the solution.
The cognitive challenge of
insight formation is made all the

Neural connections imaged using multicolor neuronal tracing18

The Anatomy of an
Insight
Not only is insight a
behaviorally
observable
and
inducible
phenomenon,
but
scientists have managed to
observe insight in people inside
MRI machines. In one study,
participants in an fMRI machine,
which measures brain activity
by detecting changes in blood
oxygen levels, were presented with
a simple word association task. In
this task, participants see three
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A schematic representation of the way memory scaffolds and promotes insight
Original image by Kevin Crawford

more demanding by the many
puzzle pieces that go into solving
any one problem. Sight, hearing,
language,
mathematical
and
semantic reasoning—the list goes
on. So the brain has a built-in
cheerleader: the ventral tegmental
area. The ventral tegmental area
sends excitatory bursts of dopamine
to the nucleus accumbens and
dorsolateral prefrontal cortex to
stave off fatigue and help them reach
a solution. It is for this reason that
the experience of solving a tough
math problem or filling in a tricky
crossword clue can feel so intensely
satisfying. The psychologist and
philosopher Alison Gopnik went
as far as to compare the formation
of insights to orgasm, because as
orgasms encourage reproduction,
the feeling that accompanies
insight encourages the creation of
scientific theories.

Thinking Outside the
Biology to Build a
Theory of Insight
The narrative of insight spun
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from fMRI data seems, at first
blush, complete. But it leaves many
questions unanswered. fMRI data
reveals nothing about the timing
of the brain activity associated
with insight: it provides only the
anatomical puzzle pieces. Scientists
speculate about what different parts
of the brain do and how they work
together based on biological data,
but the framework of cognition, let
alone insight formation, is difficult
to reduce to biological processes.
Increasingly,
researchers
are
looking outside neuroscience for
clues about the way insight works.
William James, the patriarch
of American psychology, compared
thought to a bird’s flight. As a
bird alternates between flying
and perching, our thoughts jump,
seemingly randomly, from one
topic to another. A more modern
comparison is the stock market.
The up-or-down fluctuation of
stock prices, and the mathematical
“random walk” model economists
use to understand them, is
consistent with the vagaries of
thought.
Psychologists
have
demonstrated that when people are

asked to come up with words from
a category (e.g., fruit), the way they
search for words is random in the
same binary manner as stock prices.
A person presented with the fruit
prompt in a neutral setting (i.e., a
setting that will not prime a specific
fruit) has the same chance of saying
apple as pear (in the same way a
stock price can go up or down).
Biologically, this makes sense. We
know the neurons encoding fruits
are linked by associative networks
of cells, but the way an electrical
signal cascades through these
neurons is unpredictable.
Even if you are not prompted
with a topic, your mind wanders
and generates thoughts seemingly
at random. The memories that
spontaneously pop into your
consciousness are influenced by
everything from your mood to
your environment, but are usually
related to a recent experience.
These episodic sparks kick off
cascades of related memories
and knowledge. If you have ever
answered a question incorrectly
in class and felt embarrassed, you
probably revisited that experience
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later and then recalled other times
you felt publicly embarrassed.
These anxious thought spirals are
an example of associative networks
in your brain firing in response to
episodic replay.
In the same way we relive
especially
embarrassing
or
gratifying moments, our minds
dwell on problems. Encountering
a problem primes our brains to
begin solving it, even if that is
not a conscious goal. This occurs
because insight is not the process
of overcoming something, per se,
but the process of making new
connections between things we
already know. In this way, episodic
memory is a scaffold for semantic
memory; the way you learn
something and what you learn are
inextricably bound up together.
When you spend a day struggling
with a tough problem, the
anatomical network outlined earlier
is at work. But when you take a rest,
this network is no longer engaged.
Your mind begins to wander and
episodic memories from your
day begin to replay. This replay
generates semantic memories as
a result of cascading associative
networks1. If consciousness is a
stage, these semantic memories
are the actors and the episodic
memories are the plot. Your mind is
the spotlight that brings the actors
into focus.
So how does episodic replay
lead to insight? In the model
pictured, semantic knowledge is
generated from the bottom up by
episodic replay and the internal
attention of the wandering mind is
represented as spotlights. The way
the mind wanders and the type of
episodic memories being replayed
are both affected by the control
box of your current state (e.g., how
you are feeling). By highlighting
semantic knowledge that arises
as a result of episodic replay, the
spotlight of the wandering mind
makes inadvertent connections

between previously unrelated
pieces of semantic knowledge.
These connections are perceived
as creative thought or insight.
In
simpler
terms:
the
wandering mind is unrestricted by
a specific task, which enables it
to explore the thoughts randomly
generated by the activation of
associative networks. Because we
tend to think about ourselves—our
own experiences—it is likely that
the wandering mind is dealing with
memories pertaining to problems
that preoccupy you. As a result, and
seemingly without any conscious
input from us, the brain makes
connections between memories
that we otherwise might not have,
leading us to see things in new
ways.

Wandering Minds
A lot of good work is done
by conscious, intentional problem
solving. Ben Schumacher’s qubit
theory of quantum information
would not have materialized were
it not for years of diligent thought
and mathematical problem solving.
But the bones of his theory came
from spontaneous insight—they
came from a carthought.
The
problem-solving
network formed by the nucleus
accumbens,
hippocampus,
dorsolateral prefrontal cortex,
and ventral tegmental area is very
good at figuring out solutions to
familiar problems because it uses
heuristics13. Heuristics are problemsolving strategies that work but
do not have a rational basis. For
example, similarity heuristics are
problem-solving shortcuts that
allow us to quickly solve problems
or learn things by assuming they
are similar to things we have
encountered, or believe we have
encountered, in the past. Racial
profiling is an insidious example
of the similarity heuristic at work.
A more subtle example is the
way marketing agencies play on

brand loyalty to sell new products:
because you enjoyed one product
made by a company, you are likely
to assume you will enjoy other
things made by that company.
In short: the brain can be
extremely lazy when it comes to
problem solving. Paradoxically,
quiescent states—times when
the brain is not fully engaged,
like when we shower or drive or
meditate—help us solve problems.
The dorsolateral prefrontal cortex,
which inhibits the associative
cascades of the hippocampus in
order to streamline thinking, is not
active in these states. This allows
for the messy deluge of memories
and knowledge stored across
the brain to take center stage,
where novel connections between
seemingly disparate ideas can lead
to extraordinary innovation.
Showering and driving also
allow for your attention to turn
more fully inward than usual. When
you are engaged in a familiar task,
but not one that bores you, your
brain enters a sweet spot between
engagement
and
monotony.
Whereas full engagement makes
the problem-solving network prone
to assumptions and shortcuts that
sidestep insight, boredom causes
a system called the default mode
network to kick into gear. The
default mode network is what it
sounds like: the program your
brain runs when nothing much is
going on. It is not good for creative
problem solving. Activation of
the default mode network (i.e.,
boredom) is negatively correlated
with activation of the regions of
the brain associated with memory
processing15. In contrast, when you
take a shower (or bath), meditate,
drive, or whatever you do that lets
your mind wander, your brain runs
the sort of episodic replay that leads
to cognitive reorganization and,
just maybe, your earth-shaking,
world-saving idea.
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And What About
Dreams?
Kekulé’s
dream
of
the
ouroboros, fantastical as it seems,
has a basis in scientific reality. While
sleep differs from a state of simple
restfulness, it seems to similarly
promote memory consolidation
and cognitive reorganization.
In 2018, researchers had three
groups attempt a visuospatial
reasoning task. Two groups heard
a tone during the first attempt
and were allowed to sleep before
the second attempt. One of
these groups had the same tone
played while they slept. The third
group did not hear a tone and
attempted the task a second time
after only a brief period. Both
sleep groups performed better
than the non-sleep group, which
suggests that sleep promotes
memory consolidation and the
formation of cognitive strategies.
Interestingly, the group that heard
the tone while sleeping performed
significantly better than the other

groups. This suggests that sleep is
a more permeable and malleable
state than previously thought. EEG
readings from the sleeping group
that heard the tone showed that
they had significantly more brain
activity associated with memory
and critical analysis than the
sleeping group that did not have
the tone. This activity coincided
with REM activity, the brain state
associated with dreams. Even
when we sleep, it seems, we are
thinking. Dreaming may be a form
of thought incomprehensible to the
waking mind.

What It All Adds
up to: Everyday
Moments of Genius
For those of us who do not
theorize about the potential of
quantum systems or deliberate the
molecular structures of compounds
so preposterously miniscule they
may as well not exist, there is still
room for genius. Spontaneous

insight, aha!, and eureka! moments
are all names for a phenomenon
that occurs daily and in the lives of
many.
There is nothing spectacular
about the anatomical or cognitive
bases of insight beyond the fact
that it is spectacularly difficult to
boil spontaneous problem solving
down to biology. What we do know
about insight suggests that there
are certain habits that encourage it.
The same neural and psychological
mechanisms that drive analytical
thought also trap us in cognitive
ruts if we spend too much time
on any one problem. Conversely,
wandering minds connect points
the conscious mind is not fully
aware of in the first place, but need
the memories of a working mind
if they are going to accomplish
anything. The key to balancing the
needs of these two systems ends
up sounding a little Hallmark, but it
bears repeating: sometimes we all
need a little break.
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The Brain’s Waste Removal System as
Therapy for Alzheimer’s Disease
By Katrina Simchick
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s modern medicine
and science continues
to advance, we are
able to live longer thanks to better
cures and treatments as well as
better knowledge on how to stay
healthy. This seems positive, right?
However, our ability to live longer
increases the aging population and
therefore increases the presence of
aging related problems. By 2030,
just 10 years away, US individuals
65 and older are expected to
outnumber those 18 and under10.
This increased aging population will
require more geriatric caregivers
and funding than ever before.
Additionally, as people live longer,
there will be a surge in the number
of people with age-related diseases
and afflictions, such as Alzheimer’s
disease.
Alzheimer’s disease is the
6th leading cause of death in
the United States and there is
currently no cure. Alzheimer’s
patients originally suffer from
mostly cognitive deficits, including
language
comprehension,
problem-solving, and most notably,
memory. There are countless
representations in popular media
depicting the Alzheimer’s patient
unable to remember their friends
and family. And while this is a very
real and devastating effect of the
disease, Alzheimer’s does not stop
there. As the disease worsens and
spreads, other basic functions,
such as movement, breathing,
and speaking, are also affected
and patients need round-the-clock
care. Right now, around 6 million
Americans are living with the
disease, but due to the growing
elderly population, this number is
expected to more than double by
20501. To help solve and assuage
this current problem afflicting our
society, there is an entire field of
scientific research dedicated to
uncovering how the disease works
and exploring different therapies
and possible treatments.
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A current treatment approach
involves the mechanisms employed
in cellular waste removal - basically
how our brains take out the trash. The
glymphatic system, a term coined
by Iliff and colleagues, refers to this
proposed waste removal system of
our brains. This system increases
the brain’s clearance of Alzheimer’s
causing proteins while we sleep.
Could we then use sleep, an innate
human function, as a method for
getting rid of these degenerative
proteins? Researchers are now
looking to further understand how
the glymphatic system works so
that it can potentially be harnessed
as a treatment for eradicating
those degenerative proteins in
Alzheimer’s patients5. This begs the
question: how exactly can sleep be
an Alzheimer’s cure?

How Our Brains Take
Out the Trash
Let’s set the scene: Our brains
are made up of billions of neurons
that connect to each other, helping
us to eat, sleep, breathe, and do
everything else that we do. Just
like the rest of the body, our brain
also requires oxygen to function.
This is achieved through veins and
arteries that penetrate the brain. A
barrier is made between the brain’s
vasculature and the interstitial fluid
(ISF), the fluid that sits between
cells and capillaries. The barrier is
made up of cells that are packed
tightly together so only things that
are really small can pass through.
The selected solutes and molecules
then seep past surrounding glial
cells, another type of cell found in
the brain, and into the ISF. Our brain
is also surrounded by cerebrospinal
fluid (CSF), a bodily fluid that’s
used to keep the brain buoyant, to
protect the brain, and to maintain
levels of substances that our brain
needs and secretes.
The glymphatic system arose
from research trying to uncover

how our brain got rid of its waste.
In the body, the lymphatic system
gets rid of cellular waste and
maintains the balance of fluids,
which prevents fluid build up by
draining the interstitial fluid into
lymphatic vessels34. Neurons, just
like all other cells in our body, create
waste due to the large amount of
molecules and substances they are
making and secreting in order to
function properly. This is secreted
into the ISF. However, the brain
does not have any lymphatic
vessels that could be used to move
fluid and maintain this balance in
the brain. The brain must have a
way of getting rid of this waste to
avoid build up, which could lead
to problems with neuron function.
So even though scientists know
that the brain has fluid movement
similar to the lymphatic system,
they were unsure of how it was
being done without any lymphatic
vessels 7, 16.
While the glymphatic pathway
and CSF waste removal has been a
recent interest, the study of CSF
flow into and out of the brain has
been around for a long time. In
the 1970’s Cserr and colleagues
discovered that when they injected
solutes into CSF filled spaces,
they were transported faster than
expected. This told them that
something in the brain was helping
this fluid move and circulate, that it
was not moving of its own accord7.
This sparked quite a few studies that
looked at the perivascular transport
of CSF, that is the transport of CSF
into the brain along arteries and
veins. It was discovered that when
a substance was injected into the
CSF, the substance entered the
brain along the arteries at a very
rapid speed due to the arterial
pulsations 7, 29.
In 2012, Iliff and colleagues
repeated these past experiments
but with advanced technology to
see what they would find. They
too saw that CSF was entering the
64
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Figure 1. The Glymphatic Pathway: 1) CSF enters the brain through the periarterial space. 2) It then leaves the periarterial space with the help of the
AQP4, entering the interstitial space which is filled with ISF and waste. 3) This causes the CSF and ISF to go through an exchange, 4) the CSF pushing
the ISF out of the interstitial space and into the perivenous space, 5) through which it exits the brain15,28.
Original image by Katrina Simchick

brain along the arteries very rapidly.
However, they also demonstrated
that molecules in the interstitial
space (the space between cells
where ISF resides) were cleared
from the brain along the veins.
This created a model for how the
glymphatic pathway, a term they
coined, worked15. As demonstrated
in Figure 1, the CSF enters the
brain through the periarterial
space, which is the space between
the around and the protective
sheath. It then diffuses into the
interstitial space which drives the
ISF and accumulated cellular waste
towards the veins, where it exits
the brain along the perivenous
space, the space between veins
and the protective sheath 7, 8, 14,
15
. In a way, you can think of the
glymphatic system like the ocean.
Shells and pebbles litter the beach
until suddenly a wave washes
65

ashore and then all those pebbles
and shells are gone. The CSF, like
a wave, comes in and washes the
waste and ISF back out along the
veins.

The Driver’s Seat:
What Drives the
Glymphatic System?
They next wanted to answer
the questions of scientists before
them: Why was the CSF and ISF
able to move through this pathway
so quickly? Iliff and colleagues
decided to look at the function of
AQP4. AQP4 are water channels,
so it would make sense that they
are involved in fluid distribution,
as a large component of CSF and
ISF is water. These channels hang
out around the glial sheath that
encases the blood vessels 8, 15. To

get a better picture of this, imagine
the blood vessel is a hot dog, the
glia are the bun, and the AQP4
are sesame seeds. The glia act as
a barrier between the perivascular
spaces and the interstitial space.
The job of AQP4 is to pump
fluids from within the perivascular
space across the glia and into the
interstitial space. When the AQP4
is removed from the brain, the flow
of CSF is reduced. The CSF still
enters the brain along the arteries,
but it no longer moves into the
interstitial space, which decreases
waste removal by about 70%15.
In addition to the AQP4 water
channels, there is also a physical
force that helps to move the fluids
and cellular waste. However, there
is controversial and conflicting
evidence as to what is responsible.
One possibility is the pressuredriven bulk flow model. This model
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suggests that the pulsation of our
arteries as our blood circulates
drives the CSF into the brain. This
arterial pulsation creates a “bulk
flow” or the movement of all the
liquid at once, everything moving
together at the same time 2, 12, 13,
23
. A good example of bulk flow
is a river: the water all flows down
the river together. This model also
proposes that because of a higher
fluid pressure in the periarterial
space, it pushes the CSF into the
interstitial space where it then flows
towards a low pressure area, the
perivenous space 7, 13. If we think
about rivers, the incoming pushes
the water further downstream,
where there is less, so that it doesn’t
overflow.
However,
some
research
suggests that this bulk flow
hypothesis doesn’t make sense.
Instead, they suggest that cellular
waste exits the brain because of
diffusion 3, 4, 13. This basically means
that when there is a build up of
cellular waste, it drifts to where
there is no or less waste in order
to create a balance. Diffusion is
also based on molecule size: the
smaller the molecule, the faster
the diffusion. Therefore, smaller
molecules will be able to move
faster than large molecules in the
same amount of time. In bulk flow,
the size of the molecule doesn’t
matter as everything is being
pushed together in one direction.
In diffusion models, once the CSF
enters the interstitial space, the
small molecules move faster than
the large molecules when measured
at 60 minutes 34. Current research is
trying to untangle this vast range
of evidence to find out which one,
either bulk flow or diffusion, is the
driver.

The Glymphatic Exit
As the field has continued to
expand, debate has also sparked
over how exactly the glymphatic
system gets rid of the waste. Iliff

and colleagues’ original findings
suggest that the flow of CSF pushes
the ISF and waste out of the brain
through the perivenous space15.
While most evidence agrees that
CSF enters the brain through
arterial space and mixes with the
ISF in the interstitial space, there is
conflicting evidence about how it
exits the brain (Fig. 2).
One alternative mechanism is
that instead of exiting via the veins,
it can exit via the arteries, meaning
it exits the brain the same way it
entered. Evidence supporting this
model complicates the glymphatic
concept as it shows a completely
opposite exit as it goes against
the grain of the inflow 6, 8, 13 . The
difference in evidence supporting
these two exit models could be
due to differences in experimental
technique. More research is
currently being done to figure out
whether the convective flow of
the glymphatic pathway results
in drainage along veins or along
arteries 7, 8.
Another possible exit strategy
for ISF and cellular waste is along
cranial nerves. These are the nerves
that exit our brains, but don’t go
very far as they control the motions

of our head and neck, including
tongue, eye, and nose movements.
As previously suggested, the CSF
flows into the interstitial space
through the arterial space, but
instead of exiting along any blood
vessels, it exits through the cranial
nerve 7, 8, 13. While there is strong
evidence to support this model,
it is unknown whether or not it
works in conjunction with the other
exit pathways or if it is the major
clearance route. As the field moves
forward, these different models
will be tested to determine how all
these different pieces of evidence
fit together.

So What’s the
Connection Between
the Glymphatic
System and
Alzheimer’s?
The neurons in our brain
make a protein called amyloidbeta. Neurons secrete this protein
into the interstitial space once it is
no longer needed, so it becomes
another cellular waste product.

Figure 2. The Glymphatic Exit: How does the cellular waste actually leave the brain? 1) The
glymphatic model proposes the ISF and cellular waste exits the brain along the veins. 2) Another
model suggests that the waste exits the brain along the arteries, leaving through the same route
it entered. 3) A third model proposes that the ISF and waste leaves along the cranial nerves. It is
debated whether or not it works by itself or in conjunction with the other proposed methods.
Original image by Katrina Simchick
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After it is dumped, it is cleared out of
the brain by the glymphatic system.
However, Alzheimer’s disrupts this
process. In an Alzheimer’s brain,
this protein is made incorrectly
so that they bind together and
form plaques, or clumps of the
protein. These plaques stick
to neurons and accumulate,
smothering the neurons until they
are no longer able to receive the
proper nutrients causing them to
die. It is this neuronal death, the
neurodegeneration, which causes
cognitive deficits as the neurons can
no longer communicate or function
properly20. So while a normally
functioning brain gets rid of
amyloid-beta, the Alzheimer’s brain
has a build up of these proteins
which cause neurodegeneration.
This accumulation of this “bad”
protein is likely due to the
malfunctioning glymphatic system
in Alzheimer’s disease.
Research shows that glymphatic
function is weakened in Alzheimer’s
disease27. The AQP4 channels,
which help move CSF into the brain
through to the interstitial space, are
decreased along the arteries. This
in turn causes a decrease in the
ability of CSF to exchange with the
ISF, resulting in less efficient waste
clearance which leads to build-up
of waste 11, 23, 36. Specifically, the
amyloid-beta protein will remain in
the brain for longer which increases
the likelihood of them forming
plaques and sticking to neurons.
As more and more amyloid-beta
plaques accumulate, they affect the
AQP4 further, worsening the brain’s
ability to clear amyloid-beta 38.
So researchers put two and
two together: If in a normally
functioning brain, amyloid-beta
is cleared by the glymphatic
system, and if Alzheimer’s is a
result of accumulated amyloidbeta that is in part due to a lack of
waste clearance, then promoting
glymphatic function in Alzheimer’s
brain may lead to less plaque
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build up. This could then decrease
neurodegeneration and therefore
improve cognition. The question is
- how can glymphatic function be
improved? One word: Sleep!

The Night Shift:
How the Glymphatic
System Works at
Night
The amount of amyloid-beta
present in our brains is regulated
by the sleep-wake cycle. The
protein is present at higher levels
when we are awake and lower
levels when we are asleep. This
fluctuation is caused by changes
in neuronal activity 17, 22, 31. During
the day, when we are awake, there
is a lot of activity in our brain due
to neurons constantly and rapidly
firing in order to carry out our daily
functions. This neuronal activity is
what encourages the production
of proteins like amyloid-beta.
When we go to sleep, this neuronal
activity is diminished and our brains
enter a restful period, leading to a
decrease in protein production5.
Basically,
increased
neuronal
activity while we are awake makes
the amyloid beta, leading to
the higher levels, while at night,
protein production is halted. But
what is actually lowering the levels
at night? It’s the glymphatic system!
In sleeping mice, CSF enters
the brain along the arteries and
moves into the brain tissue, which
follows the glymphatic model.
However, CSF influx is 95% less
in awake mice in comparison to
sleeping mice, illustrating that very
little CSF enters the brain while
we are awake35. Sleep regulates
the glymphatic pathway because
the sleeping brain allows for the
necessary flow of CSF into the
brain tissue while the awake brain
suppresses this influx. Additionally,
amyloid-beta clears twice as fast
in sleeping mice than in mice

who are awake 8, 15. This evidence
is consistent with the glymphatic
theory. When the brain is asleep,
the CSF enters the brain along the
arteries and enters the interstitial
space where it pushes the amyloidbeta to leave the brain. As the
brain awakens, CSF slows its influx
into the brain, leading to less
clearance during the day and an
accumulation of amyloid-beta as
it continues to be produced. The
glymphatic pathway accounts for
the difference between the amount
of amyloid-beta when you’re awake
versus when you’re asleep due to
these changes in clearance.
This influx of CSF while
sleeping is likely due to an increase
in the size of the interstitial space
of sleeping mice compared to
awake mice. One study showed
that in mice, the interstitial space
can increase more than 60% when
sleeping when compared to the
awake brain15. As the brain’s activity
slows during sleep, this area
between the neurons expands,
creating more space for CSF to fill as
it flows in. Conversely, as the brain
awakens and activity increases,
this space shrinks, preventing CSF
in flow because there is no longer
enough space for the CSF to fill.
These findings are important
beyond
just
its
relevance
to Alzheimer’s disease. The
connection between sleep and the
glymphatic system are important as
they help piece together the puzzle
of sleep. Despite the fact that we
spend around 25 years of our life
asleep, it is unclear as to the role
and function that sleep plays37.
Thanks to this glymphatic research,
one goal of sleep appears to be
clearing potentially harmful waste
from the brain and to maintain fluid
balance.
As to how sleep relates to
Alzheimer’s disease, around 65%
of Alzheimer’s patients have a
sleeping disorder, such as insomnia
or sleep apnea 5, 26,. This leads to
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not only a shorter duration of sleep
but also fragmented and poor
quality sleep. Less sleep means
less glymphatic clearance. After
sleep deprivation, amyloid beta
increases in the brain’s CSF and
ISF. The brain does not go into rest
mode so not only is it continuing
to produce amyloid beta, but also
the glymphatic system is unable to
remove the protein from the brain
21, 22, 32
. Furthermore, in Alzheimer’s
brains, sleep deprivation results in
an increase of amyloid plaques17.
Because the brain’s glymphatic
system is unable to function, the
amyloid hangs out in the brain and
is more likely to accumulate.

Sleep More! Doctor’s
Orders!
There are plenty of suggested
daily changes that doctors suggest
to help assuage and slow the
cognitive effects of Alzheimer’s.
Things such as diet, exercise, and
cognitive stimulation have all
been shown to lessen cognitive
deficits1. This current research
about the glymphatic system
shows that improving sleep may be

Micrograph of cerebral amyloid angiopathy
By Nephron from Wikimedia (CC BY-SA)

another way to relieve Alzheimer’s
symptoms. Since impaired sleep
in Alzheimer’s disease can lead to
more amyloid-beta accumulation
and impaired sleep affects the
glymphatic system, improving
sleep
quality
and
quantity
could slow neurodegeneration
by
decreasing
amyloid-beta
accumulation. A recent study
showed that in Alzheimer’s mouse
models, when their symptomatic
disrupted sleep was restored,
amyloid-beta
accumulation
slowed
down
significantly18.
Sleep can be used to harness and
promote the innate function of
the glymphatic system to get rid
of these degenerative proteins.
By sleeping more and sleeping
better, it is possible to protect our
brains from Alzheimer’s disease.
There are currently a lot of sleep
enhancement treatments, such as
melatonin and acoustic stimulation,
which are under investigation as
potential therapies5.
Additionally,
since
the
glymphatic pathway’s efficacy is
impacted in Alzheimer’s, even
before deposition, it is possible
that the early presence of sleep

disruption is the cause of impacted
glymphatic clearance, resulting
in the build-up and deposition of
amyloid-beta. Considering that
altered sleep is one of the earliest
symptoms of Alzheimer’s disease,
researchers are proposing that
paying attention to sleep disruption
appearing later in life may be used
as a tool to diagnose patients at
an earlier stage of the disease 5, 24,
31
. This would then allow patients
to implement treatments, such
as improved sleep therapies,
sooner rather than later which
could significantly slow down the
neurodegenerative effects.
While there is still no absolute
cure for Alzheimer’s disease, this
new field of research about the
glymphatic
system
proposes
an important and innovative
new
treatment
approach.
However, despite the excitement
surrounding
the
glymphatic
system, research can still be done
to better understand exactly
how it works. By increasing our
knowledge about these glymphatic
mechanisms, we will understand
how to optimize its function in
order to slow neurodegeneration
of Alzheimer’s and possibly prevent
it. Additionally, the glymphatic
system has also shown to be a
potential treatment for other
neurodegenerative diseases as well
as ischemic strokes. Furthermore,
a better understanding of the
role sleep plays in the glymphatic
system and Alzheimer’s disease is
especially important as it presents
a possible treatment approach that
is both non-invasive and affordable.
While scientific advancement aids
in the increasing aging population
and prevalence of age-related
diseases, this scientific research is
also how we will be able to conquer
and combat those same diseases.
So the next time you sleep
through your alarm, don’t feel bad
because you’re actually helping
yourself out more than you think.
68
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Illustration of a lymph gland
By E. A. Schaffer, Text-book of microscopic anatomy.
from Wellcome Collection (CC BY 4.0)
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f you’re familiar with the
changing of seasons, you’ve
experienced the temperature
start to drop over the course of a
few months, and you slowly go from
wearing shorts and light jackets to
sweaters and needing a hat and
scarf when you walk outside. Along
with the temperature dropping, the
days seem to be getting shorter as
the sun sets earlier and earlier and
earlier. Activities outside are once
enjoyable, but before you know
it, it’s hard to get outside at all. If
you’re a student, this may be most
evident as you finish practice or
dinner. It’s light outside, not sunny,
but a bright grey as you go inside to
sit down for dinner and completely
dark as you leave, difficult to see
anything outside of lit pathways.
Maybe you were even able to
watch this change take place within
an hour from a window. And now,
instead of leaving dinner with a
full belly to go toss frisbees on the
lawn with friends, you leave dinner
and take the fastest route home to
change into pajamas for the night.
If you’re working, this may look
more like a change in the drive
home, where you now find yourself
squinting, watching for deer and
making a quick, easy dinner when
you get home to end the day early.
No matter your situation, the onset
of winter seems to bring with it a
dampening of energy and activity.
This experience is one wellknown to those living in Denmark,
where its citizens have developed
a coping mechanism and coined
it “hygge” (pronounced hoogah).1,2,3,4 Hygge refers to a lifestyle,
a feeling, something that one
embodies rather than something
concrete. This phenomenon is
now gaining popularity across
different cultures.5 In order to
beat the winter blues many have
worked to adopt this new mindset.
Hygge asks one to first be aware of
surroundings and further take joy
in every part of them.1,2,3,4,5,6 Hygge
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is described as “the art of creating
intimacy”.1,6 Outside of recognizing
and enjoying the mundane,
everything from making a warm
drink before bed to taking a walk to
the mailbox, hygge has a lot to do
with light. The lighting of the space
you spend your time in creates an
atmosphere that affects mood.
Think about candle lights on dinner
tables and fires warming friends’
toes, warm light occupying every
room you pass time in. Light can
connect people to people, people
to things, and people to spaces in
ways that are just past description.7
This connection warms the soul
that gets many through the gloomy
winter season.
For some reason however,
this outward seasonal change
creates a much more dramatic
internal change than described.
About three to five percent of the
general population is affected by
Seasonal Affective Disorder, or
SAD.8,9,10,11,12 This disorder is listed
as a specifier of Major Depression
in the DSM-V and defined as
recurrent temporal depression
with symptoms that onset at a
particular time of the year, most
commonly winter, and completely
disappear the other portion of the
year, the summer and spring. The
most common symptoms of SAD
include hypersomnia or excessive
sleepiness and hyperphagia or
excessive eating. In SAD, the
excessive
sleepiness
typically
happens in daytime hours, and
hyperphagia will lead to weight
gain. Other symptoms include
depressed mood, carbohydrate
cravings, irritability, loss of interest,
and social withdrawal. A diagnosis
is not made unless an individual
experiences these episodes for at
least consecutive years.8,9,11,12,13,14,15
Much less common, SAD presents
inversely, with the onset of
symptoms occurring in the summer
months and the regression in the
winter months. Symptoms include

hyposomnia and weight loss, the
opposite of those seen in SAD
onset in the winter months, as
well as hyperactivity and elevated
mood.8,9,14 Given most cases of SAD
onset in the winter, the prevalence
is higher in populations located
at higher longitudes. We also see
a higher diagnosis rate in women
and populations already diagnosed
with a mood disorder.9,11,12,13
So what is it that causes
these seasonal changes in mood
and sleep patterns? There has
been no conclusive evidence that
confirms the pathophysiology, the
disordered mechanisms, of this
disorder. However, several theories
have been postulated based on
evidence of an effective treatment
called Bright Light Therapy
(BLT). BLT works by exposing an
individual to bright light at any
combination of morning, midday,
and/or evening.13,14,15,16 Each theory
is an explanation of SAD based
on different mechanisms and
pathways in the brain, but all share
one commonality: light.
Light
sends
information
throughout the brain via the
retinofugal tract. Light first enters
through the eye where it activates
ganglion cells, which are specific
to the retina. The ganglion cells
contain a photopigment called
melanopsin that is activated and
then sends information via the
retinohypothalamic tract to the
suprachiasmatic nucleus, the part of
the brain that controls our circadian
cycle, or 24 hour day, located in the
hypothalamus.17 This signal helps
our endogenous circadian rhythm
to sync to light-dark cycles. BLT uses
light that mimics the sun and can
trigger this pathway, thus tricking
our brain into feeling longer lightdark cycles in the winter time.14,16
This mechanism of action targeted
in BLT coupled with the positive
effects observed when using BLT
has led to the following hypotheses
of pathophysiology in SAD:
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Phase Shift
Hypothesis

This
hypothesis
suggests
that the normal circadian rhythm
has an optimal alignment to the
light-dark periods and is shifted,
presumably thrown off, by the
shortened days. The body’s natural
rhythm is thrown out of sync. This
theory posits that the timing that
BLT is administered would matter.
Exposure to bright light in the
morning would correct the shifted
circadian cycle by a phase advance,
and bright light exposure in the
evening would correct the shifted
circadian cycle through a phase
delay. The exposure to bright light
at the correct time of day would
realign the body back to the typical
circadian rhythm.11,12,14,15,18,19
Our body uses melatonin, a
hormone, to regulate our sleep
cycles. Melatonin is released in
the body about two hours before
we actually go to sleep, given our
setting is dimly lit. This period
is called the dim light melatonin
onset (DLMO) and can be used to
measure phase differences. The
suprachiasmatic nucleus, located
in the hypothalamus, controls
the pineal gland which releases
melatonin in the brain.18,20,21 We
can see how BLT would impact this
process because we know that light
sends signals through our brain that
reach the hypothalamus, the same
area of the brain that controls the
release of the hormone that makes
us sleepy.

Melatonin
Hypothesis
Melatonin is secreted in
the brain in higher amounts at
nighttime, this is referred to
as nocturnal pineal melatonin
secretion. Typically the period we
sleep through is the period it is the
darkest outside. Light suppresses
melatonin production, and the
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theory is that because it darkens
early on winter days, there is no
light to continue to suppress the
production of melatonin through
late afternoon and evening. This
could make the individual feel
sleepy earlier than usual because
this period of nocturnal pineal
melatonin secretion is occurring
earlier.15
In the melatonin theory, we
would expect to see BLT having
positive effects when administered
in the evening. Bright light entering
through the eyes would send
signals through the retinofugal
tract to the hypothalamus where it
inhibits the production and release
of melatonin by pineal gland.15,21

Serotonin Hypothesis
The serotonin hypothesis was
derived from the symptoms seen in
individuals diagnosed with SAD as
well as studies providing evidence
that both BLT and selective
serotonin
reuptake
inhibitors,
better known as SSRIs, alleviate the
symptoms associated with SAD.
Serotonin is a neurotransmitter that
has been tied to many functions
including our mood, sleep-wake
cycle, and eating habits. Since all
three of these areas are affected
in individuals with SAD, serotonin
is a good candidate to study as a
contributor to the pathophysiology
of this disorder. Naturally, serotonin
levels have been found to be lower
in the colder and darker winter
months than in the warmer and
sunnier summer months. The theory
is that this difference is even greater
in individuals with SAD, producing
depressed
moods,
impeded
sleep cycles, and increased food
consumption.11,12,14,22
The hypothalamus contains
serotonin receptors, in particular
5HT2CRs. These receptors are
associated with the regulation of
energy balance and feeding habits,
both of which relate to symptoms
seen in individuals with SAD. Since

we know that serotonin levels are
low in the winter time, and lower in
individuals with SAD, it is reasonable
to think that these receptors are
not being activated and therefore
not functioning correctly.11,12,14,23,24

Photoperiod
Hypothesis
Much like the melatonin
hypothesis,
the
photoperiod
hypothesis has a lot to do with the
function of melatonin, in this case
nocturnal melatonin. Seasonal
rhythms in humans, such as the
circadian rhythm, follow cues from
the photoperiod, a term referring
to the length of day. This hypothesis
simply posits that instead of
adjusting with the seasonal change
in photoperiod, the body responds
abnormally,
causing
longer
duration of nocturnal melatonin
in the brain, resulting in a longer
period of sleep.12,15
The light-dark cycle regulates
melatonin production via the
retinohypothalamic tract through
the
mechanisms
discussed
before. In the winter, the light
phase shortens and the body is
receiving signals timed differently
than usual.20,21 The body’s internal
clock, the circadian rhythm, is still
running on the 24-hour cycle,
giving systems conflicting signals.
In an individual with SAD, the body
struggles to synchronize with the
new environmental signals, causing
the sleep cycle shifts and depressive
moods observed in SAD.12,15

Photon-Counting
Hypothesis
To begin understanding the
photon-counting hypothesis, you
must first assume that there is
some minimum allotment of light
necessary to provide energy to
maintain a stable mental state.
From here, this theory says that an
individual affected by SAD does
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not have enough time to absorb
the appropriate amount of light
through their eyes. BLT would be
expected to be more effective
when given for longer durations of
time each day.15
The
photon-counting
hypothesis has not been widely
studied
and
therefore
no
identification of possible underlying
neural mechanisms have been
made.15
You can find several studies
that support any of these
hypotheses and several studies
that seem to provide evidence
against these hypotheses. It seems
that the brain almost never works in
a straightforward or linear pattern,
and it is likely the pathophysiology
of SAD includes some crossover
or
combination
of
affected
pathways. There are more avenues
to be explored as well, including
the role of neurotransmitters
norepinephrine and dopamine,
which play a role in mobilizing the
body and motivation, respectively,
and hormones such as cortisol and
thyroid hormones that are subject
to seasonal pattern changes.10,12

Therapies
BLT is often a first response
in the alleviation of symptoms
seen with SAD and the correction
of shifted sleep cycles. This is
because the effects of BLT are seen
rather immediately, within a few
days, especially when compared
to SSRIs, which often take weeks
to elicit positive effects, if any.
In addition, BLT can be done at
home by the individual. This type
of therapy seems like it could do
no harm. However, it is important
that before any at home remedies
are attempted, you speak with
your doctor as several factors,
such as current medications and
type of light, go into determining
if the treatment is a safe and
worthwhile.8,14,16,25

Cells showing serotonin transporter protein.
By Melanie Johnson & Linda Sharp from Welcome Collection. (CC BY 4.0)

Antidepressants
such
as
SSRIs
and
second-generation
antidepressants
(SGAs)
have
shown to have positive effects on
depressed moods in individuals
diagnosed with SAD, and even
help to correct sleep patterns in
some patients.8,15,25,26
Talk therapy is aimed at working
with the diagnosed individual to
talk through positive mindsets. In
this process, the individual would
work towards creating different
ways to see the smaller processes
and moments as well as the larger
world around them.8,25 Talk therapy
seems eerily similar to the hygge
lifestyle, with some more guidance
and intention.
Chronotherapy refers to the
process of intentionally shifting
your own sleep-wake cycle. This
is not done using supplements or
medication of any kind, but rather
by slowly adjusting your wake time
and bedtime by an hour or so over
time until the desired schedule is
reached.27 This takes intentionality
and dedication and does not come

easily.
While any kind of therapy
should begin with a consultation
with your doctor, an easy change
available to anyone is to begin
adopting the hygge philosophy.
Call an old friend and ask how they
are on that next dark drive home
from work. Light candles on the
tabletops, cozy up with a warm
mug, and watch a black and white
classic film. Stay at dinner with
friends a little longer, laugh over
a game of ‘perfect partner but’
with your classmates, and enjoy
the togetherness characteristic of
hygge. Another key characteristic is
indulgence. Pick the softest socks,
drink the bottle of wine you’ve
been saving for a special night,
or use the aromatic shower gel
that’s been waiting in the bottom
of the cabinet.1,2,3,4,5,6 Slow down
and be present in the now. Begin
to prioritize coziness, self-care, and
take delight in every activity. Focus
on enjoying the littlest things in life
and all the lovely people around
you.
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The Real Truth About
E-Cigarettes & Vaping
By Julia Green
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O

ver the past decade,
electronic cigarettes
(e-cigs) have sparked
a new health debate in the United
States. At first, these e-cigs were
hailed as a great alternative to
regular cigarettes. E-cigs were
seen as a possible way for smokers
to quit smoking tobacco cigars
& cigarettes. Then came the big
problem: people started getting
sick, some even died. How are
e-cigs affecting smokers, both old
and new?

The Beginning
Originally, e-cigs became
commercially available in the United
States in 2006 as an alternative
to typical tobacco cigarettes.5
However, it was not until 2015, when
the third generation of customized
e-cigarettes — with their personal
settings and cartridge varieties —
that e-cigs became wide-spread.2
In 2015, popular e-cig manufacturer
JUUL began marketing a novel
type of e-cigarette with a nicotine
salt preparation.11 More commonly
referred to as “nic salts”, this
preparation style decreases the
overall harshness & acidity of
the cartridge, or “pod”, while
keeping the amount of nicotine
the same; leading to users inhaling
much
higher
concentrations
without being aware of it.7 Nic
salts allow users to take more hits
from their e-cigs without their
throats hurting. JUUL’s innovative
preparation, along with flavored
pods and ads targeting youths,
took the fledgling e-cig market by
storm.12 By September 2018, JUUL
commanded over two thirds of the
e-cigarette market in the United
States,6 and is beginning to make
smoking cool and commonplace to
a new generation of consumers.
The bulk of the e-cigarette
market, and certainly JUUL’s usage,
is amongst teenagers and young
adults, and the popularity of e-cigs
and vapes has been skyrocketing
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since 2015. In 2019 alone, 1 in 4
high school seniors vaped in the
month prior to being surveyed,
while almost half of them had
vaped at some point in their lives.10
These numbers are rising quickly!
The number of teenage users
has more than doubled from the
first time this data was collected
in 2017, when only 11% of high
school seniors had vaped in the
month before taking the survey.
When asked, these teenagers and
young adults said they started
vaping for many reasons. Some
started because they thought it was
less harmful than tobacco products,
others because they like the flavors
of the pods, but the primary reason
people begin using e-cigs is
because a family member or friend
vaped as well.10 A truth that is
coming to light is that e-cigarettes
are as addictive or more so than
the cigarettes they were meant to
replace.

The Unknowns

Since e-cigs are a relatively
new phenomenon there are many
problems that have arisen, but
the most prominent one is that
scientists do not know the longterm effects of vaping and using
e-cigs can have on the body and
the brain. Scientific information
is only starting to be generated,
as e-cig users start falling ill and/
or dying. A theory as to why e-cig
users are becoming ill is due to
the introduction of flavored pods.
In 2016, a report was published
describing how over 75% of the
flavored pods they tested had a
chemical called diacetyl which was
causing bronchiolitis obliterans and
other severe respiratory diseases.1
Diacetyl, the chemical that
helps cause these respiratory
diseases, tastes buttery and
adds to the flavor of the pod. It
is a hazard that there are no FDA
rules or regulations to prevent this

Bronchitis (left) causes inflammation, swelling, & mucus production in the top branches of the lungs,
while bronchiolitis (right) leads to the exact same symptoms (inflammation, swelling, & mucus) deep
within the lungs. From www.healthline.com.
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harmful chemical from being added
to all these pods and it was only
when users of popcorn flavored
pods began to develop “Popcorn
Lung”, that the e-cig companies
recalled the popcorn flavored pod.
It is highly probable the popcorn
pods were recalled solely due to
the name association, because
other products with diacetyl are
still sold, even with the known risk
of respiratory disease.

Addiction: Is It Just
Physical?
Today, scientists report that
nicotine is addictive regardless of
how it is ingested and is recorded
as more addictive than cocaine to
the nervous system.14 Part of the
reason for this is when nicotine is
ingested the chemical dopamine
is released in the brain. Dopamine,
along with serotonin, oxytocin,
and other neurotransmitters, are
sometimes referred to as the
“happy chemicals”, because they
activate neurons in the brain that
lead to feelings of happiness and

Of the 16% of e-cigarette users who quit, half
of them still used a cigalike device (like a typical
tobacco cigarette). The majority of continued
e-cigarettes users transitioned to a mod device
(like a JUUL)15. Original image by Julia Green
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contentment. Brains are very smart
and repeat actions that generate
any of these “happy chemicals”.
While
this
is
evolutionarily
beneficial, it also sets the stage
for addiction. If doing something
makes a person feel good (because
of the dopamine released in their
brain), then they will likely want
to continue doing that thing. In
this case, since smoking nicotine
releases dopamine in a person’s
brain, it is more probable they will
want to smoke again… and again…
until they are addicted.
Primarily there are only nicotine
studies which focus on cigarette
doses, recent news reports suggest
that vaping is a special case of
nicotine addiction. The technology
has only been on the market for little
over ten years and users are already
dying!4,9 The first teenager to die
passed away in early October of
2019, and unless he started vaping
when he was in elementary school,
it was clear that a big problem is
about to hit e-cig users worldwide.
A single regular strength vape pod
is advertised as the equivalent to
one pack of cigarettes. However,
very few cigarette smokers will
smoke a complete cigarette
without pausing, which lets up to a
third of the cigarette burn while not
actively smoking it. Examined lungs
of e-cig users looked like the lungs
were chemically burned suggesting
either dangerously high usage
levels of e-cigs and the chemistry
of these e-cigarettes are not well
understood.13
In 2017, Penn State contacted
people from a study five years
previous and asked how many of
them still used e-cigs. Most of them
replied they still used some form of
e-cig. From the small minority of
those who quit, many of them had
primarily smoked cigarette-like (or
cigalike) e-cigs. They transitioned
back to using tobacco cigarettes.
The people who continued using
e-cigarettes typically upgraded

their e-cig battery life or made some
other change to their cigarette
technology.15
For
example,
advanced devices are larger than a
typical cigarette and have a button
that must be pressed before taking
a hit, they are pen-shaped and
commonly referred to as a “vape
pen”. A modified (mod) device is
a type of e-cig that is neither penshaped or cigarette-shaped; this is
typically done to allow for longer
battery life or better wattage. JUULs
are examples of mod devices.
Over the past few years,
e-cigarettes have become more
aesthetically pleasing, helping to
drive their sales and popularity.
Not only does this design make
vape pens more attractive, it also
makes them easier to hide. The
perfect storm occurred: many of
these users were teenagers who
realized e-cigarettes were relatively
easy to hide and they were easier
to smuggle into school, parties, or
festivals than a pack of cigarettes
to get the same kick; leading to a
whole new market being created to
help users hide their e-cig usage in
public or in school.

Dependent on Others
The hardest thing for a person
with an addiction is to stop. As
mentioned above, it appears that
the addiction to vaping may be
more intense than an addiction to
cigarettes. This may have to do with
dosages, flavors, and the chemistry
of e-cigs, but it also can tie into the
social aspect of using e-cigarettes
and other vape products. Smoking
is historically a social activity.8
When one thinks of smoking or
a “smoke break”, it’s typically
people spending time together
while smoking, which makes
sense since humans are extremely
social creatures. However, there’s
an issue with the combination
of smoking and spending time
with friends: both activate the
dopamine pathways in the brain.
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While this might seem beneficial
at first glance, the problem lies in
the fact that the brain is unable to
separate the two. Nicotine releases
dopamine and makes the brain feel
good, as does hanging out with
people you enjoy, so when the two
are combined and lots of “happy
chemicals” are being released in
the brain, the brain is not aware
enough to differentiate between
the distinct dopamine triggers.
The dopamine pathway in the
brain runs through the Prefrontal
Cortex (PFC). This is in the very
front of the brain, right behind one’s
forehead, and it is where functions
like memory, reward processing,
and logic take place. There are a lot
of neurons that release dopamine
in the PFC which manages the
reward processing that takes place
there, and is one of the last places
in the human brain to fully develop
(usually around the age of 25). It
is the main reason why teenagers
and young adults are known for
making horrendously detrimental
judgement calls, or why they are
über impulsive. These are all known
and accepted concepts, but what is
not known is how a young adult’s
brain will be affected if they ingest
a lot of nicotine before their brain
is fully finished developing. It is

likely their brain development will
be stunted, and possibly suffer
nicotine poisoning. The danger
of an unusually high percentage
of current and future users having
stunted brain development is real.
However, the scary thing is how
scientists and e-cigarette users do
not know about their future health
both physically and neurologically.

So What’s Next?
There are no current FDA
rules and regulations to monitor
e-cigarette production and usage,
and states are only starting to come
up with legislation to track e-cigs
as well. Beyond e-cig users, there
is also collateral damage for family
and friends who have to deal with
these struggles and outcomes; it
can already be seen in families and
friends of people who struggle with
alcoholism and drug addiction.
Substance abuse harms families
and friendships, and can cause
dysfunction across all areas of one’s
life. The damage is often both
psychological and financial, which
often branches into stunted social
growth. What is clear from many
of the crises found in the U.S.A in
the past 50 years, is that when an
issue is not addressed the result

injures a generation. Hopefully this
time round, the issue of e-cigarette
and vaping addiction can be
tackled by non-partisan policymakers applying science instead of
politics and creating policies that
help people overcome addictions
and dependencies. Hopefully this
will happen before irreversible
neurological, physical, and social
damage is done to all current and
future users of e-cigarettes.

Note from the
Author:
This article was written in
mid-November 2019. The author
understands that this topic is
very much a current one and new
information & reports are coming
out everyday.
If you, or someone you know
is struggling with addiction please
contact one of the addiction
hotlines near you. Addiction
hotlines recommend following
the same procedures for quitting
both cigarettes and vaping. If you
are uncertain where to start, the
National Institute of Health has
suggestions specified to the type of
addiction (https://www.drugabuse.
gov/).
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assumed patients would
not have a chance to
develop appetites for
the substances. This
proved to be a tragic
miscalculation, especially
for the creator of the
hypodermic
needle,
Alexander Wood, whose
wife would become the
first recorded death from
injected opiates.
Heroin was first synthesized
from morphine in 1847 by Dr. Alder
Wright in his search for a nonaddictive alternative to morphine,
and again by Heinrich Dresser, a
Bayer Laboratory chemist, in 18983.
The creators and doctors believed
at the time that heroin, which had
proved to be an excellent painkiller,
was non-addictive. The new
compound was prescribed broadly,
primarily because doctors had little
else to prescribe to ease pain and
provide relief from suffering. By
the beginning of the 20th century,
miracle remedies with morphine,
opium, and heroin as their active
ingredients, under the guise of
benign sounding names such as
Mrs. Winslow’s Soothing Syrup,
were widely used and abused. In
a letter presented to the American
Pharmaceutical Association in
May of 1903, The Committee on
the Acquirement of Drug Habits
asserted that “careful study of data
personally collected from reliable
sources forced the conclusion that
the habitual use of opium and its
various forms [was] increasing and
that this increase [was] confined
to no one class or occupation”
meaning it posed a serious and
wide reaching public health threat 4.
Unfortunately, the address goes on
to assert that the only way by which
the public appetite for narcotics
could be curbed was through the
enactment of stringent laws to act
as significant barriers to accessing
the compounds. It recommended
the termination of narcotics sales

To administer naloxone, pull or pry off the yellow cap on
the adapter, pry off the purple cap off of naloxone and grip
the clear plastic wings on the nasal atomizer, screwing it into
the adapter, then screw the capsule of naloxone into the
barrel of the adapter. Tilt the head back and insert the white
cone into one nostril; spray half of the dose of naloxone
(approximately 1 cc) into one nostril and the other half into
the other1.

T

hese directions are not
for medical professionals,
or even first responders,
but rather the instructions provided
by a short training video produced
by Project DAWN (Deaths Avoided
With Naloxone) an Ohio Health
Department initiative that aims
to teach lay people to administer
the life saving drug in the event
of opioid overdose. Currently,
an estimated 130 Americans die
per day from opioid overdose2.
Across the country, opioids are
presumably responsible for 47,600,
or almost 68%, of the 70,200
drug overdose deaths recorded in
2017, the last year for which CDC
data is available. In Ohio alone,
opioids were responsible for an
average of 46.3 of every 100,000
deaths, placing the state second
for the most opioid deaths per
capita, just behind West Virginia.
These staggering statistics beg the
question: “How did we get here?”

The History of
Opioids in Pain
Treatment
Humankind’s disastrous love
affair with opioids is nothing
new. The story begins with the
early agricultural civilizations of
Mesopotamia3. The vibrant poppy
flower is believed to have first been
cultivated along the banks of the
Tigris and Euphrates, where the
Assyrian people devised a method
for extracting the potent sap from
the golf-ball sized pod that emerges

once the flowers drop their petals.
The sap, known as opium, and
its derivative opioids, were used
widely across ancient civilizations:
The Sumerians referred to the plant
using ideograms translating to “joy
plant;” the ancient Indians grew
and consumed it; the Greeks used
potions derived from it; and the
Egyptians created its first known
derivative, Thebaine. The drugs
were widely regarded as a powerful
method by which to escape both
physical and psychic pain, and
these benefits made it easy for
early civilizations to overlook the
clear risk of addiction and lethality
of the drug.
As
medicine
began
to
advance, the opioid molecule was
recast as a miracle cure all. In 1806,
German
physician
apprentice
Friedrich
Serturner
distilled
morphine, named for Morpheus,
the Greek God of sleep3. The drug
was a powerful pain reliever and
significantly more effective than its
parent opium. Its administration
was simplified by the development
of the hypodermic needle in 1853.
The needle allowed for the drug to
be delivered directly into the blood
stream, rather than be absorbed
through the digestive tract, as
was the case for the commonly
used pills and anal suppositories,
ensuring doses were rapidly
and accurately admisitered to
the central nervous system. This
method of administration was
also believed to limit addiction:
since the drugs were not being
consumed, healthcare providers
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for any purpose aside from medical
use, with “exceedingly severe”
penalties for the sale of recreational
narcotics.
This recommendation would
come to fruition with “An act to
prohibit the importation and use
of opium for other than medical”,
approved in February of 1909,
which prohibited the possession,
distribution, or sale of opium for
any purpose aside from medical
use.5 This was soon followed by
the Harrison Narcotics Tax Act of
1914, which, at face value, aimed
to regulate the sale of opium and
tax those distributing narcotics
for medical use, but was used in
practice to enforce a prohibition on
the use of narcotics for most medical
conditions and the prescription of
maintenance opioids to addicted
clients, whose ailment was not yet
considered medical.6,7 Those in
violation of the act could face up to
$2,000 in fines, the equivalent of a
whopping $51,074 in modern U.S.
dollars, and up to 5 years in prison.
The enactment of these
legislative acts ushered in an
era of fear surrounding the
consumption and prescription of
opioids, coined opiophobia, and
severe pain went untreated for
decades. Even the terminally ill
were denied the dignity of a pain
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free death, as doctors feared the
ramifications of prescribing opioids
and obtaining even small amounts
required signatures from multiple
practitioners. During this time,
concoctions combining multiple
drugs for their synergistic effects,
such as the Brompton Cocktail an elixir consisting of high proof
alcohol,
morphine,
cocaine,
antipsychotic
sedatives,
and
chloroform water - were used to
treat pain in the absence of access
to more potent opioid painkillers.3,8
It wouldn’t be until the 1970s
that opinions on opioids would
begin to change, prompted
primarily by healthcare providers
and advocates closely involved
with cancer patients. In a 1973
article published in the Annals
of Internal Medicine, American
doctors Richard Marks and Edward
Sachar highlighted a serious
problem of undertreatment with
narcotics leading to needless
suffering in medical inpatients9.
The pair reported two key findings:
1) over 70% of the patients
interviewed reported moderate
to severe distress despite opioid
treatment, and 2) the treating
physicians possessed considerable
misinformation relating to opioid
painkillers. More often than
not, physicians underestimated

effective doses, and overestimated
both the time of action and risk of
addiction related to the amount
of opioid painkillers used in
treatment, leading to egregious
undertreatment of pain, sometimes
in the case of terminal cancer.
This article was a call for action,
reinvigorating
the
discussion
surrounding the use of the most
powerful painkillers at humankind’s
disposal, and began the process
of rescuing opioids from their long
vilification.
Across the pond, Cicely
Saunders, a nurse, researcher,
and founder of St. Christophers
Hospice in London, began to treat
terminally ill cancer patients with
opioids and gather clinical data
regarding their efficacy3. According
to Robert Twycross, a researcher
at St. Christophers, by 1975, the
vast majority of the 500 patients
to pass through St.Christopher’s
doors that year were treated with
diamorphine, better known as
heroin 10. The patients were treated
on a preemptive 4-hour cycle,
totaling 5 doses per day, which
aimed to address pain before it had
a chance to arise. Of the patients
receiving opioid therapy, most
were maintained on doses of less
than 10 mg and only 8% received
doses exceeding 30 mg. None of
these patients were believed to
have become addicted, as they did
not demonstrate an overpowering
urge to take the drugs for their
psychological effects. Further, the
high daily doses did not appear to
the researchers to be an obstacle
to daily functioning or mobility,
laying to rest concerns about
patients suffering from a “living
death”, drugged and unable to
move in their last moments, which
was a serious concern of the time.
Ultimately, Saunders and Twycross
highlighted that for the terminally ill,
who averaged only 16 days at their
center, the threat of addiction was
negligible, and thus the benefits of
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opioid use far outweighed the risk.
The pair believed people deserve
to spend their last days pain free
and die a humane, dignified death,
even if it meant the use of strong
opioids.

A Major
Breakthrough
For centuries, opioids, a class
of chemical compounds derived
from the opium poppy, were
considered drugs that by some
divine benevolence or coincidence
relieved pain and produced
euphoria in those who consumed
it. However, 1973 ushered in a
new era in the understanding of
the pain relieving and addictive
properties of opioids, and the pain
experience. Candace Pert and
Solomon Snyder, researchers at
Johns Hopkins School of Medicine,
were the first to successfully
identify opioid receptor sites,
providing groundbreaking insight
into the mechanisms through which
opioids achieved their effects and
solidifying them as an “intrinsic and
essential” component of the pain
system 11,12. Continued research
revealed the system was comprised
of three receptor types - delta,
kappa, and mu - which were acted
upon not only by opioids obtained
from the external environment, but
also proteins produced internally11.
The newly discovered system was
branded the endogenous (meaning
internal) opioid system, after the
external compounds that act upon
it.
Of particular interest to our
story is the μ receptor, named
for its high affinity with the
opioid morphine 11. An internally
manufactured class of endogenous
proteins naturally bind to and excite
μ-receptors with great affinity:
endomorphins. These proteins
play a major role in the perception
of pain and reward processes. In
this way, the endogenous opioid

system explains the inextricable
link between two fundamental
drivers of human behavior: pain
and pleasure 13. At an evolutionary
level, these elements are critical for
the survival of a species. Pleasure is
experienced as an innate biological
reward for performing behaviors
that have the potential to promote
the health and species well-being,
such as eating or procreating.
Conversely, pain is experienced
in response to harmful stimuli and
plays an important adaptive role
by promoting the avoidance of the
stimuli and encouraging behaviors
that achieve relief should pain be
incurred.
Pain is now understood to
be a multidimensional experience
comprising a sensory component
that determines the physical
quality and intensity of a stimuli,
and an affective dimension that
determines how unpleasant we

rate stimuli 14. If your affective
dimension were to disappear,
and someone poked you with a
sharp stick you would register the
pressure of the poke, and perhaps
the sharp quality, but would not
necessarily rate the experience
as unpleasant or painful. This is
essentially how opioids induce pain
relief. The anterior cingulate cortex
(ACC), is a brain region dense in
μ-receptors and essential for pain
relief 15. When pain is incurred the
region releases the endomorphins
which bind to the μ-receptors and
quiet the brain activity caused
by your injury. Opioids resemble
these compounds, but their more
compact structure allows them
to overwhelm the μ receptor,
producing
more
pronounced
pain relief than the internally
manufactured compounds3. The
painkillers work, not by addressing
the physical ailment responsible for

The Progression Cancer Pain Treatment as Instructed by the WHO’s Cancer Pain Ladder for Adults18.
Original image by Lindsay Spitz
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the pain, but rather by blunting our
affective evaluation of experience.
μ-receptors
are
also
prominently
located
in
the
“reward” system, a collection of
regions situated deep in the brain
12,16
. When an action is performed
that is good for the organism
the activation of the μ-receptors
produces pleasurable feelings
that encourage repetition of the
behavior13. This system is the
reason high calorie foods are so
tasty and hugging a loved one
makes you feel warm and fuzzy. This
is also the system that goes awry
in addiction, which is at its core
disordered reward12,16. Addiction
was not a moral failing, rather it is
an irreversible neurological disease.
Today it is common knowledge
that chronic use of opioids leads
to a gradual inability to experience
their benefits, but at the time of our
story these realities were just being
discovered. The euphoria and pain
relief associated with the drug
diminish the longer the drug is
consumed until, eventually the user
must take the drug, not as a means
to experience pleasure, but in order
to avoid the unpleasant effects of
withdrawal. Unfortunately, at the
time of the budding revolution of
pain management the system that
dictates these effects had only
just been discovered. Healthcare
practitioners possessed only a
rudimentary understanding of this
complex process, which allowed
them to forge ahead under well
intentioned but misguided notions
related to the use of opioids in the
treatment of pain.

The Dawn of the
American Opioid
Crisis
The American Opioid Crisis
began with the best of intentions.
Jan Stjernsward, an oncologist
and chief of the World Health
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Organization’s
(WHO)
cancer
program beginning in 1980,
also believed, like Saunders and
Twycross, that opioids had a
place in the treatment of cancerrelated pain. In 1986, under his
guidance the WHO released
a comprehensive manual for
cancer pain management17. In
this document, the WHO made
its message clear: freedom from
pain, especially in the case of the
terminally ill, was a universal human
right and should be treated as such.
The manual noted that doctors
must consider all the elements biological, psychological, social,
and sociocultural - that contribute
to a patient’s total pain, not just
the physical malady. Healthcare
providers were also advised to
“believe the patient’s complaint of
pain,” and treat them accordingly.
With this, the WHO provided
an “analgesic ladder” detailing
a standardized escalation of
drug therapy in cancer pain
management18.
Let’s say you approach a
doctor with complaints of pain
related to a cancerous tumor in
your chest. According to the WHO
ladder, your physician would likely
begin by prescribing you aspirin
or nonsteroidal anti-inflammatory
drugs (NSAIDs) in the case of mild
pain; the kinds of drugs average
Joes take for their various aches
and pains. An adjuvant may also be
prescribed at this time to slow tumor
growth. If the non-opioid treatment
was ineffective in controlling your
pain or it escalated to a moderate
level during your treatment
process, you would graduate to a
weak opioid medication. These are
drugs like codeine, which you may
have been prescribed following
wisdom teeth removal or similarly
mild surgeries. This treatment
could also be combined with
the aforementioned non-opioid
painkillers for additional pain
relief, as the non-opioid painkillers

operate on different systems than
the opioid medication. Now let’s
say your tumor infiltrated your
lung, further escalating the severity
of your pain. At this point your
physician would be prompted to
prescribe a strong opioid, with
morphine highlighted as the drug
of choice, with or without the
additional drug therapies.
The implementation of the
WHO analgesic ladder was met with
great success. In a retrospective
analysis of the method conducted
by the WHO Collaborating Cancer
Center at The National Cancer
Institute of Milan, correct use of the
ladder was found to reduce pain
to ⅓ of its initial intensity and was
effective in over 70% of patients,
ultimately sparing them from
invasive pain control surgeries19.
These patients reported no major
changes in functioning and the time
spent sleeping doubled. Additional
retrospective analysis indicated
comparable
positive
results,
and noted none of their cohort
developed an addiction to strong
opioids20. These analyses supported
the “regular and sufficient” use of
Old botlle of opioid pain killer
By Science Museum, London
From Welcome Collection (CC BY 4.0)
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opioids as instructed by the WHO
analgesic ladder and lauded it as
the “most suitable treatment” for
the palliative care of advanced
cancer patients. The introduction
of this policy, and its subsequent
success, marked a major turning
point in the American discussion on
opioids; with the understanding of
pain relief as a human right and the
success of opioid therapies in the
management of cancer pain, the
powerful compounds once again
entered the limelight.
The success of the WHO
ladder in treating cancer pain and
the limited reports of addiction
and/or impaired functioning, led
the medical field to contemplate
the undertreatment of other
chronic pain conditions, and
ponder whether the use of opioid
therapies could be extended
beyond cancer-related pain to
other chronic conditions. However,
the majority of these concerns
were expressed by individuals
who had been closely involved
in the research and treatment
of cancer-related pain, and had
largely ignored the developing
understanding of chronic pain not
resulting from direct tissue damage
as a complex issue incorporating
biological, psychological and social
dimensions in a manner distinct
from chronic pain secondary to a
condition such as cancer 12,21.
Additionally,
while
the
discussion of the use of opioids
progressed rapidly over the 1970s
and 80s there had been little in the
way of rigorous assessment of their
efficacy in non-malignant chronic
pain conditions. The commonly
held belief that the therapeutic
use of opioids in the treatment of
non-cancerous chronic pain rarely
resulted in addiction did not reflect
the findings of controlled safety
studies. Rather, the conclusion
was drawn from two retrospective
studies from the era, which lacked
rigorous experimental designs,

but were nevertheless utilized by
physicians and aggressive drug
marketing to support the safety and
efficacy of opioids and promote
the expansion of opioid therapy to
treat non-cancerous chronic pain.
The first of the two, a short
paragraph published in the New
England Journal of Medicine
in 1980, retroactively assessed
the rates of addiction observed
in patients who had received at
least one opioid painkiller during
inpatient care between 1970 and
197922. It stated that of those who
received the opioid therapy, only
4 became addicted. Beyond the
numbers, there is no indication
as to the cases, for how long, or
in what quantities these drugs
were used to treat. Additionally,
all were inpatients, meaning the
consumption of narcotics were
regulated by healthcare providers;
providers
who
presumably
undertreated pain in a manner
akin to the physicians described by
Marks and Sachar in 1973.
The second, published by
doctors Richard Portenoy and
Kathleen Foley in 1986, both
early advocates of the expansion
of opioid therapies, provided an
analysis of 38 patients maintained
on opioids for pain unrelated to
cancer 23. Of these individuals only
two, both of whom had a history
of substance abuse, misused the
drugs which provided adequate
relief in about 63% of patients. The
paper asserts that bad brains, not
bad drugs, led to addiction. As
long as doctors obtained adequate
patient histories, addiction to
painkillers could be avoided.
However, so little was understood
about addiction and what elements
presented an increased risk that
doctors were left to make the call
as to whether their patients were at
risk with little to no guidance.
The prescription of opioids
would rise steadily both in number
and dose over the ensuing

decades aided in part by programs
introduced to answer the lingering
concerns about the undertreatment
of pain. In 1995, the American Pain
Society introduced their “Pain: The
fifth vital sign” campaign which
operated under the logic that pain
if assessed with the same regularity
and standardization as the other
vital signs - pulse, blood pressure,
temperature, and respiration - it
would have a better chance of
being treated properly 3,24. In the
years following, The Veteran’s
Health Administration and The Joint
Commission for the Association
of
Healthcare
Organizations,
regulatory bodies that together
influenced the majority of the
American
healthcare
system,
adopted the policy, and oversight
agencies including The Medical
Board and FDA relaxed their
scrutiny of opioid prescribing24.
The swift implementation of
standardized pain management
policy led to heavy reliance on
opioid painkillers, and the idea that
pain counteracted the euphoric
and sedative qualities of the drugs
meant there was no ceiling on the
amount of opioids prescribed. As a
result, over the following 15 years,
there has been a “proportionate
quadrupling in opioid sales and
mortality” rates 3,24. Per capita
opioid
prescription
peaked
between 2010 and 2012, when
81 of every 100 individuals were
prescribed an opioid painkiller.
2012 was the height of opioid
consumption; in a single year
Americans consumed 165,525 kg
of opioids compared to 46,946 kg
consumed in 2000 24. Fortunately,
steps taken to regulate and monitor
the sale of prescription opioids and
improved education surrounding
the use of opioid painkillers have
helped to contain the epidemic
3,24
. 2018 was the first year to see a
decline in opioid overdose deaths
since 1990, dropping by 5.1% from
the previous year.21,25
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lzheimer’s runs in my
family. My grandma has
it; her mother had it.
It’s a sad reality for us. We began
to understand what it was going
to look like for my grandma when
she started to forget things that
she never used to. There’s no one
more organized than my grandma;
growing up, her family calendar is
what kept that side of the family
on top of all of the sports games,
birthdays, and religious events
that the grandkids were involved
with. When her Alzheimer’s started
setting in, my grandparents’
house was filled with post-it notes
scribbled with reminders of things
that are usually easy to remember.
It’s not so strange to see “Call soand-so” on the fridge or “Clean”
on the dishwasher, but when she
had to start writing reminders to
take her pills at breakfast or other
tasks that she had successfully
accomplished without reminders
for years, we knew something was
up. Today, she doesn’t know if I am
still in college, what day, month or
year it is, or if she ate breakfast. It
doesn’t make her any less lovely
to be around: we still enjoy our
trips for Starbucks or Dairy Queen
milkshakes. I don’t think she could
be any happier, I just wish her
brain would cooperate with her
livelihood.
One thing my grandma loves
to do is drink wine. This isn’t new,
but her Alzheimer’s has definitely
given her the ability to live in the
moment. And at any given time,
she may just want some more
wine. As it turns out, wine has
clear health benefits. Recently, our
family has been wondering if the
wine does anything to help her
brain, given that it’s deteriorating
due to her disease. Could there
be a connection between her
disease progression and wine
consumption? We cannot know
simply from Grandma Becky,
but scientists have done a hefty
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amount of research surrounding
the health benefits of wine, and
the results have implications for
both people with Alzheimer’s like
my grandmother and the general
public of aging individuals.

Alzheimer’s Disease
and Aging
Alzheimer’s disease currently
affects 5.8 million Americans
(alz.org). The disease is a type
of dementia that causes people
to have memory issues, altered
behavior, and difficulty thinking.
Symptoms of the disease arise
and progress slowly, but eventually
people with Alzheimer’s can have
a difficult time with daily tasks and
can lose important memories, like
the names of close family members.
Alzheimer’s disease is the cause of
60-80% of dementia cases, so not
all dementia is due to Alzheimer’s.
Dementia due to Alzheimer’s has
tell-tale signs such as buildup of
harmful proteins that clog and
deteriorate the brain.
Alzheimer’s is separate from
the normal aging process. Older
people have the highest likelihood
of
developing
the
disease,
but Alzheimer’s disease has
complications that do not occur in
the typical process of aging. People
younger than 65 may develop
early-onset Alzheimer’s, which is a
form of the disease that begins at
a younger age and progresses at a
steady rate. In the early stages of
the disease, behavior is only slightly
altered and dementia is mild.
However, in the later stages, most
people with Alzheimer’s lose their
ability to continue conversations,
may hallucinate, and have seizures.
Contrary to popular belief, people
die from Alzheimer’s rather than
with the disease. Death tends to
occur 8.5 years after diagnosis, but
that number varies greatly from
person to person1.
Changes in the physical brain

happen long before any behavioral
changes occur in Alzheimer’s
disease. These brain alterations can
be observed, sampled, and used
for diagnoses. A brain is made up
of many different regions that are
responsible for specific actions.
Just like there are regions specific
for interpreting visual and auditory
information from the eyes and ears,
there are brain regions responsible
for memory and emotions. It is only
after these regions are damaged
due to Alzheimer’s that memory
is impaired. One region known
for its importance of committing
short term memories to long term
memory is the hippocampus.
Oftentimes, scientists choose to test
the function of the hippocampus
in studies that assess memory.
The hippocampus, like all of the
other brain regions, is made up of
cells called neurons, which are the
microscopic cellular building blocks
that are responsible for signaling in
the brain.
Diseases that impact cognition,
like Alzheimer’s, prevent neurons
from functioning how they should.
Alzheimer’s disease is characterized
by the buildup of two harmful
proteins in the regions of the brain
that are important for memory and
cognition. The first of these two
proteins, amyloid beta, builds up
in the spaces between neurons,
altering normal communication.
Scientists refer to the buildup of
amyloid beta in the brain as plaque
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A neuron (green) affected with Alzheimer’s
disease has plaque buildup (red) along its
exterior.
Plaque by Adam Kaurman © Strittmatter Lab,
Yale University. Adapted by Ethan Bradley

formation, and these plaques can
be observed via brain imaging
and sampling of the fluid within
the brain called the cerebrospinal
fluid. Although a different type
of plaque, the damage done to
neurons by amyloid beta plaques
can be compared to the damage
done to teeth by cavity-causing
plaques. The second harmful
protein Alzheimer’s is responsible
for is phosphorylated tau. Normally,
tau is a protein that helps form the
branch-like structure of neurons.
Neurons reach in many directions
to connect with each other, and tau
is important for forming the fibrous
structure inside of the outstretched
arms of the neuron. In Alzheimer’s
disease, tau is altered so that these
fibrous structures become tangled,
hindering
neuronal
signaling.
These tangles are made up of a
form of tau called phosphorylated
tau, and doctors can see these on
brain images.
Alzheimer’s disease has no
known cure and very few effective
treatments. The most common
drug prescription for Alzheimer’s
disease is an Acetylcholinesterase
inhibitor, which makes it easier for
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signals to get from one neuron
to another1. When neurons are
signaling to each other, there are
proteins that surround the points
of contact between the neurons,
called synapses, to enhance the
transfer
of
neurotransmitters.
Acetylcholinesterase is one of these
proteins, and it clears the synapse
of
excess
neurotransmitters
by absorbing them back into
the
signal-sending
neuron.
Acetylcholinesterase
inhibitors
block acetylcholinesterase from
absorbing neurotransmitters from
the synapse, thereby allowing more
neurotransmitters to make it to the
receiving neuron.
However, acetylcholinesterase
inhibitors only modestly prolong
a person’s ability to use their
degrading brain to think and
remember. These drugs do not
reverse memory loss because
they do not directly prevent
amyloid beta or phosphorylated
tau buildup. This means that they
are not stopping the deterioration
of the brain. Sadly, mental health
disorders such as anxiety and
depression are common in people
with developing Alzheimer’s. The
most helpful treatment for this is
therapy, as many anti-depressant
drugs can worsen dementia and
confusion. To date, the outlook
for treatment is bleak for a person
being diagnosed with Alzheimer’s.
Because there are no known
cures for Alzheimer’s, scientists are
motivated to figure out the cellular
and molecular mechanisms of the
disease to find a target for potential
drugs. There are promising drug
discovery
studies
identifying
targetable pathways for alleviation
of the disease. As Alzheimer’s is a
disease that leads to cell death,
many of these therapeutic targets
are aiming to promote cellular
health in the locations that are
the most critical for cell survival
like energy production and excess
protein removal. Though normal

aging and Alzheimer’s progress
differently, many of the potential
treatments for Alzheimer’s, should
they prove to work in humans,
may be effective for the general
population. This is because these
drugs would enhance cellular
function regardless of a person’s
disease state. These neuronal
health-promoting qualities of the
potential treatments may have lifeelongating side effects for people
with and without Alzheimer’s.
Though speculative, this feature is
part of what makes research into
aging so exciting.

Pre-Clinical Health
Studies: Resveratrol
Going
back
to
my
grandmother’s love of red wine,
scientists have found that a
compound within the skin of red
grapes can clear the plaques and
tangles caused by Alzheimer’s in
the brains of mice. These mice
are born from parents that were
genetically altered by the scientists
to model familial Alzheimer’s, the
type of Alzheimer’s that can be
passed through generations. In this
way, these mice have Alzheimer’s
that develops along the time scale
of a mouse’s life. At seven months
old, they start to lose short term
memory abilities. After a year, the
mice perform horribly on memory
tasks. This mouse model also allows
scientists to study the cellular
components of Alzheimer’s because
the mice’s poor memory is due to
amyloid beta and phosphorylated
tau buildup, the same two factors
that are involved in humans2. Mice
models are the backbone of the
scientific knowledge of Alzheimer’s
because scientists can manipulate
their genes, environment, and diet
to match clinical treatments they
want to test, and can measure how
these factors affect their behavioral
and cellular health outcomes after
treatment.
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Resveratrol is found in many
different compounds: red grapes,
nuts, and berries, for example.
Comparatively, red wine has
a particularly high amount of
resveratrol because of how it is
produced. Resveratrol is found in
the skin of the grape, and a glass
of red wine has proportionally more
whole grapes than grape juice,
making wine the token dietary item
for resveratrol consumption. White
wine only uses the pulp of the
grape and contains no resveratrol.
However, when given to mice,
resveratrol is a supplement to their
diet via solid form so that scientists
can administer exact dosages. In
every study on dietary resveratrol,
the mice are given resveratrol for
many months, prior to the onset of
disease.
In a recent study, a group of
researchers from Barcelona treated
the mouse model of familial
Alzheimer’s with resveratrol for 10
months, starting at two months
of age. They tested the levels of
plaques and tangles within the
hippocampus of these resveratroltreated mice and compared these
results to the mice fed a normal diet
to determine how their brains had
been affected by the treatment. The
results showed that the diseased
mice treated with resveratrol had
the same number of plaques and
tangles as the healthy, untreated
mice. Through mechanistic work on
the cellular and molecular levels,
the scientists discovered that
resveratrol directly downregulates
the
cellular
pathways
that
synthesize the plaques and tangles
and upregulates the pathway that
breaks them down. For example,
resveratrol downregulated the
activity of a protein responsible
for generating amyloid beta
called BCAE1, upregulated the
activity of a protein responsible
for degrading amyloid beta called
neprilysin, and enhanced a proteinclearing pathway that prevents the

phosphorylation of tau. This result
showed that prolonged resveratrol
treatment is enough to clear the
plaques and tangles from the
hippocampus of diseased mice,
which is a critical finding, as many
other treatments for the disease fail
to have an effect on both plaques
and tangles3.
Alongside the finding that
resveratrol-treated
mice
had
healthier, younger-looking brains,
these
authors
showed
that
resveratrol treatment had a marked
effect on the mice’s memory. To
test this, they used a variety of
memory tests that have been
developed to determine what the
mice are thinking. The strongest
data for resveratrol came from
an object recognition test. Mice
have an ingrained preference for
new things; they love to explore.
Scientists can use this characteristic
to determine how well they
remember objects over some span
of time. In the first session, the mice
are shown two identical objects and
allowed to explore them. They will
smell and play with the objects until
the end of the session. Later, the
mice are given two objects again,
but one of them is replaced with a
new object. Because the mice like
new things, they will spend more
time playing with the new object if
they remember the old one. If they
spend about the same amount
of time with both objects, the
scientists conclude that the mouse
does not remember seeing one of
the objects before; it’s as if both
objects are new to the mouse.
In the resveratrol study, the
scientists did just this and found that
the untreated, diseased mice forgot
the object that they were given
after two hours, but the diseased
mice treated with resveratrol could
remember the object a day later3.
This was an exciting finding because
the mice’s ability to remember the
object after resveratrol treatment
overlapped, logically, the finding

that the resveratrol-treated mice
had healthier brains with less
plaques and tangles. Interestingly,
resveratrol has positive effects
on healthy aging mice as well.
In a separate study, a group of
scientists found that resveratrol
treatment strengthens neurons in
the hippocampus of these healthy
older mice, which lead to the
treated mice having better memory
than untreated mice4. Over and
over in the research on resveratrol,
scientists have shown that it has
beneficial effects on memory for
both healthy and Alzheimer’s mice.
The goal of all of these studies
in mice is to determine how
resveratrol affects the brain. The
question each study leaves us with
is simple: can wine do for humans
what resveratrol does for the mice?
My grandma would tell you yes, the
wine is helping her brain do what it
needs to. However, she is drinking
a fair amount of alcohol (safely,
of course), and her disease is still
progressing. If what is happening
in the mice is true for us, shouldn’t
her brain be getting better instead
of worse? It turns out, you need

According to studies done in mice, red wine can
promote brain function
Original image by Ethan Bradley
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Genetically modified Alzheimer’s mice perform better on memory tasks after prolonged treatment with resveratrol (a compound found in red wine)
“Wine” by TotoBaggins from Wikimedia (CC BY-SA 3.0), Original image by Ethan Bradley

more wine than anyone should
drink to get the dose of resveratrol
that the scientists are giving the
mice in the pre-clinical trials. In
a study published in the Journal
of Neuroscience, healthy older
adults were given resveratrol to
test if the drug could have the
predicted beneficial effect in
humans. Resveratrol increased
the connectivity of the adults’
hippocampi and thus improved
their memory. There was only
one issue: the participants were
given two hundred milligrams of
resveratrol per day5. For reference,
a glass of wine contains up to 2 mg
of resveratrol. So, in this resveratrol
pill, the participants were ingesting
the resveratrol-equivalent of 200
glasses of wine. Clearly, this pill is
much safer than asking someone to
drink 200 glasses of wine, but this
outlines a striking issue with wine
as an Alzheimer’s treatment: you
cannot drink enough wine to get
the full disease-preventing benefits
that we can see in mice. However,
drinking wine for the benefits of
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resveratrol may not be a lost cause.
To answer that question, we will
need to look into the research on
what happens to people who drink
wine, on a populational level, so that
we can understand if the benefits
of resveratrol hold up outside of a
clinical-controlled environment.

Does Drinking Wine
Prevent Dementia in
Humans?
The reason that it takes such
a high dose of resveratrol to make
a difference in the brain is due to
a structure that neuroscientists
call the blood brain barrier. The
brain gets nutrients and oxygen
from the blood to function, but
not everything in the bloodstream
makes it into the brain. There are
things floating in the bloodstream
that could be harmful to the brain:
bacteria, for example. To ensure
brain health, the body has a system
that connects the arteries in the
head to the brain with a selective

passing point between the two. In
this way, the brain is selective about
what is allowed across the blood
brain barrier. Resveratrol has a
hard time crossing the blood brain
barrier because, on a molecular
level, it’s larger than many of the
things that go through that passing
point. Therefore, humans have to
take a high dose to get enough
resveratrol into the brain to make a
difference.
Although buildup occurs over
time, it is feasible that drinking
a small amount of resveratrol
routinely for many years could
accumulate in the brain and have
positive effects. By this logic,
resveratrol would need to reach a
high enough concentration in the
brain to be effective. To test this
hypothesis, scientists compared
people who consume alcohol to
those who do not, at a populational
level. A 2017 study looked at the
relationship
between
alcohol
consumption (from any source: beer,
wine, whisky, etc.) and dementia.
If asked to predict the results of
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the study given no information on
resveratrol, one would imagine,
through experience or observation,
that drinking alcohol would have
negative effects on one’s ability
to remember things over time. It’s
true; too much alcohol in too short
of a time span can cause you to
‘black out,’ or have no memory
of what you did while under the
influence. However, after analyzing
data from over a hundred thousand
people, these scientists found that
people who drink modestly (6
drinks per week) had the lowest risk
of dementia, even after controlling
for age, sex, and education level6.
Hence, you can drink to remember,
if you drink a little bit every day for a
long time. Moreover, as expected,
these scientists found that wine
was the drink that best prevents
dementia.

Diet and Dementia:
You Are in the
Driver’s Seat!
So, this leaves us in a tricky
spot. Wine is good for us, to some
degree, but it is not going to
reliably prevent dementia. It only
reduces the risk by some small
factor. Is dementia worth worrying
about, or do we have too little
control over our future health? As
it turns out, choosing what you
want in your diet has a profound
effect on your mental and physical
health. In a study of older adults
in a retirement community around

Chicago, researchers found that
adherence to a newly developed
diet called the MIND diet reduced
the risk of Alzheimer’s disease by
more than half. Interestingly, the
MIND diet was more successful
in reducing dementia than the
famous
Mediterranean
diet.
Fittingly, the MIND diet is full of
items that are high in resveratrol
like wine, berries, and nuts7. The
best part of this diet is that it does
not ask participants to give up on
foods that are easy, like fried fast
food. It just asks you to limit the
rate of consumption of that type
of food to once per week. In this
way, diets such as the MIND diet
are likely to be helpful to people,
and this research can be used to
inform doctor’s recommendations
for diet. At the end of the day,
wine is not going to be a cureall for dementia and Alzheimer’s.
That being said, committing to
consistently putting good foods,
especially high-resveratrol foods,
into your body over a long time is
one of the clearest ways that we
can prevent dementia and keep
our minds healthy.
The real takeaway from
the preclinical mice research on
resveratrol is not that we should be
drinking as much wine as we can.
What the research tells us is that
the foods and drinks found in our
diet that have clear effects on the
brain. We can use the research to
our advantage and choose to put
things into our bodies that will
promote our health. Therefore,

since Alzheimer’s runs in my family,
I’m going to think through these
dietary recommendations when
I’m choosing what to eat and drink.
There’s no telling how things will
end up in the future, but choosing
healthy options is the best thing I
can do. If I am like the participants
in the MIND study, it will reduce
my risk of Alzheimer’s by more than
half.
There are no known successful
treatments for Alzheimer’s. Scientific
research is currently attempting to
uncover genetic causes of familial
Alzheimer’s, but my family does not
know what makes us so susceptible
to the disease. However, that does
not mean that the situation is
entirely out of control. We have the
ability to make behavioral decisions
that will mitigate how the genes
we inherit affect our lives. In the
preclinical mouse research, we’ve
seen that eating a diet that enables
our bodies to fight off diseases
like Alzheimer’s can promote our
brain’s function. We are not mice in
a super-controlled environment, so
the cellular effects of these choices
on the neurons in our brains are
harder to parse out. That being
said, we have more agency in how
we age than we may have initially
thought. Until a promising cure for
Alzheimer’s reaches the scientific
horizon, I’m going to support my
grandmother’s red wine drinking
habits and join her, on occasion.
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Hippocampus Alzheimer’s Patient.
Red: Amyloid Beta Plaques; green: Neurofibrillary Tangles;
Purple: Neurofilament H; Blue: Dapi nuclear stain.
By Danielle Beckman © MBF Bioscience
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Hippocampus schizophrenia mouse model
White/magenta spots show depletion of CA2 inhibitory neurons
By Vivien Chevaleyre
© Columbia’s Zuckerman Institute

98

Class of 2020
July 2020 | Volume 4

